Interleukin-7 and hematopoietic stem cell transplantation: beyond the thymus by Broers, A.E. (Anna Elisabeth Clasine)
Interleukin-7 and hematopoietic 
stem cell transplantation: 
beyond the thymus
Annoek Broers
ISBN 978-90-8559-331-7
© 2007 A.E.C. Broers. All rights reserved. No part of this thesis may be reproduced, stored in 
a retrieval system, or transmitted in any form or by any means, without the permission of the 
author.
Cover design: Nanna Koekoek (www.nannakoekoek.com)
Layout: Optima Gra sche Communicatie, Rotterdam
Print: Optima Gra sche Communicatie, Rotterdam
Publication of this thesis was  nancially supported by
Pharmion B.V.
Genzyme Nederland
Novartis Pharma B.V.
Janssen-Cilag B.V.
Sano -Aventis Netherlands B.V.
Bristol-Myers Squibb B.V.
Beckman Coulter Nederland B.V.
Interleukin-7 and hematopoietic stem cell transplantation:
beyond the thymus
Over interleukine-7 na hematopoietische stamceltransplantatie
en het aandeel van de thymus
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magni cus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
28 november 2007 om 11.45 uur
door
Anna Elisabeth Clasine Broers
geboren te Schiedam
Promotiecommissie
Promotoren: Prof.dr. J.J. Cornelissen
  Prof.dr. B. Löwenberg
Overige leden: Prof.dr. J.J.M. van Dongen
  Prof.dr. G. Wagemaker
  Prof.dr. H. Spits
The studies described in this thesis were performed at the Department of Hematology of the 
Erasmus University Medical Center in Rotterdam, the Netherlands.
Contents
Chapter 1 General introduction 7
Based on:
Lymphocyte recovery following allogeneic stem cell transplantation: 
new possibilities for improvement. 
Clin Appl Immunol Rev 2002;2:217-227.
Chapter 2 A comparison of postengraftment infectious morbidity and 
mortality after allogeneic partially T-cell-depleted peripheral blood 
progenitor cell transplantation versus T-cell-depleted bone marrow 
transplantation.
Exp Hematol 2005;33:912-919.
25
Chapter 3 Quanti cation of newly developed T cells in mice by real-time 
quantitative PCR of T-cell receptor rearrangement excision circles.
Exp Hematol 2002;30:745-750.
43
Chapter 4 Interleukin-7 improves T-cell recovery after experimental T-cell-
depleted bone marrow transplantation in T-cell-de cient mice by 
strong expansion of recent thymic emigrants.
Blood 2003;102:1534-1540.
55
Chapter 5 IL-7 mediated protection against minor antigen-mismatched 
allograft rejection is associated with enhanced recovery of regulatory 
T cells.
Haematologica 2007;92:1099-1106.
73
Chapter 6 General discussion 89
Chapter 7 Summary/Samenvatting 107
Addendum Abbreviations 117
Dankwoord 119
Curriculum Vitae 121
Publications 123

Chapter 1
General introduction

General introduction 9
Hematopoietic stem cell transplantation
Allogeneic stem cell transplantation (allo-SCT) has been established as important treat-
ment modality for patients with hematological malignancies, aplastic anemia, and inborn 
errors of hematopoietic progenitor cells. Since its  rst successful application in a patient 
with severe combined immunode ciency in 1968,1 a continued increasing application of 
allo-SCT is apparent,2 which may in part be explained by several important developments. 
First, in addition to HLA-matched related donors, stem cells from HLA-matched unrelated 
donors, including cord blood stem cells, and stem cells from haplo-identical donors have 
become available on a broader scale and are increasingly being used.3-7 Second, due to 
the appreciation of graft-versus-leukemia and graft-versus-tumor e ects, indications have 
gradually broadened.8 Antitumoral activity has been shown in various solid tumors including 
advanced renal cell carcinoma, breast- and ovarian carcinoma and allo-SCT is increasingly be-
ing used for the treatment of patients with malignant lymphomas.9-12 Moreover, even elderly 
or debilitated patients may now bene t from allo-SCT due to the development of reduced 
intensity conditioning regimens.13 Nevertheless, major lethal and non-lethal complications 
still hamper a full implementation of allo-SCT. Transplant-related mortality (TRM) has been 
reported to vary between 15% in younger patients with standard-risk features to 30-40% in 
older patients and/or patients with high-risk features.14 TRM in recipients of stem cells from 
alternative donors may even increase up to 50-60%.3-4 Although development of reduced 
intensity conditioning regimens has been associated with a substantial reduction in TRM, this 
only holds true for the early day-100 TRM whereas TRM continues to rise for at least two years 
thereafter.15 TRM is mainly caused by severe opportunistic infections, which may develop 
due to an impaired immune reconstitution following allo-SCT. Immune reconstitution after 
allo-SCT is a protracted process, adversely a ected by patient age, graft-versus-host disease 
(GVHD), application of T-cell depletion of the stem cell graft, and use of immunosuppressive 
drugs for prevention and treatment of GVHD.16 Although restoration of epithelial barriers and 
innate immunity occurs rapidly, adaptive immunity including B- and T lymphocytes may be 
de cient for a prolonged period of time. Whereas TRM in the early posttransplant period has 
gradually decreased due to better supportive care and prophylaxis measures, it is especially 
the prolonged period of B- and T-cell lymphopenia that causes signi cant susceptibility to 
opportunistic infections and subsequent transplant-related morbidity and mortality in the 
later posttransplant period.17
Immune reconstitution following allogeneic stem cell transplantation
Regeneration of a fully functional immune system requires recovery of both its innate and 
adaptive components. Whereas reconstitution of innate immunity including natural killer 
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(NK) cells, polymorphonuclear (PMN) cells, monocytes, macrophages and dendritic cells oc-
curs rapidly, reconstitution of adaptive immunity is considerably delayed following allo-SCT.
Innate immune system
PMN cells, monocytes and macrophages recover in the early posttransplant period with neu-
trophil recovery usually preceding recovery of monocytes and macrophages. NK cells are the 
most rapid lymphocyte subset to recover following allo-SCT reaching normal levels within 
1-2 months posttransplant irrespective of transplant type, stem cell source, patient age and 
GVHD. In contrast to NK cells, cellular recovery of myeloid cells is strongly in uenced by 
transplant-related factors such as stem cell source and GVHD. Moreover, even after quantita-
tive regeneration of PMN cells, immune competence may still be impaired due to prevailing 
functional defects in chemotaxis, superoxide production and bactericidal activity, especially 
in the presence of GVHD. (Reviewed in reference 18)
Adaptive immune system
B-lymphocyte recovery
Peripheral blood B-cell numbers are very low during the  rst months following allo-SCT and 
gradually rise thereafter to normalize by approximately 1 year posttransplant.19 Recapitula-
tion of normal B-cell ontogeny is suggested by a relatively fast rise of naive IgD+ B cells and a 
relatively slow rise of IgD- memory B cells. High expression of CD38, membrane IgM and CD5 
are also reminiscent of fetal B-cell development.20-22 The B-cell receptor repertoire, as evalu-
ated by immunoglobulin (Ig) heavy-chain variable (VH) segments usage, appears restricted, 
which is re ected by a long-lasting restricted repertoire of antibodies and reduced overall 
production of IgG2, IgG4 and IgA, even beyond 1 year following transplantation.23-25 Anti-
body responses following immunization may re ect the functional capacity of reconstituted 
B cells and have been evaluated for a number of viral and bacterial antigens. Responses may 
depend on the type of antigen as antibody responses to protein antigens may recover faster 
(< 1-2 years) than responses to polysaccharide antigens (usually > 2 years).26 Chronic GVHD 
has consistently been associated with delayed B-cell recovery and antibody responses.27-30
Restoration of B-cell function is (among other factors) dependent on T-cell recovery. T-cell 
depletion and delayed T-cell recovery may be associated with a delayed recovery of antibody 
responses.30,31 Slow recovery of CD4+ T cells, in particular, has been associated with delayed 
restoration of antibody responses. Both reduced B-cell numbers and reduced CD4+ T-cell 
counts have been shown to correlate with the cumulative incidence of opportunistic infec-
tions in the later posttransplant time period.19
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CD4+ T-lymphocyte recovery
CD4+ T lymphocytes are pivotal for the development of primary immune responses and for 
providing help to CD8+ cytotoxic T lymphocytes (CTL) and B lymphocytes. Impaired recovery 
of immune competence following allo-SCT may be ascribed for a considerable degree to a 
long-lasting de ciency of circulating CD4+ T lymphocytes. Indeed, several clinical studies in 
patients have shown a correlation between the occurrence of opportunistic infections and 
low CD4+ T-cell counts.19,32,33 Blood CD4+ T-cell counts are usually below 200 x 106/L during 
the  rst 3 months following marrow grafting. Thereafter, numbers gradually rise but may still 
be below normal levels by 12 months posttransplant. CD4+ T cells are divided in two pheno-
typically and functionally di erent subsets according to their CD45 isoform expression: naive 
CD4+CD45RA+ T cells and memory CD4+CD45RO+ T cells. In the  rst months posttransplant, 
CD4+ T cells predominantly express a memory phenotype whereas the thymic generation 
of naive CD4+ T cells may require months to even years posttransplant, especially in adult 
patients due to thymic involution and impairment of thymic function by direct e ects of 
radiotherapy and GVHD.34-36 Moreover, even after quantitative regeneration of CD4+ T-helper 
(Th) cells, immune competence may still be impaired for a prolonged period of time due 
to prevailing Th-cell dysfunction following allo-SCT, a ecting both thymus-independently 
and thymus-dependently regenerated CD4+ Th cells.37 However, Th-cell dysfunction may in 
part be due to the quantitative decrease in CD4+ T lymphocytes, as Th-cell function is usually 
studied in a pool of peripheral blood mononuclear cells containing widely varying numbers 
of CD4+ Th cells.
CD8+ T-lymphocyte recovery
CD8+ T-cell numbers tend to normalize more rapidly after allo-SCT as compared to CD4+ T-cell 
numbers. Blood CD8+ T-cell counts are usually below 200 x 106/L during the  rst 3 months 
following transplantation. Thereafter, numbers rise quickly to reach normal levels by 4-6 
months after allo-SCT.38,39 Reconstituting CD8+ T cells are predominantly memory T cells, 
which often display an activated antigen-primed phenotype.40 The recovery of naive CD8+
T cells is slow, although faster as compared to the reconstitution of naive CD4+ T cells after 
transplantation. Monitoring of antigen-speci c HLA-restricted CD8+ T cells has provided im-
portant information with respect to restoration of cytomegalovirus (CMV)- and Epstein-Barr 
virus (EBV)-speci c immunity and may be of help in the identi cation of patients at high risk 
of speci c opportunistic infections.41-43 Absence of adequate CD8+ cytotoxic activity in vitro is 
associated with an increased risk of developing severe CMV disease.44 Furthermore, impaired 
recovery of HLA-speci c CD8+ CMV-speci c CTL, as quanti ed by using so-called tetramers, is 
strongly associated with recurrent CMV antigenemia and CMV disease.45 Additionally, recipi-
ents of allo-SCT developing a reactivation of the EBV virus progressing towards lymphoprolif-
erative disease show a higher mortality in case of persistent lymphopenia.46 Considering the 
essential protective role of virus-speci c CD8+ CTL, several studies have reported successful 
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adoptive transfer of CMV- and EBV-speci c CD8+ T-cell clones.47-50 However, help provided by 
CD4+ T cells seems indispensable, as illustrated by the observation that CMV-speci c CD8+ T 
cells tend to disappear in the absence of CD4+ T cells with CMV speci city.51
T-lymphocyte recovery and thymic output
As impaired recovery of immune competence following allo-SCT may be ascribed for a con-
siderable degree to de cient thymic generation of naive CD4+ T cells, adequate assessment 
of posttransplant thymic output is important. Several indirect approaches are available to 
estimate the contribution of the thymus to naive T-cell recovery following stem cell trans-
plantation. Chest computer tomography may be used to estimate thymic volume. Several 
studies predominantly performed in HIV-infected patients under highly active antiretroviral 
therapy have shown a signi cant positive correlation between thymus volume and peripheral 
naive CD4+ T-cell numbers.52-54 Alternatively, naive T cells may be characterized by a distinct 
immunophenotype. Combined expression of CD45RA, CD62L and/or CD27 is generally 
accepted as de nition of the naive T-cell population in humans. Both measures however 
are associated with signi cant shortcomings. Parenchymal thymic tissue as identi ed by 
computer tomography may not necessarily be representative of true thymic tissue or output. 
Furthermore, immunophenotypic analysis is complicated by the longevity of naive T cells, 
which makes it impossible to phenotypically distinguish recently emigrated naive T cells from 
long-lived naive T cells in the periphery. In 1998, Douek and colleagues  rst reported the 
use of so-called T-cell receptor rearrangement excision circles (TRECs) as measure of thymic 
output in healthy and HIV-infected individuals.55 TRECs are extrachromosomal circular exci-
sion products formed during the T-cell receptor (TCR) gene rearrangement process. TRECs are 
stable, not duplicated during mitosis and therefore diluted out with each cellular division.56,57
At  rst sight de ning the optimal target TREC common to most recent thymic emigrants 
(RTEs) seems di  cult as a large variety in TRECs is produced during the TCR gene rearrange-
ment process due to the large combinatorial diversity of the TCR encoding gene segments. 
Moreover, TRECs produced during the early rearrangement steps are not suitable as these 
TRECs are already strongly diluted in the thymus before entering the periphery. However, 
functional rearrangement of TCR alpha (TCRA) gene segments  rst requires deletion of the 
TCR delta (TCRD) locus, which occurs late after the phase of thymocyte expansion and by 
preferentially using two TCRD deleting elements. In 1988, De Villartay and colleagues identi-
 ed δRec and ψJα as TCRD deleting elements  anking the TCRD locus, which preferentially 
recombine resulting in deletion of the TCRD locus (Figure 1).58 The signal joint TRECs (sjTRECs) 
produced in that rearrangement process are common to the majority of TCRαβ+ T cells and 
speci c to phenotypically naive T cells55,59 and might therefore be used as measure of thymic 
output and frequency of RTEs.
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An exponential decline in TREC-containing CD4+ and CD8+ T cells with age is apparent 
and indicative of an age-dependent decrease in thymic function although TREC-containing 
cells may be present in older individuals re ecting a sustained albeit lower output of RTEs 
from the thymus.55 Following autologous SCT, substantial numbers of TREC+ cells have been 
detected even in elderly patients suggesting that the adult thymus may indeed still con-
tribute to posttransplant T-cell reconstitution.60 Weinberg et al studied thymic function in 
seventy-six adult recipients of unmanipulated allo-SCT during 12-24 months posttransplant 
and showed thymic activity as measured by a posttransplant increase of peripheral blood 
CD4+ and CD8+ TREC levels which appeared critically a ected by a history or presence of 
GVHD and age.61 Lewin et al reported their  ndings in recipients of T-cell-depleted allo-SCT 
and showed comparable results. Moreover, low TREC levels appeared to be associated with 
an increased incidence of opportunistic infections.62
Improvement of thymopoiesis following allogeneic stem cell transplantation
Improvement of thymopoiesis following allo-SCT has become subject of interest as the 
thymus has proven to be essential for naive CD4+ T-cell recovery, which is necessary for a 
complete and durable immune reconstitution. Strategies to improve posttransplant thymic 
function may include approaches to protect or amplify the nursing stromal cell compart-
ment, which may be accomplished by administration of keratinocyte growth factor (KGF) or 
growth hormone (GH). In preclinical murine transplantation models, KGF-treated transplant 
recipients showed enhanced thymopoiesis and increased numbers of functional peripheral 
T cells.63 Prospective analysis of a small cohort of HIV-infected individuals showed increased 
thymic mass and a concomitant increase in circulating naive CD4+CD45RA+CD62L+ T cells 
following GH treatment.64 Alternatively, cytokines may directly a ect thymopoiesis by stimu-
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Figure 1. Signal joint TREC.
Schematic representation of the TCRD locus  anked by the TCRA locus. Recombination of the two TCRD deleting elements δRec and ψJα 
results in deletion of the TCRD locus and subsequent production of a single TREC with a unique signal joint sequence.
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lating the process of proliferation and di erentiation of bone marrow-derived lymphocyte 
precursors towards naive T lymphocytes. Among the cytokines directly a ecting thymopoi-
esis is interleukin-7 (IL-7), a non-redundant cytokine for T-cell development in men and T- and 
B lymphopoiesis in mice.65-67
IL-7: basic principles
IL-7, formerly known as lymphopoietin-1 (LP-1), was  rst identi ed as growth factor of B-cell 
precursors in mice. Cloning of murine IL-7 was reported in 1988 and soon thereafter a highly 
homologous cDNA clone was found in humans.68-70 The human IL-7 gene is located on chro-
mosome 8 and represents a single chain glycoprotein of 25kDa, which is mainly produced by 
stromal and epithelial cells in various locations including bone marrow, thymus, intestine and 
skin.71-74 Human IL-7 shows 60% sequence homology to murine IL-7 at the protein level and 
has activity in murine cells. IL-7 interacts with a complex of the IL-7 receptor alpha (IL-7Rα) 
chain (shared with thymic stromal-derived lymphopoietin (TSLP)) and the common cytokine 
gamma (γc) chain (shared with IL-2, IL-4, IL-9, IL-15 and IL-21 and expressed ubiquitously on 
lymphoid cells), which are both required for signalling en subsequent biological e ects of 
IL-7.75,76 Mice de cient in IL-7 or IL-7Rα and mice treated with neutralizing anti-IL-7 antibodies 
display severely impaired B- and T-cell development.68 In humans, defects in the IL-7 system 
result in severe combined immunode ciency (SCID) syndromes including a complete γc 
de ciency characterized by absence of T- and NK cells and IL7Rα de ciency characterized by 
absence of T cells only.65,77
IL-7 and B lymphocytes
IL-7 was  rst described as a B-cell growth factor in mice and has a role in survival, di erentiation 
and proliferation of B-cell precursors whereas mature B cells are IL-7 unresponsive. Consistent 
with its role in B-cell development, IL-7-/- mice show a developmental arrest at early stages of 
B-cell development in the transition of pro-B to pre-B cells and reduced numbers of mature 
B cells.67 IL-7Rα-/- mice have a block at an even earlier stage of B-cell development, namely in 
the transition of pre-pro B to pro-B cell suggesting involvement of TSLP.66 Additionally, IL-7 
is required for the rearrangement of VH segments resulting in impaired Ig rearrangement 
in IL-7Rα-/- mice.78 Although in vitro e ects of IL-7 on human B-cell precursors have been 
described, IL-7 is not essential for B-cell development in man as demonstrated by normal 
B-cell lymphopoiesis in SCID patients with an IL-7Rα or γc de ciency.65,77
IL-7 and T lymphocytes
IL-7 has an important role at various stages of T-cell development from T-cell precursors in 
the thymus to mature T cells in the periphery.
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Thymopoiesis
T-cell development in the thymus proceeds through a complex series of stages in di erent 
anatomic structures of the thymus (Figure 2).79 The  rst stage is represented by di erentiation 
of CD3-CD4-CD8- triple negative (TN) immature thymocytes, which occurs in the subcapsular 
zone of the thymus and contains four cell populations that may be discriminated on the basis 
of CD25 and CD44 expression. After loss of both CD25 and CD44 expression, thymocytes 
attain the double positive (DP) CD4+CD8+ phenotype and migrate to the cortex where they 
encounter cortical epithelial cells, macrophages and dendritic cells, which are important for 
positive and negative selection. After negative selection in the cortico-medullary junction of 
the thymus, thymocytes migrate to the medulla and attain their  nal single positive (SP) CD4+
or CD8+ phenotype. IL-7Rα is expressed at all developmental stages in the thymus except for 
DP thymocytes, which show decreased IL-7Rα expression. After re-expression at the SP stage, 
IL7Rα is maintained throughout the life of the T cell.
IL-7 primarily acts as a survival factor for developing thymocytes in the TN stage through 
modulation of apoptosis by alterations in apoptosis-related molecules including Bcl-2 
and Bax.80,81 Additionally, along with other growth factors including stem cell factor (SCF), 
IL-7 may contribute to expansion of the pre-T-cell pool. Both maintenance of survival and 
proliferation result in a substantial enlargement of the pre-T-cell pool which is necessary, as 
most of these precursors are lost to apoptosis in the DP stage during positive and negative 
selection. In IL-7-/- mice, thymic cellularity is decreased 20-fold due to inhibition of transition 
of CD44+CD25+ to CD44-CD25+ cells resulting in a relative accumulation of TN thymocytes.82
CD4+CD8+ DP T cells and their CD4+CD8- and CD4-CD8+ SP progeny, however, display normal 
proportions. Although IL-7Rα-mediated signalling may be important for rearrangement of 
the γ locus, involvement of IL-7 in rearrangement of the other TCR loci is less well established. 
Presence of TCRαβ T cells in IL-7-/- mice, albeit at a lower level, might even argue against a 
role of IL-7 in TCRA and TCR beta (TCRB) gene rearrangements. Nevertheless, TCRγδ T cells are 
completely absent in IL-7-/- and IL-7Rα-/- mice.83,84 Summarizing, IL-7 primarily has a trophic 
function during thymopoiesis by a ecting survival and proliferation of developing T cells. 
IL-7RĮ IL-7RĮ 
  HSC   CLP  T1  T2  T3  T4 DP SP SP 
bone marrow thymus periphery
subcapsular zone medulla cortex 
 CD44+
 CD25-
 CD44-
 CD25+
 CD44-
 CD25-
 CD44+
 CD25+
 CD4+
 CD8+
 CD4+
  or 
 CD8+
 CD4+
  or 
 CD8+
Figure 2. Schematic representation of T-cell development.
Abbreviations: HSC, hematopoietic stem cell; CLP, common lymphoid progenitor; T1-T4, triple negative CD3-CD4-CD8- thymocytes; DP, double 
positive; SP, single positive; IL-7Rα, alpha chain interleukin-7 receptor.
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In addition, IL-7 may have a mechanistic function especially by a ecting di erentiation of 
TCRγδ T cells.
Mature T lymphocytes
Although IL-7 is best known for its function during B- and T-cell development, various e ects 
on mature T-cell function have been described including proliferative and anti-apoptotic 
e ects, induction of Th1 immune responses and enhancement of lytic activity.85 Moreover, 
IL-7 has been identi ed as key regulator of T-cell homeostasis characterized by a dramatic 
expansion of adoptively transferred naive T cells in a lymphopenic host.86 Peripheral ho-
meostatic expansion may be driven by high a  nity or cognate antigens resulting in greatly 
exaggerated T-cell expansion in T-cell-depleted hosts vs. T-cell-replete hosts. In addition, 
T-cell-depleted hosts may expand T cells in response to low a  nity antigens including self-
peptides. Contribution of so-called low a  nity T cells, in particular, critically depends upon 
IL-7. Apart from homeostatic T-cell expansion in T-cell-depleted hosts, IL-7 may contribute to 
postthymic homeostatic cycling of RTEs and provide important survival signals for the naive 
T-cell pool in hosts with normal T-cell numbers.86
IL-7 and hematopoietic stem cell transplantation
Several studies using experimental animal models have assessed the e ects of IL-7 admin-
istration following stem cell transplantation. Reports concerning cyclophosphamide- and 
irradiation-induced lymphopenia had already shown enhanced thymic-dependent lympho-
cyte recovery.87,88 Bolotin et al studied posttransplant immune reconstitution in recombinant 
human (rh) IL-7-treated mice following syngeneic bone marrow transplantation (BMT).89
Two weeks of rhIL-7 treatment resulted in enhanced T-lymphocyte reconstitution including 
normalization of thymic cellularity and thymic subsets. Comparable results were obtained 
by Abdul-Hai et al.90 IL-7 and its e ect on mature T-cell populations following BMT were 
 rst appreciated by Mackall et al.91 Exogenous rhIL-7 administration resulted in a dramatic 
antigen-driven expansion of peripheral mature T cells both in thymectomized and thymus-
bearing recipients of syngeneic T-cell-replete BMT. The e ects of IL-7 on mature T cells raise 
the possibility that IL-7 might result in increased alloreactivity if used in allo-SCT. So far, 
reports con ned to GVHD have yielded con icting results demonstrating either no e ect on 
or an enhancement of the development of GVHD in IL-7-treated recipients of allo-SCT.92,93
Aims and outline of the thesis
Allo-SCT is associated with serious posttransplant infectious morbidity and mortality due to 
impaired posttransplant immune reconstitution in general and delayed naive CD4+ T-cell re-
covery in particular. IL-7 has been identi ed as non-redundant cytokine for T-cell lymphopoi-
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esis and key regulator of peripheral homeostatic T-cell expansion. Preclinical evaluation of 
posttransplant administration of IL-7 has shown e ects both on thymic T-cell development 
and peripheral T-cell expansion. Considerable controversy exists with respect to IL-7 and 
its e ect on alloreactivity. The work described in this thesis aims to further clarify the im-
munorestorative capacities of posttransplant IL-7 administration and its role in alloreactivity 
using experimental murine transplantation models. The experimental work is preceded by 
a retrospective study of the incidence of opportunistic infections in our own population of 
allogeneic HLA-identical T-cell-depleted (TCD) transplant recipients as described in Chapter 
2. We focused on day 30 to day 365 infections, as postengraftment infections in particular are 
associated with increased non-relapse mortality. Furthermore, as unmanipulated peripheral 
blood progenitor cell transplantation is associated with faster hematopoietic recovery and 
subsequent fewer infections, incidence and outcome of postengraftment infections were 
compared between recipients of bone marrow vs. recipients of peripheral blood progenitor 
cells. Chapter 3 marks the start of the experimental work with the development of a sensitive 
and speci c real-time quantitative PCR assay to assess thymic output in mice via detection 
of sjTRECs in peripheral blood leukocytes. SjTREC levels declined in aging and thymecto-
mized mice and showed remarkable and signi cant mouse strain-dependent di erences. 
In Chapter 4, quanti cation of these sjTRECs supplementary to adequate  ow cytometric 
analysis of various T-cell subsets were used to study the e ect of exogenous IL-7 on post-
transplant lymphocyte recovery using T-cell-de cient RAG-1-/- mice as recipients of congenic 
TCD- or T-cell-replete bone marrow grafts. As both thymic T-cell development and peripheral 
T-cell expansion may be a ected by exogenous IL-7, we asked the question whether IL-7 
would preferably promote thymopoiesis or rather expand RTEs or mature peripheral T cells 
following stem cell transplantation in the setting of compromised thymopoiesis. Peripheral 
expansion of T cells appeared to be the dominant e ect of posttransplant administration of 
IL-7, either of RTEs following TCD-BMT or of mature peripheral T cells following T-cell-replete 
BMT. Chapter 5 addresses the major concern of posttransplant IL-7 administration, which is 
its possible aggravating e ect on alloreactivity by enhancement of the alloantigen-reactive 
T-cell population. We applied IL-7 in an experimental stem cell transplantation model us-
ing RAG-1-/- mice supplied with congenic T cells to study the e ect of IL-7 administration on 
host-versus-graft reactivity following SCT across major and minor histocompatibility barriers. 
Posttransplant administration of IL-7 resulted in a reduced incidence of allograft rejection in 
recipients of minor antigen-mismatched bone marrow, which appeared to be associated with 
enhanced recovery of regulatory T cells. Finally, in Chapter 6, the observed immunorestor-
ative and tolerogenic e ects of IL-7 are discussed in more depth and within the perspective 
of current and future developments in immune reconstitution following hematopoietic stem 
cell transplantation.
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Abstract
Objective: Postengraftment infections are a major cause of transplant-related morbidity and 
mortality following allogeneic hematopoietic stem cell transplantation. Allogeneic periph-
eral blood progenitor cell transplantation (PBPCT) is associated with faster hematopoietic 
recovery compared to bone marrow transplantation (BMT) and unmanipulated PBPCT may 
be associated with fewer postengraftment infections. We set out to evaluate and compare the 
incidence, cause and outcome of infections following HLA-identical sibling T-cell-depleted 
PBPCT versus T-cell-depleted BMT between days 30 and 365 posttransplant. Patients: Forty 
recipients of peripheral blood progenitor cells (PBPC) and 47 recipients of bone marrow (BM) 
were included. The two groups of patients were comparable with respect to their baseline 
characteristics. Results: PBPC grafts contained signi cantly more CD34+ cells and PBPCT was 
associated with signi cantly faster neutrophil and lymphocyte recovery as compared to BMT. 
PBPC recipients experienced more chronic graft-versus-host disease (GVHD; 55% vs. 34%; P 
= 0.02). The number of de nite and clinical infections per 100 patient days was comparable 
between recipients of PBPC and BM with similar contribution of causative microorganisms. At 
one year post SCT, 68% of PBPC recipients had experienced at least one CTC grade 3-4 infec-
tion vs. 65% of BM recipients. Treatment-related mortality at one year from transplantation 
was 34% after PBPCT vs. 30% after BMT, and no di erence in infection-related mortality was 
observed. Conclusion: Postengraftment infectious morbidity and mortality were comparable 
between recipients of PBPC and BM despite a higher CD34+ cell content of PBPC grafts and 
faster lymphocyte recovery after PBPCT, which may in part be explained by the higher inci-
dence of chronic GVHD.
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Introduction
Recombinant granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood 
progenitor cells (PBPC) have currently been adopted as the preferred source of hematopoi-
etic stem cells for allogeneic transplantation.1,2 Transplantation of unmanipulated allogeneic 
PBPC (PBPCT) is associated with faster neutrophil and lymphocyte recovery as compared 
to bone marrow transplantation (BMT) resulting in fewer infections.3-6 Especially posten-
graftment infections cause substantial transplant-related morbidity and mortality and the 
occurrence of postengraftment infections has been described as the dominant independent 
factor associated with increased non-relapse mortality.7 We recently reported a randomized 
comparison of HLA-identical allogeneic PBPCT vs. BMT using CD34+ selection for partial 
T-cell depletion and showed signi cantly faster neutrophil recovery following PBPCT.8 In 
the present study we set out to evaluate whether T-cell-depleted (TCD) PBPCT may also be 
associated with faster lymphocyte recovery and if faster lymphocyte recovery might result 
in fewer postengraftment infections following PBPCT as compared to BMT. We show that 
TCD-PBPCT is associated with faster lymphocyte recovery. However, recipients of PBPC grafts 
do not experience fewer postengraftment infections as compared to recipients of TCD-bone 
marrow (BM), despite higher CD34+ cell numbers and faster lymphocyte recovery.
Patients and methods
Patients and donors
This retrospective study involved 87 consecutive adult patients who received a  rst HLA-
identical sibling partially TCD stem cell transplantation at the Erasmus University Medical 
Center/Daniel den Hoed Cancer Center in Rotterdam between December 1997 and April 2003. 
During this period 47 patients received progenitor cells from BM (between December 1997 
and April 2001) and 40 patients received PBPC (between December 1997 and April 2003). 
Patients were considered “standard risk” in case of a diagnosis of acute myeloid leukemia in 
 rst complete remission, acute lymphoblastic leukemia in  rst complete remission, chronic 
myeloid leukemia in  rst chronic phase, and untreated aplastic anemia. All other diagnoses 
were considered “high risk”. All donors were genotypically HLA-matched. The institutional re-
view board approved the protocols, and all patients and donors provided informed consent.
Bone marrow and peripheral blood harvest; T-cell depletion
BM and PBPC were harvested as described.8 T-cell depletion was performed either by selec-
tion of CD34+ cells or by sheep-erythrocyte rosetting. CD34+ cells were positively selected 
using an immunoadsorption biotin-avidin column (Ceprate SC system; CellPro, Bothell, WA, 
USA) or by immunomagnetic cell selection using the CliniMACS system (CliniMACS, Miltenyi 
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Biotec, Bergisch Gladbach, Germany). If the CD34+ selection procedure resulted in less than 1 
x 105 CD3+ T cells/kg, then the graft was supplemented to contain an intended minimum of 
1-2 x 105 CD3+ T cells/kg.
Conditioning regimen and supportive care
Conditioning therapy consisted of total-body irradiation, which was fractionated (2 x 6 Gy) 
with partial shielding of the lungs in combination with cyclophosphamide (2 x 60 mg/kg) 
or, alternatively, if patients had received irradiation before, busulfan (total dose: 16 mg/kg) 
followed by cyclophosphamide (total dose: 120 mg/kg). All patients received cyclosporin as 
additional graft-versus-host disease (GVHD) prophylaxis from day –3 until day 90 with gradual 
tapering of the drug thereafter. Patients were nursed in single rooms equipped with high-
e  ciency particulate air  ltration from admission until discharge. All patients received food 
with a low microbial count until discharge, and parenteral alimentation was given in case of 
severe mucositis. Patients received transfusions of irradiated red blood cells and platelets to 
maintain their hemoglobin above 80 g/L and platelets above 10 x 109/L. All patients received 
prophylactic cipro oxacin (500 mg orally twice daily) and prophylactic  uconazole (200 mg 
once daily) as infection prevention until neutrophil recovery. Trimethoprim-sulfamethoxazol 
(480 mg once daily) was administered for the prevention of infections with Pneumocystis 
carinii from neutrophil recovery (> 0.5 x 109/L) until at least 6 months after transplantation or 
prolonged in case of chronic GVHD. All patients received prophylactic acyclovir from trans-
plantation until cessation of cyclosporin.
GVHD
Acute GVHD was graded according to the Glucksberg criteria.9 Patients with grades 2-4 GVHD 
were treated with prednisone, 1 mg/kg of body weight twice daily for 10 days, which was 
then tapered according to clinical response. Grade 1 GVHD was treated with topical steroids. 
Chronic GVHD was treated with the combination of cyclosporine and prednisone according 
to clinical response.
Infections
As especially postengraftment infections are associated with treatment-related mortality7
and to facilitate a comparison with published data obtained in recipients of unmanipulated 
PBPCT,6 we focused on infections occurring between days 30 and 365 posttransplant. All 
infections diagnosed between day 30 and day 365 following transplantation were evaluated 
and scored by grade, localisation and causative microorganism of infection according to the 
NCI common toxicity criteria (CTC). CTC grade 1-2 infections were de ned as non-severe (mild 
to moderate) infections without need for admission and/or intravenous antimicrobial treat-
ment. CTC grade 3-4 infections were de ned as severe to life-threatening (CTC grade 4) infec-
tions with need for admission and intravenous treatment. A de nite infection was de ned 
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as an illness with signs and symptoms consistent with an infection and the microbiological 
documentation of a pathogen, including culture, histology and/or immunohistology. In cases 
of dermatomal Zoster, the clinical diagnosis was considered su  cient to classify the infection 
as de nite. Culture-documented bacteremia, viremia or fungemia were considered de nite 
infections even without signs or symptoms of an infection. Clinical infection was de ned as 
symptoms and signs consistent with an infection, but without microbiological proof. Fever 
of presumed infectious cause was included only if the patient’s body temperature was above 
38.5°C and the condition responded to antibiotic therapy within three days. A chronic infec-
tion was scored as a single infection. A recurrent infection was scored as multiple infections 
only if episodes were clearly separated by an asymptomatic period of longer than 4 weeks. 
A polymicrobial infection of one organ or several adjacent organs was considered as a single 
infection. Death associated with a de nite infection was de ned as  ndings consistent with 
an infection and detection of the pathogen in an autopsy specimen, or death after a de nite 
infection that was considered causative, either directly (e.g., pneumonia) or indirectly (e.g., 
sepsis with subsequent adult respiratory distress syndrome). Cytomegalovirus (CMV) reac-
tivation was de ned either as at least one immediate early antigen (IEA)-positive-staining 
leukocyte identi ed by histo-immunologic preparations or as a plasma CMV–DNA level 
exceeding 50 geq/mL. CMV reactivations characterized by ≥ 4 IEA-positive-staining leuko-
cytes or a CMV-DNA level exceeding 500 geq/mL were treated with ganciclovir (5 mg/kg) 
until two negative test results had been obtained. Epstein-Barr virus (EBV) reactivation was 
de ned as a plasma EBV-DNA level exceeding 50 geq/mL. Test results below the 50 geq/mL 
were considered negative. EBV reactivations exceeding 1000 geq/mL were treated with a 
single infusion of rituximab (375 mg/m2) with intensi ed molecular monitoring thereafter.10,11
Recurrent reactivations were de ned by a positive IEA staining or polymerase chain reaction 
(PCR) after (at least) 2 consecutive negative test results following a preceding episode of 
reactivation.
Immune monitoring
In a subset of patients, absolute numbers of peripheral blood CD4+ and CD8+ T lymphocytes 
were determined by a four-color single-platform  ow cytometric assay using a “dual-anchor” 
gating strategy.12,13 By inclusion of a calibrated number of  uorescent beads (TruCOUNT 
tubes; BD Biosciences, San Jose, CA) in a lyse-no-wash technique, the assay allows for direct 
calculation of absolute numbers of labeled cells per microliter of blood according to the ratio 
between beads and labeled cells. The monoclonal antibodies (mAbs) used for  ow cytomet-
ric analysis were  uorescein isothiocyanate (FITC)-labeled CD3, phycoerythrin (PE)-labeled 
CD8, peridinyl cholorophyllin (PerCP)-labeled CD45, and allophycocyanin (APC)-labeled 
CD4 (MultiTEST cocktail, BD Biosciences). Flow cytometric analysis was performed using a 
FACSCalibur (BD Biosciences). List mode data were collected and analyzed using CELLQuest 
software (BD Biosciences).
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Statistical analysis
Patient characteristics were compared between BM recipients and PBPC recipients using 
Fisher’s exact test or Pearson’s chi-squared test in case of discrete variables, whichever appro-
priate, or the Wilcoxon rank-sum test in case of continuous variables. Endpoints of the study 
included hematological recovery, acute GVHD grades 2-4, chronic GVHD (limited + extensive 
as well as extensive alone), infections of CTC grade 3 to 4, or grade 4 alone, overall survival 
(OS) and treatment-related mortality (TRM). Time to hematological recovery (neutrophils > 
0.5 × 109/L and platelets > 50 × 109/L) was measured from the date of transplantation; the 
few patients who died without hematological recovery were censored at the date of death. 
Time to acute GVHD grades 2-4 was calculated from transplantation until occurrence of acute 
GVHD (by de nition until day 100). The two patients who died before day 100 posttransplant 
without having su ered from acute GVHD were censored at the date of death. Time to chronic 
GVHD was only calculated for patients who survived at least 100 days after transplantation. 
Death without having su ered from chronic GVHD was considered a competing risk. Patients 
without having su ered from chronic GVHD and still alive at the date of last contact were then 
censored. Infections of CTC grade 3-4, or grade 4 alone, that occurred between day 30 and 
day 365 posttransplant were taken into account. Relapse before, or death without such infec-
tions, were considered competing risks. OS was calculated from the date of transplantation 
until death. Patients still alive at the date of last contact were then censored. Causes of death 
were classi ed as TRM or relapse-related mortality, and these were considered competing 
risks. All time-to-event end points were calculated using the actuarial method of Kaplan and 
Meier taking into account the competing risks if applicable, and Kaplan-Meier curves were 
generated to illustrate the di erence between BM and PBPC recipients. The log-rank test was 
used to compare the time-to-event end points between BM and PBPC recipients. Patients 
who were considered a failure due to the competing risks were censored. All reported P-
values are two-sided, and a signi cance level α = 0.05 was used.
Results
Characteristics of patients
The characteristics of all 87 patients are detailed in Table 1. The median ages of BM and PBPC 
recipients were 43 and 42 years respectively (P = 0.6). Fifty- ve percent of BM recipients were 
male as compared to 60% of PBPC recipients (P = 0.7). The distribution of the diagnostic 
categories at transplantation was comparable between the two groups of patients. Fifty- ve 
percent of BM recipients and 63% of PBPC recipients were classi ed as high-risk patients 
according to disease status (P = 0.5). The conditioning regimens did not di er between the 
two groups. Two PBPC recipients received additional antithymocyte globulin as part of the 
conditioning regimen. The marrow graft was depleted of T cells either by positive selection 
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of CD34+ cells or by sheep-erythrocyte rosetting of T cells. The number of patients being CMV 
and/or EBV seropositive was not signi cantly di erent between the two groups.
Graft characteristics
BM and PBPC were collected and T-cell depletion was performed either by CD34+ selection 
or E-rosetting. PBPC grafts contained signi cantly higher numbers of CFU-GM (median: 49.4 
× 104/kg, range: 13.4-187) as compared to 18.6 × 104/kg (range: 3.9-120) in BM grafts (P < 
0.0001). Likewise, PBPC grafts contained signi cantly more CD34+ cells. The median numbers 
of CD34+ cells infused were 4.54 × 106/kg (range: 0.91-11.1) for recipients of PBPC vs. 1.32 × 
106/kg (range: 0.51-8.76) for BM recipients (P < 0.0001). The median number of infused CD3+ T 
cells was not signi cantly di erent between the two groups of patients. BM grafts contained 
2.0 x 105/kg CD3+ T cells (range: 0.03-5.37) vs. 1.0 x 105/kg CD3+ T cells (range: 0.02-4.90) in 
PBPC grafts (P = 0.09).
Engraftment
The median time to neutrophil recovery (> 0.5 x 109/L) was 18 days and 15 days in recipients of 
BM and PBPC respectively (P < 0.001). By day 28 after transplantation, all PBPC recipients had 
recovered their neutrophil count while 13% of BM recipients had neutrophil numbers below 
Table 1. Patient characteristics
BMT (n = 47) PBPCT (n = 40) P-value
Age (median, range) 43 (16-56) 42 (18-55) 0.6
Sex (male/female) 26/21 24/16 0.7
Diagnosis
Leukemia 26 19
Lymphoma 9 11
MDS 1 2
AA 1 1
MM 10 6
Other - 1
Risk status (standard/high) 21/26 15/25 0.5
Conditioning regimen
Cy/TBI 45 39
Cy/Bu 2 1
T-cell depletion
CD34 selection 26 40
E-rosetting 21 -
CMV serology (negative/positive) 23/24 17/22 0.6
EBV serology (negative/positive) 3/44 4/36 0.5
Abbreviations: BMT, bone marrow transplantation; PBPCT, peripheral blood progenitor cell transplantation; AA, aplastic anemia; MDS, 
myelodysplastic syndrome; MM, multiple myeloma; TBI, total body irradiation; Cy, cyclophosphamide; Bu, busulfan; CMV, cytomegalovirus; EBV, 
Epstein-Barr virus.
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0.5 x 109/L. Postengraftment infections were monitored as from day 30. By day 30, 94% of all 
patients had e ectively recovered their neutrophil count and by day 39 after transplantation 
all patients had recovered neutrophils. As for the neutrophils, platelet recovery (> 50 x 109/L) 
progressed signi cantly faster in PBPC recipients (P = 0.03; data not shown). In addition to 
neutrophil and platelet recovery, absolute numbers of CD4+ and CD8+ T lymphocytes were 
assessed. Both CD4+ and CD8+ T-cell recovery were faster following PBPCT. Although the CD4+
T-cell recovery was slow in both groups of patients, PBPC recipients had recovered their CD4+
T cells to a median level of 200 CD4+ T cells/μL at day 180 post SCT whereas BM recipients 
were still below that critical value at day 180 (P = 0.02; Figure 1A). Comparable to the CD4+ T 
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Figure 1. Boxplots of the recovery of CD4+ T lymphocytes (A) and CD8+ T lymphocytes (B) in time in recipients of BM (n = 20; open bars) vs. 
PBPC (n = 20; dotted bars). Each box shows the median, quartiles and extreme values. Outliers are represented by  and –.
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cells, initial CD8+ T-cell recovery was slow in all patients. Nevertheless, CD8+ T-cell numbers 
were clearly higher in PBPC recipients (median: 745 cells/µL) as compared to BM recipients 
(median: 216 cells/μL) at day 180 posttransplantation (P = 0.004; Figure 1B).
GVHD
Recipients of marrow and recipients of PBPC were not signi cantly di erent with respect to 
the incidence of acute GVHD grade 2-4. At day 100 after transplantation, 45% of BM recipi-
ents had developed grades 2-4 GVHD vs. 55% of PBPC recipients. Recipients of PBPC grafts 
experienced more chronic GVHD. At one year after transplantation, 34% of BM recipients had 
experienced limited or extensive chronic GVHD as compared to 55% of PBPC recipients (P = 
0.02; Figure 2). No signi cant di erence was observed in the occurrence of extensive chronic 
GVHD in the two groups of patients (23% vs. 36% at one year posttransplant; P = 0.08).
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Figure 2. Kaplan-Meier curve of time from transplantation to chronic GVHD (limited + extensive) by source of stem cells. Death without having 
su ered from chronic GVHD was considered a competing risk.
Infections
The total number of infections per 100 patient days was comparable between recipients 
of BM and PBPC. No di erences were observed in the incidence of infections over time 
independent of stem cell source (data not shown). Additionally, no signi cant di erences 
were observed in the distribution of the four infectious toxicity grades (Table 2). At one year 
following transplantation, 65% of BM recipients had experienced at least one severe grade 
3 or 4 infection from day 30 onward compared to 68% of PBPC recipients (P = 0.93; Figure 
3A). Also, no signi cant di erence was observed in CTC grade 4 infections alone between the 
two groups (P = 0.91; Figure 3B). One or multiple causative microorganisms were identi ed 
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in 63% and 60% of reported infections following BMT and PBPCT, respectively. Results are 
shown in Table 3. Viruses were the most important infectious agents both in BM and PBPC 
recipients, followed by bacteria and fungi. Members of the herpesviridae family including 
herpes simplex virus, varicella zoster virus, CMV and EBV were most frequently involved in 
viral infections. All CMV infections presented as reactivations without subsequent CMV dis-
ease. Fifteen episodes of EBV reactivation were treated successfully with rituximab without 
progression to lymphoproliferative disease (LPD). Four recipients of BM developed overt 
EBV-LPD without preceding pre-emptive therapy and were treated with donor lymphocyte 
infusion and/or rituximab. Bacteria were involved in 29% of de nite infections with an 
equal contribution of gram-positive vs. gram-negative pathogens and culture-documented 
bacteremia and pneumonia as predominant clinical presentations both following BMT and 
PBPCT. Fungi represented 17% of de nite infections. Aspergillus species were involved in 12 
out of 23 fungal infections. Aspergillus pneumonia was reported in 8 BM recipients and 4 
PBPC recipients causing 50% mortality in both groups of patients. Death between day 30 and 
365 following transplantation associated with a de nite infection diagnosed between day 
30 and day 365 occurred in 9 BM recipients and 7 PBPC recipients. GVHD was considered a 
contributing factor in 7 out of 9 and 3 out of 7 deaths respectively (Table 4).
Treatment-related mortality, relapse mortality and overall survival
After a median follow-up period of 26 months, 23 BM recipients had died as compared to 21 
PBPC recipients. TRM at one year following transplantation was 30% versus 34% in recipients 
of BM and PBPC respectively. Infection-related mortality was not signi cantly di erent be-
tween the two groups of patients. Also, no di erence in relapse-related mortality could be 
observed between the two groups of patients (Table 5).
Table 2. Infection rates between day 30 and day 365 post SCT *
BMT (n = 47) PBPCT (n = 40) ratio BM/PB P-value
Total infections 1.09 1.03 1.06 0.7
de nite infections 0.69 0.62 1.11 0.5
clinical infections 0.41 0.42 0.97 0.9
CTC
grade 1 0.04 0.07 0.61 0.4
grade 2 0.38 0.29 1.31 0.3
grade 3 0.53 0.55 0.96 0.8
grade 4 0.14 0.13 1.13 0.8
Abbreviations: SCT, stem cell transplantation; BMT, bone marrow transplantation; PBPCT, peripheral blood progenitor cell transplantation; BM, 
bone marrow; PB, peripheral blood; CTC, common toxicity criteria.
*Number of infections/100 patient days: number of infections in all recipients of bone marrow or peripheral blood progenitor cells divided by the 
number of days at risk and multiplied by 100. The number of days at risk (day 30 through day 365, or the day of death or relapse if before day 
365) was 11800 for recipients of bone marrow and 8607 for recipients of peripheral blood progenitor cells.
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Discussion
Peripheral blood progenitor cells have become a preferred source of hematopoietic stem 
cells for allogeneic stem cell transplantation.1,2 Unmanipulated PBPCT is associated with 
faster neutrophil and lymphocyte recovery, which may result in reduced infectious morbidity 
and mortality.3-6 As TCD-PBPCT may also be associated with faster hematopoietic recovery, 
we set out to evaluate and compare the cumulative incidence, characteristics and outcome 
of infections following HLA-identical sibling TCD-PBPCT in comparison to TCD-BMT in the 
postengraftment period from day 30 to day 365 following transplantation. Results of the 
Cu
m
ula
tiv
e 
pe
rc
en
ta
ge
 
0 3 6 9 12
0
25
50
75
100
BM
PB
Logrank P=.93
BM 47 31
PB 40 28
N I
months
At risk:
BM 47
PB 40
23 14 13
7
13
427 11
A
Cu
m
ula
tiv
e 
pe
rc
en
ta
ge
 
0 3 6 9 12
0
25
50
75
100
BM
PB
Logrank P=.91
BM 47 14
PB 40 10
N I
months
At risk:
BM 47
PB 40
42 35 26 22
35 22 16 12
B
Figure 3. Kaplan-Meier curve of time to a  rst severe CTC grade 3-4 infection (A) or a  rst life-threatening CTC grade 4 infection alone (B) by 
stem cell source. Relapse before, or death without an infection of grade 3-4 or grade 4 alone, were considered competing risks.
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present study indicate that TCD-PBPCT is associated with faster neutrophil and lymphocyte 
recovery. However, the faster lymphocyte recovery appears not be associated with fewer 
postengraftment infections following TCD-PBPCT. The higher incidence of chronic GVHD as 
observed in PBPC recipients may possibly blunt the favorable e ect of better hematopoietic 
recovery by putting the patients at an increased risk of opportunistic infections.
Infection rates in both BM and PBPC recipients were higher as compared to reported 
numbers following unmanipulated stem cell transplantation.6 Storek et al reported 0.88 
infections/100 patient days in BM recipients compared to 1.09 in our study and 0.62 
Table 3. De nite infections occurring between day 30 and day 365 post SCT
Contributing pathogen BMT (n = 47) PBPCT (n = 40)
Virus 54 32
herpes simplex virus 10 3
varicella zoster virus 11 4
cytomegalovirus 12 10
Epstein-Barr virus 11 8
human herpes virus 6 - 1
respiratory virus 7 5
rotavirus 2 1
astrovirus 1 -
Bacteria 20 19
gram-positive 11 10
bacteremia 5 7
pneumonia 2 2
colitis - 1
otitis 1 -
urinary system infection 1 -
CNS infection 1 -
mucocutaneous infection 1 -
gram-negative 9 9
bacteremia 3 1
pneumonia 3 8
urinary system infection 2 -
mucocutaneous infection 1 -
Fungus 13 10
Aspergillus pneumonia 8 4
Candida
oropharyngeal infection 4 4
mucocutaneous infection - 1
urinary system infection - 1
Other 1 -
Abbreviations: SCT, stem cell transplantation; BMT, bone marrow transplantation; PBPCT, peripheral blood progenitor cell transplantation; CNS, 
central nervous system.
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infections/100 patient days in PBPC recipients opposed to 1.03 in our study. The distribu-
tion of causative pathogens was similar. Manipulation of the stem cell graft is the most likely 
Table 4. Mortality between day 30 and day 365 post SCT associated with a de nite infection diagnosed between day 30 and day 365
Type of transplantation/infection Contributing 
factors
BMT
EBV-LPD none
EBV-LPD cGVHD
Sepsis due to Enterococcus faecalis aGVHD
Sepsis due to Klebsiella pneumoniae cGVHD
Aspergillus fumigatus and VZV pneumonia cGVHD
Pneumonia due to Aspergillus and Candida species and In uenza A cGVHD
RSV pneumonia none
Pseudomonas aeruginosa and Aspergillus fumigatus pneumonia cGVHD
Pneumonia due to Aspergillus fumigatus and Stenotrophomonas maltophilia cGVHD
PBPCT
Pneumonia due to Stenotrophomonas maltophilia and Enterobacter cloacae ARDS
Pseudomonas aeruginosa pneumonia none
Enterobacter cloacae pneumonia cGVHD, BOOP
Pneumonia due to RSV and Nocardia cGVHD
Pneumonia due to Pseudomonas aeruginosa, Aspergillus fumigatus, and HHV 6 leading to  brosing 
alveolitis and ARDS
cGVHD
Pneumonia due to Candida species BOOP
Pneumonia due to Aspergillus species and Pseudomonas aeruginosa none
Abbreviations: SCT, stem cell transplantation; BMT, bone marrow transplantation; PBPCT, peripheral blood progenitor cell transplantation; 
EBV-LPD, Epstein-Barr virus lymphoproliferative disease; VZV, varicella zoster virus; RSV, respiratory syncytial virus; HHV6, human herpes virus 6; 
aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; ARDS, adult respiratory distress syndrome; BOOP, bronchiolitis 
obliterans organizing pneumonia.
Table 5. Cause of death
BMT (n = 47) PBPCT (n = 40)
Relapse mortality 8 7
Treatment-related mortality 15 14
Infection 10 9
infection + GVHD 8 4
infection – GVHD 2 5
GVHD 1 1
BOOP 2 -
VOD - 2
HUS - 1
Other 2 1
Abbreviations: BMT, bone marrow transplantation; PBPCT, peripheral blood progenitor cell transplantation GVHD, graft-versus-host disease; 
BOOP, bronchiolitis obliterans organizing pneumonia; VOD, venoocclusive disease; HUS, hemolytic uremic syndrome.
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explanation for the higher number of infections reported in our patients. T-cell depletion 
may exacerbate posttransplant immunode ciency, especially in adults with impaired thymic 
function.14,15 The rate of recovery of CD4+ T cells in particular has been shown to correlate with 
the risk of developing opportunistic infections.16,17 In addition, di erences in prophylactic 
antimicrobial regimens between the two studies might have contributed to the observed 
di erence. Moreover, the more intensive follow-up regimen applied in our group of patients 
might also, in part, account for a relatively high incidence of infections.
PBPCT was not associated with fewer infections despite faster hematopoietic recovery. The 
incidence of chronic GVHD was signi cantly higher in recipients of PBPC. Chronic GVHD is a 
well-known major risk factor for developing infections in the later time period following stem 
cell transplantation.18 Both GVHD per se and the immunosuppressive drugs used for its treat-
ment delay the recovery of the immune system. Patients with ongoing chronic GVHD only 
marginally reconstitute their naive T-cell compartment as indicated by very low numbers of 
T-cell receptor rearrangement excision circles (TRECs), suggesting adverse e ects on thymic 
output.19,20 Therefore, more e ective prevention of GVHD and improvement of thymopoiesis 
should be aimed for in the prevention of opportunistic infections in the later time period 
after allogeneic PBPCT.
In our study, viruses were most frequently documented as causative infectious agents, fol-
lowed by bacteria and fungi. CMV, responsible for 22 reactivations, was successfully treated 
by pre-emptive intravenous therapy with ganciclovir as none of the reactivations were fol-
lowed by CMV disease. Pre-emptive therapy with CD20 monoclonal antibody (rituximab) in 
patients developing EBV reactivations exceeding 1000 geq/mL has proven to be e ective 
in reducing EBV-LPD incidence and abrogating EBV-LPD mortality.10,11 Indeed all 15 EBV 
reactivations exceeding 1000 geq/mL were treated successfully without development of 
LPD. Bacteria were documented in 29% of all de nite infections with equal contribution of 
gram-positive and gram-negative pathogens. Although no Pneumocystis carinii pneumonia 
was observed in our group of patients, several infections due to encapsulated bacteria were 
reported. Fungi were involved in a minority of de nite infections. Aspergillus species, how-
ever, were involved in 50% of fatal pneumonias diagnosed between day 30 and day 365 post 
transplantation. Although neutropenia has been considered as the primary risk factor for 
invasive aspergillosis, susceptibility to aspergillosis after engraftment may be increased by 
factors in uencing T-lymphocyte immune responses as T-cell depletion of the stem cell graft, 
GVHD and immunosuppressive therapy.21-24 Extension of prophylactic therapy through the 
intermediate and late postengraftment period might be useful in reducing the incidence of 
invasive fungal infections, especially in patients with chronic GVHD.
In conclusion, although TCD-PBPCT was associated with faster lymphocyte recovery as 
compared to TCD-BMT, no reduction in postengraftment infectious morbidity and mortal-
ity was observed. Most likely, the higher incidence of chronic GVHD associated with PBPCT 
accounts for the lack of a protective e ect. These results indicate that a procedure of partial 
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T-cell depletion leaving 1-2 x 105 T cells/kg in the PBPC graft does not su  ciently prevent 
GVHD and its complications in HLA-identical transplantations using sibling donors. A more 
stringent depletion of T cells might be preferred in patients at high risk of GVHD. Patients at 
lower risk of GVHD might bene t from the conventional approach based on unmanipulated 
stem cell transplantation and posttransplant prophylaxis using a combination of immuno-
suppressive drugs, which e ectively prevents GVHD while graft-versus-leukemia activity and 
immune reconstitution may be preserved.
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Abstract
Objective: Thymic output of newly developed αβ T cells in humans can be measured via 
signal joint T-cell receptor rearrangement excision circles (sjTRECs). Deletion of the TCRD
locus via δRec to ψJα recombination during TCRA rearrangement results in the production 
of such sjTRECs. The deleting elements δRec and ψJα are highly conserved between humans 
and mice and used in a comparable manner. We developed and evaluated a real-time quan-
titative PCR (RQ-PCR) to detect and quantify δRec-ψJα sjTRECs in murine peripheral blood 
leukocytes for estimation of thymic output of newly developed αβ T cells in mice. Methods: 
The threshold cycle (Ct) of the sjTREC RQ-PCR was related to the Ct value of an endogenous 
reference gene. The di erence in Ct value (∆Ct) was correlated to the absolute numbers of 
CD45+ and CD3+cells per μL of blood, as obtained by a single-platform  ow cytometric assay, 
resulting in the frequency of sjTRECs in CD45+ and CD3+ cells. Results: The RQ-PCR proved 
to be sensitive with a detection level of approximately one sjTREC copy in 100 ng of DNA. 
SjTRECs could not be detected in peripheral blood leukocytes of RAG-1-/- mice, demonstrat-
ing the speci city of the assay. As in humans and primates, sjTREC levels declined in aging 
and thymectomized mice. Remarkably, signi cant mouse strain-dependent di erences in 
sjTREC levels were observed. 129Sv and C57BL/6 mice had signi cantly lower sjTREC levels in 
blood than Balb/c and DBA2 mice. Conclusion: Quanti cation of murine sjTRECs by RQ-PCR 
may allow for accurate assessment of thymic output in mice.
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Introduction
Quanti cation of newly developed T cells is hampered by lack of phenotypic markers able 
to identify cells that have recently left the thymus (recent thymic emigrants: RTEs). During 
rearrangement of the gene segments encoding the T-cell receptor (TCR), certain chromo-
somal sequences are excised to produce episomal DNA by-products, called T-cell receptor 
rearrangement excision circles (TRECs).1,2 TRECs are stable, not duplicated during mitosis, and 
diluted out with each cellular division.3-5 TRECs have therefore been proposed as markers for 
RTEs.6
The gene segments encoding the TCR delta (TCRD) protein chain reside within the TCR 
alpha (TCRA) locus in humans and mice.7-9 Functional rearrangement of TCRA gene segments 
 rst requires deletion of the TCRD locus.3,5 Two elements (δRec and ψJα)  anking the TCRD
locus preferentially recombine, resulting in deletion of the TCRD locus during human and 
murine αβ T-cell development.9-12 The signal joint TREC (sjTREC) produced in this rearrange-
ment process is common to most human αβ T cells and can be used as a marker for RTEs in 
humans.5,12,13 Recent studies in humans have shown an accurate assessment of thymic output 
by quanti cation of sjTRECs.13-20
In this paper, we describe a real-time quantitative polymerase chain reaction (RQ-PCR) 
to quantify sjTRECs in peripheral blood leukocytes of mice. Our results demonstrate di er-
ences in sjTREC levels among various mouse strains, and reduction in sjTREC levels following 
thymectomy. Levels appeared to be dependent on age and on the presence of a functional 
recombination activation gene.
Materials and methods
Mice
Balb/c, DBA2, 129Sv, and C57BL/6 mice were purchased from Charles River Laboratories 
(Wilmington, MA, USA). RAG-1-/- mice were originally obtained from The Jackson Laboratory 
(Bar Harbor, ME, USA) and bred at the Experimental Animal Center, Erasmus University Medi-
cal Center, Rotterdam, The Netherlands. Mice were maintained under speci c pathogen-free 
conditions. All animal procedures were performed in accordance with protocols approved by 
the local Committee for Animal Experiments.
Thymectomy
At 6 weeks of age, C57BL/6 mice were anesthetized with midazolam 1.25 mg/mL (Dormicum; 
Roche, Basel, Switzerland), fentanyl 0.08 mg/mL, and  uanisone 2.5 mg/mL (Hypnorm; Jans-
sen Pharmaceutica, Beerse, Belgium) via intraperitoneal injection at a volume of 0.1–0.15 mL 
per mouse. Suction thymectomy was performed via the upper thoracic aperture, leaving the 
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sternum intact. Completeness of thymectomy was veri ed by visual inspection at autopsy. 
Age-matched sham-thymectomized C57BL/6 mice were used as controls.
Flow cytometric analysis
At serial time points blood was collected from the murine retroorbital plexus. Peripheral 
blood was analyzed by  ow cytometry for the CD45+, CD3+, and CD3+CD62L+ subsets using 
Cy-Chrome-labeled anti-CD45, FITC-labeled anti-CD3ε (BD Pharmingen, San Diego, CA, USA), 
and PE labeled anti-CD62L (Beckman Coulter, Fullerton, CA, USA). Flow cytometric analysis 
was performed using a FACScan (Becton-Dickinson, San Jose, CA, USA) or a FACSCalibur 
(Becton-Dickinson). Absolute numbers of CD45+ and CD3+ cell subsets were determined by a 
single-platform  ow cytometric assay.21 In this assay the inclusion of a calibrated number of 
 uorescent beads (Beckman Coulter) in a lyse-no-wash technique allows for direct calcula-
tion of absolute numbers of CD45+ and CD3+ cells according to the ratio between beads and 
labeled cells.
DNA isolation
One hundred μL of blood was used for every DNA isolation. After lysing of the erythrocytes 
(ammonium chloride lysing solution), cells were resuspended in 200 μL of phosphate-bu ered 
saline (PBS; Gibco, Paisley, UK). DNA was puri ed from the cells using the QIAamp DNA mini 
kit (Hilden, Germany) according to manufacturer’s instructions, resulting in an average yield 
of 19 ± 6 ng DNA per μL of blood.
Real-time quantitative PCR (RQ-PCR)
A 5′ nuclease-based RQ-PCR assay was developed using the ABI PRISM 7700 sequence detec-
tor (Applied Biosystems, Foster City, CA, USA), in which speci c ampli cation is measured 
as the increase in  uorescence due to degradation of a nonextendible dual-labeled internal 
probe. The PCR was performed in a 50-μL reaction containing 1.0 × TaqMan Bu er A (Applied 
Biosystems), 4 mM MgCl2, 250 μM dNTPs (Amersham Biosciences, Piscataway, NJ, USA), 1.25 
U AmpliTaq Gold (Applied Biosystems), 300 nM forward and reverse primers, 200 nM probe, 
and 5 μL of isolated DNA (representing 95 ng DNA on average). All reactions were performed 
in duplicate. PCR conditions were 95°C for 10 minutes followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute.
Sequences of the sjTREC primers and probe used for Balb/c, DBA2, and 129Sv mice were: 
forward primer 5′-CAAGCT GACAGG GCAGGTTT-3′, reverse primer 5′-TGAGCAT GGCAAGC-
AGTACC-3′, and probe FAM-5′-TGCTGTGTGCCCTACCCTGCCC-3′-TAMRA (Eurogentec, Seraing, 
Belgium). Sequences of the sjTREC primers and probe used for C57BL/6 mice were: forward 
primer 5′-CCAAGCTGACGGCAGGTTT-3′, reverse primer 5′-AGCATGGCAAGCAGCACC-3′, and 
probe FAM-5′-TGCTGTGTGCCCTGCCCTGCC-3′-TAMRA (Eurogentec). To compensate for varia-
tions in input DNA, we used the constant gene segment of the TCRA gene (Cα) as endogenous 
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reference gene. The sequences of the primers and probe were the following: forward primer 
5′-TGACTCCCAAATCAATGTG-3′, reverse primer 5′-GCAGGTGAAGCTTGTCTG-3′, and probe 
FAM-5′-TGCTGGACATGAAAGCTATGGA-3′-TAMRA (Applied Biosystems). These three primer 
combinations resulted in amplicons of 131, 128, and 136 base pairs respectively, without 
aspeci c background bands as visualized on an agarose gel. Primers and probes were de-
signed using the computer programs Primer Express (Applied Biosystems) and OLIGO 6 (W. 
Rychlik, Molecular Biology Insights, Cascade, CO, USA) according to published sequences of 
the murine δRec1, ψJα, and Cα,9,22 and sequence analysis of the sjTREC region.
Calculation of sjTREC frequency in CD3+ T lymphocytes
The PCR e  ciencies (E) for the sjTREC and Cα were determined by a standard curve, showing 
the relation between Ct values for serial dilutions of Balb/c thymus DNA in water and the 
logarithm of the dilution factor. The slope of this standard curve is a measure for reaction e  -
ciency.23 The frequency of sjTRECs in CD3+ T lymphocytes could be calculated by normalizing 
the sjTREC RQ-PCR to the Cα RQ-PCR,23 on the assumption that the total number of nucleated 
cells in the peripheral blood is represented by the CD45+ cell subset (Equation 1):
№ of sjTREC copies/105 CD3+ T cells = 2 x 105 x ((1 + E)-(CtTREC-CtCα) x CD45/CD3)
RQ-PCR sensitivity
The sensitivity of the assay was determined using fourfold serial dilutions of Balb/c thymus 
DNA in DNA isolated from a negative control cell line. P815, a murine mastocytoma celline 
of DBA2 origin,24 was used as negative control. The RQ-PCR was performed in sextuple and 
every sample contained 100 ng of DNA. The number of sjTREC copies still detectable with 
the assay could be calculated by normalizing the sjTREC RQ-PCR to the Cα RQ-PCR, on the 
assumption that 1 μg of DNA represents 150 000 nucleated cells with every nucleated cell 
containing two Cα copies (Equation 2):
№ of sjTREC copies = (1 + E)-(CtTREC-CtCα) x № of Cα copies
Sequence analysis
Nucleotide sequence analysis of the δRec1-ψJα signal joint region was performed in Balb/c, 
DBA2, 129Sv, and C57BL/6 mice. Sequences of the primers used to amplify the signal joint 
region were: forward primer 5′-AAGGAAGGCAGTCCCTTCTCA-3′ and reverse primer 5′-
AAAGCGACACGAAGAGCTGAA-3′. The PCR was performed in a 50-μL reaction containing 1.0× 
PCR bu er (Amersham Biosciences), 250 μM dNTPs (Amersham Biosciences), 1.25 U Taq DNA 
polymerase (Amersham Biosciences), 300 nM forward and reverse primer, and 5 μL of isolated 
DNA. Cycling conditions were 94°C for 1 minute, followed by 32 cycles of 94°C for 20 seconds, 
55°C for 30 seconds, and 72°C for 45 seconds, completed with an additional extension step 
of 72°C for 10 minutes after the last cycle. Ampli cation resulted in PCR products of 262 
base pairs, which were isolated from agarose gel by JETSORB (Genomed, Bad Oeynhausen, 
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Germany) and used in a second PCR. The second PCR was performed in a 20-μL reaction con-
taining 4 μL Big Dyes (ABI PRISM dye terminator ready reaction kit; Applied Biosystems), 6 μL 
dilution bu er, 200 nM forward primer (see above), and 1 μL of PCR product. PCR conditions 
were 96°C for 1 minute, followed by 25 cycles of 96°C for 30 seconds, 50°C for 15 seconds, and 
60°C for 4 minutes. PCR products were sequenced directly using the ABI PRISM 3100 genetic 
analyzer (Applied Biosystems).
Statistical analysis
SjTREC levels among various mouse strains were compared by a two-sided Mann-Whitney 
U-test. P-values below 0.05 were considered signi cant.
Results
Validation of the RQ-PCR assay
SjTREC levels were quanti ed using an RQ-PCR assay. The sjTREC RQ-PCR and Cα RQ-PCR 
had similar ampli cation e  ciencies of E = 0.97 ± 0.01 (n = 4) and E = 0.93 ± 0.01 (n = 4), 
respectively.
The sensitivity of the RQ-PCR was determined using fourfold serial dilution of Balb/c 
thymus DNA in DNA of a sjTREC negative control celline. Every sample contained 100 ng of 
DNA equivalent to 15 000 nucleated cells and 30 000 Cα copies. Mean Ct-values of the Cα 
and sjTREC RQ-PCR in the undiluted samples were 20.0 ± 0.09 and 26.2 ± 0.06 respectively, 
resulting in a ΔCt of 6.2. Using Equation 2 (E = 0.95, ΔCt = 6.2, Cα = 30 000), this adds up to 
a mean of 477 sjTREC copies in the undiluted samples. As shown in Table 1, a dilution of 
256 times still resulted in equal Ct-values for the sjTREC reaction in all six replicates (100%). 
In a subsequent fourfold dilution, two out of six replicates (33.3%) were positive while for 
four samples no Ct-value was obtained. According to the Poisson probability of distribution, 
63.2% of the replicates are positive at the detection limit, due to the random distribution of 
limiting numbers of target DNA across the replicates. As this percentage is reached between 
the 1:256 and 1:1024 dilutions, corresponding with 2 and 0.5 sjTREC copies respectively, the 
detection limit of the sjTREC RQ-PCR is approximately 1 sjTREC copy in 100 ng of total DNA.
The speci city of the assay was con rmed by the absence of sjTRECs in peripheral blood 
leukocytes of RAG-1-/- mice, which lack the recombination activation gene necessary for the 
rearrangement of T-cell receptors and immunoglobulins (Table 2).
SjTREC levels in various mouse strains
The frequency of sjTRECs was examined in peripheral blood leukocytes of female Balb/c, 
DBA2, 129Sv, and C57BL/6 mice between 6 and 12 weeks of age. C57BL/6 and 129Sv mice had 
a signi cantly lower sjTREC level compared to the other mouse strains. Sequence analysis of 
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the sjTREC region was performed for the various mouse strains, to exclude polymorphisms 
as explanation for the strain dependent di erences. SjTREC primers and probe used were 
developed according to published sequences of Balb/c mice.9 Sequence analysis of the 
sjTREC region in DBA2 and 129Sv mice revealed a complete match with the Balb/c primers 
and probe sequences. However, sequence analysis of the signal joint region in C57BL/6 mice 
revealed deletions and mismatches in both the primer and probe sequences (Figure 1). The 
polymorphisms in the sjTREC sequence may have contributed to the lower sjTREC frequency 
observed in C57BL/mice. Therefore, a new primer/probe combination was designed ac-
cording to the C57BL/6 sjTREC sequence, which performed with a comparable e  ciency to 
the Balb/c sjTREC RQ-PCR (data not shown). This resulted in a threefold increase in sjTREC 
frequency in C57BL/6 mice. However, frequencies remained signi cantly lower compared to 
Balb/c and DBA2 mice, as shown in Figure 2. C57BL/6 and 129Sv mice did not have a lower 
Table 1. Sensitivity of the sjTREC RQ-PCR
Dilution TREC copy # Ct TREC (mean ± SD) * Positive replicates/total replicates
undiluted 477 26.22 ± 0.06 6/6
1:4 119 28.26 ± 0.15 6/6
1:16 30 30.33 ± 0.26 6/6
1:64 7 32.81 ± 0.55 6/6
1:256 2 36.39 ± 1.42 6/6
1:1024 0.5 37.18 ± 1.58 2/6
Abbreviations: (sj)TREC, (signal joint) T-cell receptor rearrangement excision circle; RQ-PCR, real-time quantitative polymerase chain reaction; 
Ct, threshold cycle; SD, standard deviation.
*Mean Ct TREC and SD were calculated from the Ct values of the positive replicates.
Table 2. Cell numbers and sjTREC frequencies in various mouse strains and RAG-1-/- mice
Balb/c (n = 20) DBA2 (n = 19) 129Sv (n = 24) C57BL/6 (n = 21) RAG-1-/- (n = 3)
CD45+/μL blood, mean (range) 8430 (4100-13130) 7890 (4820-10670) 10420 (6680-13110) 9180 (6230-12310) 1060 (880-1490)
CD3+/μL blood, mean (range) 3700 (1850-4960) 2310 (1430-2890) 5080 (3200-6440) 2390 (1600-3410) 0
CD62L+CD3+ (%), mean 40 60 60 65 n.a.
Ct Cα, mean (range) 21.0 (20.0-22.3) 21.2 (20.9-22.3) 20.6 (19.2-21.3) 21.5 (20.5-22.3) 23.6 (23.0-24.5)
Ct TREC, mean (range) 27.7 (26.4-29.9) 28.4 (27.3-29.3) 27.7 (26.1-28.8) 29.6 (28.6-30.7) negative*
∆Ct (CtTREC-CtCα), mean 6.7 7.3 7.1 8.1 n.a.
SjTRECs/105 CD3+, mean 5360 5360 3620 3610 n.a
Peripheral blood of various mouse strains was examined between 6 and 12 weeks of age. Absolute numbers of CD45+ cells and CD3+ cells 
were determined using a single-platform  ow cytometric assay. SjTREC frequencies were determined by an RQ-PCR assay using strain-speci c 
primer/probe combinations. Results represent the mean values of 19-24 mice per group. SjTRECs could not be detected in three 10-week-old 
RAG-1-/- mice (C57BL/6 background), con rming the speci city of the assay.
Abbreviations: (sj)TREC, (signal joint) T-cell receptor rearrangement excision circle; Ct, threshold cycle; Cα: constant gene segment of TCRA; 
RAG, recombination activation gene; n.a., not applicable.
*> 40 cycles performing a PCR of 40 cycles.
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percentage of naive T cells in the peripheral blood compared to the other two mouse strains, 
as measured by the coexpression of CD3 and CD62L (Table 2).
Changes in sjTREC levels with age
SjTREC levels were studied in peripheral blood leukocytes of C57BL/6 mice of various ages. In 
total, 25 C57BL/6 mice were evaluated. Results of the sjTREC frequencies in CD45+ and CD3+
cells are shown in Figure 3. As depicted in panels A and B, the frequency of sjTRECs in CD45+
and CD3+ cells declined in aging C57BL/6 mice. Two-month-old C57BL/6 mice had a mean 
frequency of 3748 sjTRECs per 105 CD3+ cells (range: 3170/105-4974/105) compared with a 
mean frequency of 1716 sjTRECs per 105 CD3+ cells (range: 1641/105-1790/105) in 20-month-
old C57BL/6 mice. C57BL/6 mice of 28 months of age had the lowest frequency with a mean 
value of 329 sjTRECs per 105 CD3+ cells (range: 98/105-717/105). Balb/c mice showed a similar 
decline in sjTREC frequency with age (data not shown).
1                           54 
Balb/c   GAACCAAGCTGACAGGGCAGGTTTTTGTAAAGGTGCTCACTTCTGTG//CACAGTG 
C57BL/6  GAACCAAGCTGACņņGGCAGGTTTTTGTAAAGGTGCTCACTTCTGTG//CACAGTG 
 
55                        109 
Balb/c   GTGCACAAGCACCTGCACCCTgTGCATAAACCCACAGCTGCTGTGTGCCCTaCCC 
C57BL/6  GTGCACAAGCACCTGCACCCTaTGCATAAACCCACAGCTGCTGTGTGCCCTgCCC 
 
   110          135    
Balb/c   TGCCCGGGTaCTGCTTGCCATGCTCA 
C57BL/6  TGCCCGGGTgCTGCTTGCCATGCTCA 
Figure 1. Comparison of the nucleotide sequence of the sjTREC region between Balb/c and C57BL/6 mice. Deletion of a nucleotide is depicted 
by “-”; nucleotide mismatches are printed in lower case, and the location of the signal joint is depicted with “//.” The sequences of the primers 
and probe used in the RQ-PCR are underlined.
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Figure 2. SjTREC frequency in various mouse strains.
sjTREC levels in Balb/c, DBA2, 129Sv, and C57BL/6 mice were quanti ed between 6 and 12 weeks of age using strain-speci c primer/probe 
combinations. 129Sv and C57BL/6 mice had signi cantly lower levels of sjTRECs compared to Balb/c and DBA2 mice. SEs of the mean are shown 
by error bars. *P < 0.005.
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SjTREC levels in thymectomized mice
C57BL/6 mice were thymectomized at the age of six weeks. SjTRECs were quanti ed before 
thymectomy and at 7 months following thymectomy. Age-matched sham-thymectomized 
C57BL/6 mice were used as controls. Results are shown in Figure 4. Thymectomized C57BL/6 
mice showed a signi cant reduction in sjTREC frequency in blood compared to sham-
thymectomized mice 28 weeks following (sham) thymectomy.
Discussion
In this study we developed and evaluated a speci c RQ-PCR to quantify sjTRECs in peripheral 
blood leukocytes of mice. The frequency of sjTRECs in blood appeared to be dependent 
on strain, age, and thymic function. SjTRECs were absent in peripheral blood leukocytes of 
RAG-1−/− mice.
Several studies in humans, primates, and chickens have used the sjTREC, produced during 
TCRD deletion by δRec to ψJα rearrangement, to assess thymic output of newly developed T 
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Figure 3. Decreasing sjTREC frequencies in aging mice.
Change in sjTREC frequency with respect to age within C57BL/6 mice. Results of sjTREC frequencies are presented within CD45+ cells (A) and 
CD3+ cells (B). Exponential curves are shown.
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Figure 4. SjTREC frequency in thymectomized C57BL/6 mice.
Thymectomy resulted in a signi cant reduction in sjTREC frequency compared to sham-thymectomy 28 weeks following (sham) thymectomy. 
SEs of the mean are shown by error bars. **P < 0.05.
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cells.13-20,25,26 Mice also use the δRec and ψJα gene segments to delete the TCRD locus, result-
ing in a δRec-ψJα sjTREC.
We were able to detect sjTRECs in peripheral blood leukocytes of adult 12-week-old Balb/c 
mice with a mean frequency of 5000 sjTRECs per 105 CD3+ cells, which is approximately 
twofold lower compared to sjTREC levels found in humans.13,14 This di erence in frequency 
may be explained by the  nding that in humans approximately 70% of the TCRD gene dele-
tion rearrangements are mediated via the δRec and ψJα gene segments.12 Mice may use the 
δRec-to-ψJα rearrangement less frequently. Three homologous sequences of the human 
δRec have been found in mice, which may use multiple Jα acceptor sites.3,27 Consequently the 
twofold lower frequency of δRec-ψJα sjTRECs observed in Balb/c mice might be explained by 
the detection of only one (δRec1) out of three δRec sequences and one Jα sequence (ψJα) in 
our sjTREC assay.
The frequency of sjTRECs per 105 CD3+ cells varied between di erent mouse strains. Balb/c 
and DBA2 mice had signi cantly higher levels of sjTRECs compared to C57BL/6 and 129Sv 
mice. A study of sjTRECs in monkeys revealed a similar di erence in frequency between two 
monkey species, which was in agreement with the di erence in the percentage of naive T 
cells.25 Assessment of CD62L+ naive T cells in the peripheral blood showed no di erences 
between DBA2, 129Sv, and C57BL/6 mice. This argues against a lower thymic output of RTEs 
or a higher peripheral expansion of T cells in 129Sv and C57BL/6 mice. The mouse strain-
dependent di erences in sjTREC levels may be due to di erential usage of the three δRec 
segments in the δRec-ψJα recombination. Currently we are analyzing the δRec2-ψJα and 
δRec3-ψJα recombination in the various mouse strains.
Studies of sjTREC levels in humans and primates have shown a decrease in sjTRECs within 
CD4+ and CD8+ T cells with age.13,14,25 We quanti ed sjTRECs in aging C57BL/6 mice. The fre-
quency of sjTRECs within CD45+ and CD3+ cells declined in aging mice. A tenfold drop in 
sjTREC frequency in C57BL/6 mice was observed over the lifespan of 2.5 years. Concomitant 
with decreasing sjTREC levels, a twofold decrease in absolute number of CD3+ cells in the 
peripheral blood was detected.
The in uence of thymic output on sjTREC levels was further studied in thymectomized 
C57BL/6 mice. Thymectomy resulted in a signi cant reduction in sjTREC frequencies com-
pared to sham-thymectomy 28 weeks following thymectomy. These  ndings are comparable 
with earlier observations in humans and primates.13,25
In conclusion, we have developed a speci c and sensitive RQ-PCR assay to assess thymic 
output in mice via quanti cation of δRec-ψJα sjTRECs. It has enabled us to assess di erences 
in sjTREC levels between mouse strains, to evaluate thymic output with age, and to evaluate 
sjTREC levels following thymectomy. Quanti cation of sjTRECs may allow for the investiga-
tion of the role of thymic output for strain- and age-matched animals in murine stem cell 
transplantation models, and for evaluating the e ect of di erent immune modulating factors 
on thymic output.
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Abstract
Interleukin-7 (IL-7) has been shown to enhance thymic output of newly developed T cells 
following bone marrow transplantation (BMT) in mice. In addition, IL-7 may a ect peripheral 
expansion of T cells. In order to study the relative contribution of thymopoiesis versus periph-
eral T-cell expansion in the setting of compromised thymopoiesis, we have applied IL-7 in an 
experimental stem cell transplantation model using T-cell-de cient RAG-1-/- mice. C57BL/6 
RAG-1-/- mice received transplants of congenic T-cell-depleted (TCD) bone marrow (Ly5.1) 
with or without supplemented T cells (Ly5.2). IL-7 was administered until day 63 after BMT. 
Peripheral blood T- and B-cell recovery was quanti ed by  ow cytometry and thymopoiesis 
was studied by quanti cation of T-cell receptor rearrangement excision circles (TRECs). In 
mice receiving a T-cell-replete BMT, IL-7 selectively expanded mature CD45.2+ T cells without 
a ecting the recovery of new bone marrow-derived CD45.1+ T cells. In contrast, IL-7 signi -
cantly enhanced the recovery of bone marrow-derived T cells after TCD-BMT. Quanti cation 
of TRECs in mice receiving a TCD-BMT revealed that enhanced T-cell recovery following IL-7 
treatment resulted from a strong expansion of newly developed naive T cells. These results 
suggest that peripheral expansion of recent thymic emigrants or mature T cells may be a 
preferential mechanism by which IL-7 enhances T-cell recovery after BMT.
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Introduction
Hematopoietic stem cell transplantation is an established modality to treat a variety of 
hematologic disorders. Although epithelial barriers, granulocytes, and natural killer cells 
are usually restored within 1 month following transplantation, T- and B lymphocytes may be 
de cient for a prolonged period of time.1 In particular, the recovery of naive CD4+CD45RA+
T cells is extremely slow.2-4 The slow reconstitution of naive CD4+ T cells in older patients 
may be related to the natural involution of the thymus, and thymic output may be further 
compromised by radiotherapy and graft-versus-host disease (GVHD).5-8 Until recently, thymic 
output of T cells could be quanti ed only by the measurement of CD4+CD45RA+ naive T cells 
in the peripheral blood. Enumerating naive CD4+ T cells by  ow cytometry may serve as a 
surrogate marker, but naive CD4+ T cells may persist in the circulation for a prolonged period 
of time before converting to a memory phenotype.9 Recently, episomal DNA circles gener-
ated during rearrangement of the gene segments encoding the T-cell receptor (TCR) have 
been proposed as markers for thymic output.10-13 These circles, named TCR rearrangement 
excision circles (TRECs), are stable, are not duplicated during mitosis, and are diluted with 
each cellular division.14 Recent studies have shown an accurate assessment of thymic output 
by the quanti cation of these TRECs in humans.8,10-16 We and others recently developed a real-
time quantitative polymerase chain reaction (RQ-PCR) of TRECs in mice and showed accurate 
assessment of peripheral blood and thymic TRECs, which appeared dependent on age, strain, 
and thymic function.17,18
New therapeutic agents to enhance immune recovery are currently being developed. 
Interleukin-7 (IL-7) has been identi ed as a potent thymopoietic agent.19,20 IL-7 is a pleiotropic 
cytokine, which is indispensable for murine T- and B lymphopoiesis and essential for human 
T-cell development.21-23 In addition, recent studies have shown that IL-7 plays an essential 
role in the homeostatic expansion of peripheral naive T cells and the expansion of memory 
T cells.24-26 These properties of IL-7 have led to the idea that exogenous IL-7 may overcome 
immunode ciencies after transplantation both by accelerating thymic T-cell development 
and by expanding the peripheral pool of newly developed T cells. Indeed, both direct e ects 
of IL-7 on thymopoiesis and expansion of peripheral T-cell numbers have been shown in 
di erent experimental models.27-31 However, the di erential contribution of central versus 
peripheral T-cell recovery remains poorly understood. In non-human primates, e ects of IL-7 
on peripheral T-cell numbers by expanding naive and non-naive T cells predominated an 
e ect on thymopoiesis.32,33 In mice, however, administration of IL-7 increases both thymopoi-
esis and peripheral T-cell expansion following stem cell transplantation.26,28,31 At present, it is 
unknown whether IL-7 preferably promotes thymopoiesis or rather expands recent thymic 
emigrants (RTEs) or mature T cells in mice in the setting of compromised thymopoiesis. To 
address these questions, we applied IL-7 in an experimental bone marrow transplantation 
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(BMT) model using T-cell-de cient RAG-1-/- mice. We show that IL-7 preferably a ects the 
expansion of peripheral T cells, either RTEs or mature T cells.
Materials and methods
Mice
C57BL/6-RAG-1-/- mice, originally obtained from The Jackson Immunoresearch Laboratories 
(Bar Harbor, ME), and C57BL/6-Ly5.1 mice were bred at the Experimental Animal Center, 
Erasmus University Medical Center, Rotterdam, the Netherlands. C57BL/6-Ly5.2 mice were 
purchased from Charles River Laboratories (Wilmington, MA). Male and female 10- to 14-
week-old C57BL/6-RAG-1-/- mice were used as recipients of 5 x 106 congenic CD45.1+ T-cell-
depleted (TCD) bone marrow (BM) cells from 10- to 12-week-old C57BL/6-Ly5.1 mice. T cells 
(CD45.2+) were obtained from congenic C57BL/6-Ly5.2 mice. Mice were maintained under 
speci c pathogen-free conditions in individual ventilated cages with acidi ed water and 
antibiotics. All animal procedures were performed in accordance with protocols approved by 
the local Committee for Animal Experiments.
Bone marrow transplantation
To obtain bone marrow cells, femurs of donor mice were crushed, passed through a nylon 
mesh, washed, and resuspended in RPMI medium (Gibco BRL, Grand Island, NY) containing 
1% fetal calf serum (FCS; Gibco BRL) and 2 mM ethylenediaminetetraacetic acid (EDTA; Sigma, 
St Louis, MO). Bone marrow cells were depleted of T cells by incubation with rat antimouse 
CD4 (YTS191, YTA312) and rat antimouse CD8 (YTS169) monoclonal antibodies (mAbs)34 for 
30 minutes on ice, followed by a wash and incubation with goat antirat immunoglobulin G 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for 15 minutes at 4°C. Labeled 
cells were removed by passing the cell suspension over a magnetic column, using the Au-
toMacs according to the manufacturer’s instructions (Miltenyi Biotec). The e  cacy of T-cell 
depletion was checked by  ow cytometry and was always found to be more than 2 log. To 
obtain T cells, spleens were harvested, dispersed, and counted by a Sysmex microcellcounter 
(Toa Medical Electronics, Kobe, Japan). T cells were puri ed from donor spleens by negative 
selection using a cocktail of non-T-cell mAbs according to the manufacturer’s instructions 
(Stem-Sep; Stemcell Technologies, Vancouver, BC, Canada). Purity of the T-cell fraction was 
con rmed by  ow cytometry and was always found to exceed 95%. Nonirradiated recipient 
RAG-1-/- mice received 5 x 106 TCD CD45.1+ BM cells either alone or together with 0.5 x 106
puri ed CD45.2+ T cells. Cells were suspended in phosphate-bu ered saline (PBS) containing 
1% FCS and transplanted by tail-vein infusion (0.5 mL volume per infusion).
IL-7 improves posttransplant T-cell recovery by peripheral T-cell expansion 59
Interleukin-7
Recombinant human (rh) IL-7 was kindly provided by Dr Michel Morre (Cytheris, Vanves, 
France). The biological activity of each batch of rhIL-7 was determined by a 3H-thymidine 
incorporation proliferation assay using the murine IL-7-dependent B-cell line 2E8 obtained 
from American Type Culture Collection (ATCC; Manassas, VA). Between day 7 and day 63 after 
BMT, recipient mice received IL-7 twice daily by subcutaneous injection at a dose of 500 
or 2500 ng per injection, diluted in PBS plus 1% FCS at 0.25 mL per injection. Control mice 
received injections of PBS plus 1% FCS at 0.25 mL per injection, twice daily.
Flow cytometric analysis
At serial time points following transplantation, blood was collected from the murine retro-
orbital plexus. Absolute numbers of peripheral blood T- and B cells were determined by a 
single-platform  ow cytometric assay: inclusion of a calibrated number of  uorescent beads 
(Flow-Count Fluorospheres; Beckman Coulter, Fullerton, CA) in a lyse-no-wash technique 
allows for direct calculation of absolute number of labeled cells per microliter of blood ac-
cording to the ratio between beads and labeled cells. mAbs used for  ow cytometric analysis 
were  uorescein isothiocyanate (FITC)-conjugated anti-CD3ε, anti-CD45.1, and anti-CD44 
(Becton Dickinson, San Jose, CA); phycoerythrin (PE)-conjugated anti-CD4, anti-CD19, anti-
CD45.1, anti-CD45.2, anti-CD69, anti-NK1.1, anti-Gr-1, and anti-MAC-1 (Becton Dickinson); 
anti-CD25, anti-CD45R (B220), and anti-CD8 (Beckman Coulter); Cy-Chrome-conjugated 
anti-CD45, allophycocyanin (APC)-conjugated anti-CD3ε, anti-CD4, and anti-CD25 (Becton 
Dickinson); biotin-conjugated anti-CD25 and anti-CD45.2 (Becton Dickinson). Streptavidin-
PE and streptavidin-APC (Becton Dickinson) were used to detect biotinylated mAbs. TCR 
Vβ usage was assessed by staining with FITC-conjugated TCR Vβ2, Vβ3, Vβ4, Vβ5.1, Vβ5.2, 
Vβ6, Vβ7, Vβ8.1, Vβ8.2, Vβ8.3, Vβ9, Vβ10b, Vβ11, Vβ12, Vβ13, Vβ14, and Vβ17a (mouse Vβ TCR 
screening panel, Becton Dickinson). Staining with 7-amino-actinomycin D was performed for 
single-cell suspensions of bone marrow and thymus to exclude dead cells. Thymuses were 
harvested at days 28 and 43 following transplantation. To obtain a single-cell suspension, 
thymuses were minced with scissors and passed through a nylon mesh. Cells were washed 
and counted by a Sysmex microcellcounter (Toa Medical Electronics). Absolute numbers of 
thymic cell subsets were determined by multiplying the number of nucleated cells by the 
percentage of positive cells for the indicated cell surface marker(s). Flow cytometric analysis 
was performed using a FACScan or FACSCalibur (Becton Dickinson). Flow cytometric data 
were collected and analyzed using CELLQuest software (Becton Dickinson).
Real-time quantitative PCR of sjTRECs
DNA was puri ed from blood, isolated splenic CD4+ and CD8+ T cells, and thymic cell suspen-
sions using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to manufacturer’s 
instructions. Signal joint (sj) TRECs were detected with our recently developed 5’ nuclease 
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based RQ-PCR assay using the ABI PRISM 7700 sequence detector (Applied Biosystems, Foster 
City, CA).17 In short, the PCR was performed in a 50 µL reaction containing 1.0 x TaqMan Bu er 
A (Applied Biosystems), 4 mM MgCl2, 250 µM dNTPs (Amersham Biosciences, Piscataway, NJ), 
1.25 units AmpliTaq Gold (Applied Biosystems), 300 nM forward and reverse primers, 200 
nM probe, and 5 µL isolated DNA. All reactions were performed in duplicate or triplicate. 
PCR conditions were 95°C for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute. Sequences of the sjTREC primers and probe used were as follows: forward 
primer, 5’-CCAAGCTGACGGCAGGTTT-3’; reverse primer, 5’-AGCATGGCAAGCAGCACC-3’; 
probe, FAM-5’-TGCTGTGTGCCCTGCCCTGCC-3’-TAMRA (Eurogentec, Seraing, Belgium). To 
compensate for variations in input DNA, we used the constant gene segment of the TCRA
gene (Cα) as endogenous reference gene. The sequences of the primers and probe were as 
follows: forward primer, 5’-TGACTCCCAAATCAATGTG-3’; reverse primer, 5’-GCAGGTGAAGCT-
TGTCTG-3’; probe, FAM-5’-TGCTGGACATGAAAGCTATGGA-3’-TAMRA (Applied Biosystems). 
These 2 primer combinations resulted in amplicons of 128 and 136 base pairs, respectively, 
without nonspeci c background bands as visualized on an agarose gel. SjTREC copies in the 
peripheral blood, spleen, and thymus were calculated as recently reported17 and expressed 
per 105 CD3+ T lymphocytes or per 105 CD45.1+ donor-derived thymocytes.
Statistical analysis
Numbers of peripheral CD3+ T cells (and their subsets) as well as CD19+ B cells were compared 
between groups of IL-7-treated and PBS-treated mice at di erent time points after trans-
plantation using the Student’s t-test. All signi cant results were con rmed by the Wilcoxon 
rank-sum test. All P-values are two-sided and a signi cance level of α less than or equal to 
0.05 was used. Numbers of TREC copies per 105 T cells were also compared between groups 
of mice by Student’s t-test.
Results
IL-7 preferentially expands mature T cells after T-cell-replete BMT
After a T-cell-replete BMT, T cells may originate either from BM-derived thymic precursors 
or from mature T cells infused with the marrow graft. To evaluate the e ects of IL-7 on these 
two sources of T cells, we subjected RAG-1-/- mice to congenic TCD-BMT from C57BL/6-Ly5.1 
donor mice supplemented with CD45.2 mature splenic T cells. BM-derived newly developed 
T cells (CD45.1) and mature (supplemented) T cells (CD45.2) were distinguished by  ow 
cytometry and their absolute numbers were determined at weekly intervals in peripheral 
blood samples (Figure 1). Administration of IL-7 from day 7 onward led to an early (day 21) 
and sustained increase of CD45.2+CD3+ T cells as compared with PBS treatment. Newly devel-
oped, BM-derived, CD45.1+CD3+ T cells appeared in the peripheral blood from day 35 onward. 
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IL-7 administration did not enhance the recovery of BM-derived T cells, and increasing the 
dose of IL-7  vefold did not accelerate or enhance the recovery of those newly developed 
CD45.1+CD3+ T cells (results not shown). Absolute numbers of CD45.2+CD3+ T cells measured 
approximately 200 T cells/µL from day 21 onward, resulting in a persistent chimerism ratio of 
more than 1 in favor of CD45.2 mature T cells. The relative contribution of CD4+CD3+ T-helper 
cells and CD8+CD3+ cytotoxic T cells to the total absolute number of CD3+ T cells was as-
sessed in time (Table 1). An early high CD4/CD8 T-cell ratio after T-cell-replete BMT gradually 
decreased from 2.0 to 0.7 in PBS-treated mice and from 2.7 to 1.0 in IL-7-treated mice. Higher 
numbers of CD4+CD3+ T cells versus CD8+CD3+ T cells were induced by IL-7 than by PBS early 
after BMT and until day 42 following T-cell-replete BMT.
IL-7 enhances T-cell recovery in RAG-1-/- mice after TCD-BMT
As IL-7 appeared to exert no enhancing e ect on the recovery of BM-derived T cells following 
T-cell-replete BMT, we next wished to evaluate the e ect of IL-7 on the recovery of newly 
developed T cells following TCD-BMT. RAG-1-/- mice received a TCD-BMT followed by IL-7 or 
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Figure 1. IL-7 expands naive T cells after T-cell-replete BMT.
C57BL/6-RAG-1-/- mice (n = 30) received 5 x 106 congenic T-cell-depleted CD45.1+ BM cells, supplemented with 0.5 x 106 CD45.2+ T cells. IL-7 
was administered subcutaneously (500 ng twice daily) from day 7 to day 63. Bone marrow (BM)-derived newly developed T cells (CD45.1) and 
mature (supplemented) T cells (CD45.2) were distinguished by  ow cytometry and their absolute numbers were determined in peripheral blood 
samples taken at weekly intervals. Mean absolute numbers (±SEM) are shown for CD45.1+CD3+ T cells/μL blood and CD45.2+CD3+ T cells/μL 
blood in PBS-treated mice (, n = 15) and IL-7-treated mice (, n = 15). *P < 0.05. **P < 0.01.
Table 1. CD4+/CD8+ T-cell ratios after BMT
Type of BMT and treatment Days after BMT
14 28 42 56 63
T-cell-replete
IL-7 2.7 2.8 1.7 1.1 1.0
PBS 2.0 1.4 1.5 1.2 0.7
TCD
IL-7 n.a. n.a. 1.0 1.9 3.1
PBS n.a. n.a. 1.3 1.5 1.9
Ratios of absolute median numbers of periheral blood CD3+CD4+ and CD3+CD8+ T cells/μL per group of 6 mice.
Abbreviations: BMT, bone marrow transplantation; TCD, T-cell-depleted; IL-7, interleukin-7; PBS, phosphate-bu ered saline; n.a., not applicable.
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PBS administration from day 7 onward until the end of the experiment (Figure 2). As in mice 
receiving a T-cell-replete BMT, BM-derived CD45.1+CD3+ T cells appeared in the peripheral 
blood by 35 days after BMT. IL-7 did not accelerate the early recovery of newly developed T 
cells, but, in contrast to T-cell-replete BMT, the ultimate level of recovery was enhanced by 
IL-7. The recovery of CD3+ T cells to more than 200/µL was achieved by day 42 in IL-7-treated 
mice, whereas the number of T cells in PBS-treated control mice did not achieve that level by 
day 63. Increasing the dose of IL-7  vefold (to 2500 ng twice daily) did not enhance the level 
of recovery, nor did it shorten the time lag between BMT and  rst signs of T-cell recovery (re-
sults not shown). As in recipients of replete grafts, high CD4/CD8 T-cell ratios were observed 
in recipients of TCD-BMT (Table 1). The highest ratio was observed in recipients treated with 
IL-7, indicating the generation of approximately two to three times higher numbers of CD4+
T cells than of CD8+ T cells.
Thymopoiesis versus peripheral T-cell expansion after TCD-BMT
Treatment with IL-7 resulted in enhanced recovery of newly developed BM-derived T cells 
after TCD-BMT. To evaluate whether that e ect was due to increased thymopoiesis or expan-
sion of RTEs after export from the thymus, we assessed TREC frequencies directly in thymo-
cytes as well as in the peripheral blood. Groups of mice (n = 9) were killed at days 28 and 43 
after TCD-BMT for analysis of the thymus by  ow cytometry and RQ-PCR of TRECs. As shown 
in Figure 3, IL-7 administration resulted in a moderate but not signi cant increase in the 
frequency of TREC copies per 105 donor-derived CD45.1+ thymocytes at day 28. PBS-treated 
recipients showed a median frequency of 1990 (range: 0-6396) TREC copies per 105 CD45.1+
thymocytes, as compared with a median frequency of 3093 (range: 0-5064) TREC copies per 
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Figure 2. IL-7 enhances T-cell recovery after TCD-BMT. 
C57BL/6-RAG-1-/- mice received 5 x 106 congenic TCD CD45.1+ BM cells. IL-7 was given subcutaneously twice daily (2 x 500 ng) from day 7 to day 
63. T-cell recovery was evaluated weekly in mice treated with PBS (, n = 21) and mice treated with IL-7 (, n = 21). Mean absolute numbers 
(± SEM) of CD3+ T cells/µL blood are shown. *P < 0.01.
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105 CD45.1+ thymocytes in IL-7-treated mice (P = 0.1). In addition, the median number of TREC 
copies per 105 CD45.1+ thymocytes was not a ected by IL-7 at day 43 after transplantation 
(median [range] for PBS vs. IL-7, 6693 [4225-7095] vs. 5217 [2961-9699]). Absolute numbers of 
donor-derived CD45.1+ thymocytes were not signi cantly increased by IL-7 at days 28 and 43. 
Apart from TREC analysis, thymocyte subset distribution was evaluated by  ow cytometry. 
The relative distribution of CD44+CD25–, CD44+CD25+, and CD44+CD25+ pro-T cells was not 
a ected by IL-7, nor did IL-7 change the percentages of CD4+CD8+ (double positive) or single 
positive T cells.
In addition to thymocyte TREC levels, peripheral blood samples were evaluated at 42, 49, 
and 56 days after BMT for the presence of TREC+CD3+ lymphocytes. Healthy C57BL/6 mice may 
show 2000 to 3000 TREC copies per 105 CD3+ T cells at the age of 3 to 6 months, as recently re-
ported.17 Those levels were not observed in RAG-1-/- mice, which received a congenic C57BL/6 
TCD (RAG-1+/+) BMT. Peripheral blood TREC frequencies were below the detection limit at 
day 42 in 4 of 5 PBS-treated mice, only 1 showing 2576 TREC copies per 105 T cells, and were 
also undetectable in 4 of 6 IL-7-treated mice. As shown in Figure 4, 2 IL-7-treated mice had 
detectable TREC frequencies (1036 and 846 TREC copies per 105 CD3+ T-lymphocytes) at day 
42 after BMT. However, while absolute numbers of CD45.1+CD3+ T cells in these IL-7-treated 
mice increased in time, TREC frequencies dropped to a lower or even undetectable level.
Taken together, our results indicate that IL-7 induces expansion of newly developed T 
cells after export from the thymus. Spleens were harvested in separate groups of mice (n 
= 10) for additional analysis of activation status of peripheral T cells as well as analysis of 
TREC frequencies at day 43 after transplantation. Among PBS-treated mice, a median of 7.2% 
(range: 3.8%-10.4%) of CD3+ T cells were CD25+, and a median of 6.3% (range: 1.8%-10.8%) 
of all T cells were CD69+. Comparable percentages were observed in IL-7-treated mice: of 
all CD3+ donor T cells, a median of 6.1% (range: 2.2%-12.1%) were CD25+ and a median of 
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Figure 3. IL-7 moderately a ects thymopoiesis. 
Recipients of TCD-BMT treated with IL-7 (n = 9) or PBS (n = 9) were killed at day 28 and thymuses were evaluated for numbers of sjTREC copies 
per 105 BM-derived CD45.1+ thymocytes. Horizontal bars indicate medians.
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7.2% (range: 2.6%-14.5%) were CD69+. Following selection of CD4+ and CD8+ T cells and DNA 
isolation, TREC copies were fewer than 50 per 100 000 T cells in all IL-7-treated mice, whereas 
the frequency of TREC copies detected in PBS-treated mice varied between 112 and 267 per 
105 CD3+ T lymphocytes, again suggesting dilution of TREC-positive T cells by IL-7.
IL-7 treatment does not skew the T-cell receptor repertoire
As antigen-driven expansion of peripheral T cells may result in a skewed and limited TCR 
repertoire,39 we evaluated the e ect of IL-7 on the TCR repertoire of the reconstituted 
peripheral blood T cells by  ow cytometric analysis of the expression of 15 TCR Vβ families 
at day 70 following stem cell transplantation. Both recipients of TCD-grafts and recipients 
of T-cell-replete stem cell transplants showed a broad TCR repertoire, independent of the 
administration of IL-7. Results are shown in Figure 5.
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Figure 4. Individual results of 2 IL-7-treated mice after BMT.
Peripheral blood numbers of CD3+ T cells/µL() and numbers of sjTREC copies per 105 CD3+ T cells () were evaluated following TCD-BMT and 
IL-7 treatment.
0
5
10
15
20
25
2 3 4 5.1/5.2 6 7 8.1/8.2 8.3 9 10b 11 12 13 14 17a
Vβ repertoire
%
 T
 c
el
ls
Figure 5. IL-7 treatment does not skew the T-cell receptor repertoire.
Following TCD- and T-cell-replete BMT, the Vβ repertoire was evaluated at day 70 for PBS-treated (  TCD,  T-cell-replete) and IL-7-treated (
TCD,  T-cell-replete) recipients. Percentages per Vβ type are expressed as percentage of all Vβ types per treatment modality.
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IL-7 accelerates B-cell recovery in RAG-1-/- mice following congenic TCD- and T-cell-replete BMT
Apart from its e ect on T-cell progenitors and mature T cells, IL-7 is known to promote B-cell 
development in mice.19,20 The e ect of IL-7 on B-cell progenitors was studied concurrently 
in RAG-1-/- mice receiving BM grafts depleted of T cells and in RAG-1-/- mice receiving T-cell-
replete BMT. As shown in Figure 6, IL-7 administration resulted in accelerated B-cell recovery 
in mice receiving a TCD-BMT. A level of 50 CD19+ B cells/µL blood was reached at day 21 in 
IL-7-treated mice, whereas PBS-treated mice did not reach the mean level of 50 CD19+ B cells 
at day 63 following transplantation. The e ect of IL-7 following T-cell-replete transplantation 
was signi cantly less. The mean level of 50 CD19+ B cells/µL was not reached until 49 days 
following transplantation in IL-7-treated mice. Increasing the dose of IL-7  vefold, to 2500 ng 
twice daily, did not accelerate or enhance the recovery of B cells following T-cell-replete BMT 
(Figure 7). However, the higher dose of IL-7 did transiently a ect recipient B-cell progenitor 
expansion, as demonstrated by an immediate sharp increase of CD45.2+CD19+ B cells, fol-
lowed by a sharp decrease, concurrently with expansion of donor CD45.1+CD19+ B cells and 
donor T cells (Figure 7).
0
75
150
0 14 28 42 56 70
0
75
150
0 14 28 42 56 70
T-cell-depleted BMT T-cell-replete BMT
*
C
D
19
+  
B
 c
el
ls
 / 
µL
C
D
19
+  
B
 c
el
ls
 / 
µL
* * * * ** * ** * **
Time (days) Time (days)
Figure 6. IL-7 administration resulted in accelerated B-cell recovery in mice receiving TCD- BMT.
Recovery of CD19+ B cells/µL was evaluated after TCD- and T-cell-replete (2 groups of 15 mice each) BMT. Groups of mice were treated with PBS 
() or IL-7 () at a dose of 500 ng twice daily on days 7 to 63. Absolute mean numbers (± SEM) are depicted. *P < 0.01. **P = 0.03.
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Figure 7. E ect of IL-7 following T-cell-replete transplantation.
Recovery of CD45.1+CD19+ (recipient) and CD45.2+CD19+ (donor) B-cell numbers was evaluated in recipients of T-cell-replete BMT followed by 
treatment with IL-7 at a dose of 2500 ng twice daily (, n = 5), IL-7 at a dose of 500 ng twice daily (, n = 9), or PBS (, n = 9). P-values 
shown correspond to both the comparison of 2500 ng IL-7 versus PBS and the comparison of 500 ng IL-7 versus PBS. *P < 0.01.
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Discussion
Thymic output of newly developed T cells may be severely impaired in recipients of he-
matopoietic stem cell grafts. Especially, adult patients experiencing chronic GVHD following 
allogeneic stem cell transplantation (allo-SCT) may show extremely retarded and reduced 
recovery of naive T cells.8,15 The quanti cation of those T cells by PCR of TRECs has facilitated 
the monitoring of thymic output and highlighted the de cient function of the thymus after 
allo-SCT.8,10-16 The adverse clinical consequences of impaired recovery of T cells, both CD4+
T-helper cells and CD8+ cytotoxic T cells, has been demonstrated in studies showing a cor-
relation between opportunistic infections and low T-cell numbers after allo-SCT.35,36 It may 
be anticipated that new therapeutic approaches that accelerate T-cell recovery may be of 
considerable clinical bene t. One of these approaches may be the use of exogenous IL-7, a 
cytokine involved in thymopoiesis as well as in peripheral T-cell expansion.19,20,31,32,37,38 In order 
to study the relative contribution of each of these e ects of IL-7, we applied IL-7 in T-cell-
de cient RAG-1-/- mice following T-cell-depleted or T-cell-replete BMT. The model allows the 
evaluation of T-cell recovery in time in a setting of partially impaired thymopoiesis. We show 
that peripheral expansion of T cells is a dominant e ect of exogenous IL-7 after T-cell-replete 
BMT. Moreover, after TCD-BMT, a strong expansion of BM-derived RTEs also predominated 
over an e ect on thymopoiesis. These e ects in mice with compromised thymopoiesis com-
pare well to recent observations in non-human primates.32,33 No e ects on thymopoiesis were 
observed in irradiated baboons receiving a TCD autologous stem cell graft followed by IL-7 
therapy,33 and the peripheral e ects of IL-7 also predominated over an e ect on thymopoiesis 
in healthy juvenile cynomolgus monkeys.32
Recipients of replete grafts, which were not treated with IL-7, predominantly repopulated 
their peripheral blood T cells by expansion of mature T cells infused with the BM graft. Newly 
developed BM-derived T cells appeared after 5 weeks and their number gradually increased, 
accompanied by an increase in BM-derived T-cell chimerism in time. The cumulative number 
of T cells in mice receiving either a TCD- or a T-cell-replete graft (without IL-7 treatment) was 
estimated at approximately 200 CD3+ T cells/µL (Figures 1 and 2) at day 60 and did not di er 
between these two groups. These results support the hypothesis formulated by Mackall et 
al that both mature T cells and RTEs may compete for available T-cell active cytokines that 
support clonal expansion in the periphery.31 Mature T cells added to the graft may have 
inhibited the recovery of newly developed BM-derived T cells. This was especially evident in 
mice treated with IL-7. While both recipients of TCD grafts and recipients of replete grafts re-
covered their peripheral T-cell numbers up to 300 to 400 CD3+ T cells/µL following treatment 
with IL-7, BM-derived T cells contributed to that cumulative number to only a minor degree 
following T-cell-replete SCT. This may be explained by e ective competition for available IL-7 
by the mature T cells added to the graft. A preferential use of available IL-7 by those T cells 
was further supported by the downregulation of B-cell lymphopoiesis in recipients of replete 
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versus TCD grafts (Figure 6). The preferential use of IL-7 by rapidly proliferating peripheral T 
cells may be explained by synergistic or amplifying e ects of IL-7 and other cytokines involved 
in T-cell proliferation and activation. IL-7 has been shown to induce and to act in concert with 
IL-2, and IL-7 synergizes with IL-12 in inducing T-cell proliferation, T-cell activation, and the 
development of a type I immune response.39-45 Such amplifying e ects induced by IL-7 may 
be bene cial in the development of an immune response toward potentially lethal infectious 
microorganisms, but such e ects may be harmful in the development of graft-versus-host 
reactions after allo-SCT. Although a recent study reported no evidence for enhancement of 
GVHD by IL-7,30 a study by Sinha et al showed that IL-7 may lower the threshold T-cell dose 
required to induce GVHD as well as enhance lethality and tissue damage in an experimental 
murine model.46 Both the latter results and our  ndings suggest that IL-7 should be restricted 
to the setting of T-cell depletion and that proin ammatory e ects by IL-7 on alloreactive T 
cells should be avoided.
The proin ammatory e ects of IL-7 may also have contributed to the preferential expansion 
of CD4+ T cells as opposed to CD8+ T cells, as observed following both T-cell-replete and TCD-
BMT. A key intermediate in that e ect may be IL-27, which is a recently identi ed proin am-
matory cytokine that synergizes with IL-12 to trigger interferon-α (IFN-α) production of naive 
CD4+ T cells and, more important, selectively drives rapid clonal expansion of naive CD4+ T 
cells.47 Apart from IL-7-treated mice, high CD4+/CD8+ ratios were also observed in control mice 
(Table 1), which may be explained by a proin ammatory background already present in these 
severely immunode cient RAG-1-/- recipients. Clinically, a strong correlation has been shown 
between CD4 counts and IL-7 levels,26,48 and weaker correlations between IL-7 levels and CD8+
T cells. In particular, strong inverse correlations between IL-7 and CD62L+CD45RA+CD4+ naive 
T cells have been observed in patients with HIV.26 The relationship may suggest a feedback 
mechanism between IL-7 and CD4+ T-cell counts. Clearly, the relationship between IL-7 and 
CD4+ T cells needs to be studied in more detail to elucidate the mechanism responsible for 
a preferential outgrowth of CD4+ T cells as observed in the present study and to clarify the 
mechanism by which CD4+ lymphopenia may increase IL-7 levels in lymphopenic patients.
We planned to study the e ects of IL-7 in T-cell-de cient mice, which exhibit compromised 
thymic function after transplantation of normal bone marrow. As previously reported, 
RAG-1-/- mice exhibit a small thymus with residual arrested thymopoiesis in the cortex and an 
involuted medulla, which may partially regenerate following restoration of thymopoiesis.49,50
Persistent impaired thymic function after transplantation was evidenced by a relatively low 
frequency of TREC+ thymocytes. Using a similar TREC assay, Sempowski et al showed 4000 to 
8000 TREC copies per 100 000 thymocytes in healthy BALB/c mice.18 We observed a median 
copy number of 2000 per 100 000 thymocytes, which compares well to the lower numbers 
Sempowski et al observed in older mice (aged 90 weeks and older). Although IL-7 moderately 
increased donor thymopoiesis and the frequency of TREC+ thymocytes, a normalization of 
the TREC copy number was not achieved. In contrast, Okamoto et al recently found that 
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exogenous IL-7 may strongly enhance the generation of TRECs in vitro and in vivo, using 
normal human thymus of fetal origin.51 Our results suggest that IL-7 may be necessary, but 
not su  cient, to fully restore thymopoiesis in the setting of impaired medullary function 
as exhibited by RAG-1-/- mice. Also, the de cient thymopoiesis observed in older adult mice 
was not fully restored by exogenous IL-7 in two experimental studies evaluating IL-7 in aged 
C57BL/6 mice31 or BALB/c mice,18 although Pido-Lopez et al observed augmented thymopoi-
esis in their model.52 Together, these results suggest that additional factors are required to 
fully restore thymic function in RAG-1-/- mice and aged mice with involuted thymuses. A puta-
tive additional factor may be stem cell factor, a cytokine, which may act in concert with IL-7 
at a very early stage of thymopoiesis.53 Furthermore, the recent identi cation of the murine 
thymic epithelial stem cell may provide new insights into the essential nursing requirements 
provided by the epithelium in thymopoiesis.54,55
In conclusion, although exogenous IL-7 may improve thymopoiesis, the cytokine is prefer-
entially consumed by rapidly proliferating T cells in the periphery, including RTEs and mature 
T cells. These results suggest that potential clinical applications may have particular promise 
in the setting of T-cell depletion in order to optimally pro t from the e ects on thymopoiesis 
and expansion of recent thymic emigrants and to avoid expansion and activation of potential 
harmful alloreactive T cells.
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Abstract
Background and objective: Interleukin-7 (IL-7) has been studied for its possible immu-
norestorative capacities following stem cell transplantation and has been shown to enhance 
posttransplant immune recovery predominantly by peripheral T-cell expansion. A major 
concern of IL-7 is its possible aggravating e ect on graft-versus-host and host-versus-graft 
reactivity. Design and methods: To study the e ect of IL-7 on host-versus-graft reactivity, 
we applied IL-7 in an experimental transplantation model using RAG-1-/- mice supplied with 
B6 CD45.1 congenic T cells as recipients of T-cell-depleted allogeneic bone marrow grafts. 
Results: Rejection of minor antigen-mismatched bone marrow was signi cantly reduced in 
IL-7-treated recipients as compared to PBS-treated control mice. Rejection was observed in 
2 out of 18 IL-7-treated mice as compared to 9 out of 17 PBS-treated mice (11% vs. 53%; P 
= 0.012). IL-7 administration resulted in enhanced recovery of peripheral blood CD4+CD25+
regulatory T cells (Treg) with a concomitant increase in peripheral blood Foxp3 mRNA expres-
sion. IL-7Rα (CD127) was expressed by the vast majority of CD4+Foxp3+ T cells. The incidence 
of graft rejection following fully MHC-mismatched bone marrow transplantation was not 
reduced nor enhanced by IL-7 administration. Interpretation and Conclusions: Posttransplant 
IL-7 administration protects against minor antigen-mismatched bone marrow rejection, 
which may be due to enhanced Treg recovery.
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Introduction
The histocompatibility barrier between donor and recipient manifested as either graft-
versus-host (GVH) or host-versus-graft (HVG) reactions continue to a ect outcome after 
allogeneic hematopoietic stem cell transplantation (allo-SCT).1 Graft-versus-host disease 
(GVHD) mediated by immunocompetent donor-derived T cells recognizing genetically dis-
parate host cells is one of the major causes of death following allo-SCT.2 While advances in 
matching of recipient and donor by molecular HLA typing and improvement of pretransplant 
conditioning measures have reduced graft rejection, allo-SCT from alternative donors and 
allo-SCT following reduced intensity conditioning may still be complicated by impaired en-
graftment and overt graft rejection.3-6 Apart from immunosuppressive agents administered 
prior to transplantation, the intensity of postgrafting immunosuppression has been shown 
to a ect HVG reactivity and the incidence of rejection.7-9 Accumulating data from various 
murine models demonstrate that CD4+CD25+Foxp3+ regulatory T cells (Treg) are important 
mediators of postgrafting immunosuppression. Pretransplant depletion of recipient CD25+
T cells has been shown to reduce levels of donor engraftment and the adoptive transfer of 
large numbers of CD4+CD25+ Treg at the time of allo-SCT may prevent bone marrow graft 
rejection.10-12
The lymphopoietic cytokine interleukin-7 (IL-7) has been studied for its possible im-
munorestorative capacities following stem cell transplantation in murine and non-human 
primate models. Whereas IL-7 administration might a ect thymopoiesis, IL-7 is most impor-
tantly identi ed as key regulator of homeostatic peripheral T-cell expansion.13-22 A major 
concern of posttransplant administration of IL-7 is its possible aggravating e ect on GVH and 
HVG reactivity. Reports concerning the e ect of IL-7 on the incidence and severity of GVH 
have yielded con icting results.15,23,24 At present, reports concerning the e ect of IL-7 on HVG 
alloreactivity are lacking. To evaluate the e ect of IL-7 on HVG reactivity, we applied IL-7 in 
experimental murine stem cell transplantation models with major and minor histocompat-
ibility barriers. We show that IL-7 administration protects against minor antigen-mismatched 
allograft rejection, which is associated with an increased recovery of Treg.
Materials and methods
Mice
C57BL/6-RAG-1-/- mice, originally obtained from The Jackson Immunoresearch Laboratories 
(Bar Harbor, ME), and C57BL/6-Ly5.1 mice were bred at the Experimental Animal Center, 
Erasmus University Medical Center, Rotterdam, the Netherlands. 129Sv and Balb/c mice were 
purchased from Charles River Laboratories (Wilmington, MA). Mice were maintained under 
speci c pathogen-free conditions in individual ventilated cages with acidi ed water and 
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antibiotics. All animal procedures were performed in accordance with protocols approved by 
the local Committee for Animal Experiments.
Bone marrow transplantation
Bone marrow obtained from crushed femurs and tibias of donor mice was depleted of T cells 
by incubation with rat antimouse CD4 (YTS191, YTA312) and rat antimouse CD8 (YTS169) 
monoclonal antibodies (mAbs)25 followed by magnetic separation using the AutoMacs ac-
cording to the manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). 
The e  cacy of T-cell depletion was monitored by  ow cytometry and always found to be 
more than 2 log. Splenic T cells were obtained by negative selection using a cocktail of non-
T-cell mAbs according to the manufacturer’s instructions (Stem-Sep; Stem cell Technologies, 
Vancouver, BC, Canada). Purity of the T-cell fraction was always found to exceed 95% as 
con rmed by  ow cytometry. Ten- to fourteen-week-old RAG-1-/- mice supplied with graded 
doses of puri ed CD45.1+ congenic C57BL/6 T cells received either 12.5 x 106 T-cell-depleted 
129Sv bone marrow cells (minor antigen-mismatched) or 6 x 106 T-cell-depleted Balb/c bone 
marrow cells (fully MHC-mismatched) by tail vein infusion (0.5 mL total volume) preceded by 
3 and 6 Gy of total body irradiation respectively (137Cs gamma-source, Gammacell, Atomic 
Energy of Canada, Ottawa, Canada). During six to seven weeks following transplantation 
mice received a daily subcutaneous injection of either PBS or 1 μg of recombinant human 
IL-7 (0.25 mL total volume), which was kindly provided by Dr Michel Morre (Cytheris, Vanves, 
France). Rejection was de ned as a sustained peripheral blood CD45.2+CD3+ T-cell number 
below 50 cells/μL, which was monitored by  ow cytometry at weekly intervals.
Flow cytometric analysis
At serial time points following transplantation, blood was collected from the murine retro-
orbital plexus. Absolute numbers of peripheral blood lymphocytes were determined by a 
single-platform  ow cytometric assay as described previously.18 MAbs used for  ow cytomet-
ric analysis were  uorescein isothiocyanate (FITC)-conjugated anti-CD3ε, and anti-CD45.1 
(Becton Dickinson, San Jose, CA); phycoerythrin (PE)-conjugated anti-CD19, anti-CD45.1, 
anti-CD4 (Becton Dickinson), anti-CD127 (e-Bioscience), anti-CD8 (Beckman Coulter), and 
anti-IgG2a (BD Pharmingen, Alphen a/d Rijn, the Netherlands); Cy-Chrome-conjugated anti-
CD45; allophycocyanin (APC)-conjugated anti-CD4, and anti-CD25 (Becton Dickinson); biotin-
conjugated anti-CD45.2 (Becton Dickinson). Streptavidin-PE and streptavidin-APC (Becton 
Dickinson) were used to detect biotinylated mAbs. The expression of Foxp3 was analyzed 
by intracellular staining with anti-Foxp3 (e-Bioscience) after  xation and permeabilization of 
peripheral blood cells according to the manufacturer’s instructions (e-Bioscience, San Diego, 
CA). Intracellular IL-4 and IFN-γ staining was performed on single-cell suspensions prepared 
from spleen. Two million spleen cells were stimulated with either 25 ng/mL of phorbol-12-
myristate 13-acetate (PMA; Sigma) and 1 μg/mL of ionomycin (Sigma) or with medium for 5 
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hours at 37°C and 5% CO2. Brefeldin A (Sigma) was added at a  nal concentration of 10 μg/
mL for the  nal 4 hours of incubation. Next, cells were stained with anti-CD45.1 and anti-
CD4 mAb and after  xation and permeabilization (BD Pharmingen), cells were stained with 
anti-IL-4 and anti-IFN-γ (BD Pharmingen). Activation of the cells was con rmed by analysis of 
CD69 expression, which was over 95% in all stimulated samples. All analyses were performed 
in duplicate. All  ow cytometric analyses were performed using a FACSCalibur (Becton Dick-
inson). Flow cytometric data were collected and analyzed using CELLQuest software (Becton 
Dickinson).
In vitro Treg activity assay
CD4+CD25high Treg were isolated from spleen cells of IL-7-treated mice using a FACSAria cell 
sorter (Becton-Dickinson). The purity of the sorted cell population was always found to exceed 
95% as con rmed by  ow cytometry. Sorted CD4+CD25high Treg cells from IL-7-treated mice 
(5 x 104) were evaluated for their ability to suppress T-cell proliferation by co-culture with 
sorted CD4+CD25- C57BL/6 responder T cells (5 x 104) that were stimulated with 0.5 µg/mL 
anti-CD3 antibody and RAG-1-/- spleen cells (2 x 105) as antigen presenting cells. Cultures were 
performed in 96-well U-bottom plates. Responder cells with or without Treg were cultured in 
RPMI 1640 medium at 37°C and 5% CO2 for 3 days. Tritium thymidine (
3H-TdR) was added at 1 
µCi/well for the last 18 hours of culture. All assays were performed in quadruplicate.
Real-time quantitative PCR of Foxp3
RNA was puri ed from blood using the Qiagen Blood Mini kit (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions after which cDNA was synthesized. The PCR was 
performed in a 25-μL reaction containing 20 μL of PCR mix (Sybergreen (Applied Biosystems, 
Nieuwerkerk a/d IJssel, The Netherlands), 20 pmol/mL forward- and 20 pmol/mL reverse 
primer (Invitrogen, Merelbeke, Belgium), 6 μl sterile water) and 5 μL of cDNA. All reactions 
were performed in duplicate. PCR conditions were 95°C for 10 minutes, followed by 45 cycles 
of 95°C for 15 seconds, and 60°C for 1 minute. Sequences of the Foxp3 primers were: forward 
primer 5’-GCAATAGTTCCTTCCCAGAGTTCT-3’ and reverse primer 5’-GGATGGCCCATCG-
GATAAG-3'. To compensate for variations in input cDNA the constant gene segment of the 
ribonuclease inhibitor (RI) gene was used as endogenous reference gene. Sequences of the RI 
primers were: forward primer 5’-TCCAGTGTGAGCAGCTGAG-3' and reverse primer 5’-TGCAG-
GCACTGAAGCACCA-3'. Foxp3 mRNA was detected with real-time quantitative RT-PCR using 
the ABI PRISM 7700 sequence detector (Applied Biosystems, Foster City, CA) and computer 
software package SDS2.2. The mean threshold cycles (Ct) of the duplicates were used to 
calculate the expression of Foxp3 mRNA relative to the RI-control. Relative Foxp3 transcripts 
were calculated by the ∆Ct method: ∆Ct = ∆CtFoxp3- ∆CtRI. Relative Foxp3 transcript = 1/2
∆Ct
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Statistical analysis
Mann-Whitney U test was used to compare numbers of peripheral blood CD3+ T-cell subsets 
and peripheral blood Foxp3 expression between PBS- and IL-7-treated recipient mice and to 
compare Foxp3 expression in mice with and without graft rejection. Fisher’s exact test was 
used to compare the incidence of graft rejections between PBS- and IL-7-treated transplant 
recipients. All reported P-values are two-sided, and a signi cance level of α ≤ 0.05 was used.
Results
IL-7 and allograft rejection
Peripheral homeostatic expansion of T cells has been shown to be the predominant e ect 
of exogenous IL-7 after T-cell-replete bone marrow transplantation (BMT).18 Following that 
observation, we wished to evaluate the e ect of IL-7 administration on host-versus-graft al-
loreactivity. Three Gy irradiated C57BL/6-RAG-1-/- mice, supplied with escalating numbers of 
B6 CD45.1 congenic T cells, received an allogeneic MHC-matched minor antigen-mismatched 
T-cell-depleted 129Sv bone marrow (BM) graft followed by IL-7 or PBS administration from 
day 1 until day 42. Engraftment was monitored at weekly intervals. The incidence of minor 
antigen-mismatched graft rejection depended on the numbers of B6 CD45.1 T cells sup-
plied prior to transplantation (Figure 1). Posttransplant administration of IL-7 reduced the 
incidence of graft rejections in mice supplied with 105 B6 T cells. Rejection was observed 
in 2 out of 18 IL-7-treated mice as compared to 9 out of 17 PBS-treated mice (11% vs. 53%; 
P = 0.012). No rejections were observed in recipients of 1 x 104 B6 T cells and recipients of 
1 x 106 B6 T cells all rejected their minor antigen-mismatched BM graft irrespective of IL-7 
treatment. Results are shown in Table 1. As shown before,18 IL-7 administration resulted in a 
sustained increase in numbers of B6 CD45.1+ T cells as compared to PBS. At day 42 following 
BMT, PBS-treated mice supplied with 1 x 105 B6 T cells showed a mean number of 217 cells/
µL (range: 41-707) as compared to 578 cells/µL (range: 54-1344) in IL-7-treated mice (P = 0.02; 
Figure 2A). Thus, posttransplant IL-7 administration reduced the incidence of graft rejection 
despite an increase in the numbers of peripheral blood congenic B6 T cells.
Analogous to the analysis concerning IL-7 and minor antigen-mismatched bone marrow 
rejection, experiments were performed using 6 Gy irradiated C57BL/6-RAG-1-/- mice supplied 
Table 1. Incidence of graft rejection following minor antigen-mismatched BMT
Treatment modality
Numbers of infused B6 T cells
0 104 105 106
PBS 0/5* 0/5 9/17 5/5
IL-7 n.d. 0/5 2/18 5/5
Abbreviations: BMT, bone marrow transplantation; PBS, phosphate-bu ered saline; IL-7, interleukin-7; n.d., not determined.
*Number of allograft rejections per total number of performed transplantations.
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with escalating numbers of B6 CD45.1 congenic T cells as recipients of 6 x 106 T-cell-depleted 
Balb/c bone marrow to study the e ect of IL-7 on MHC-mismatched graft rejection. No di er-
ence in the frequency of graft rejection was observed between PBS- and IL-7-treated recipi-
ents. In PBS-treated mice supplied with 1 x 103 B6 T cells 4 out of 8 transplantations ended in 
rejection compared to 5 out of 9 transplantations in IL-7-treated mice (50% vs. 56%). All re-
cipients of 1 x 104 and 1 x 105 B6 T cells rejected their MHC-mismatched allograft. Comparable 
to minor antigen-mismatched BMT, administration of IL-7 following fully MHC-mismatched 
transplantation resulted in expansion of the supplied B6 CD45.1 congenic T cells. IL-7-treated 
mice supplied with 1 x 103 B6 T cells had a mean number of 566 cells/μL (range: 32-2512) at 
day 42 as compared to 107 cells/μL (range: 14-296) in PBS-treated mice (P = 0.04; Figure 2B).
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Figure 1. Allograft rejection following minor antigen-mismatched BMT.
3 Gy irradiated C57BL/6-RAG-1-/- supplied with escalating numbers of congenic B6 T cells received 12.5 x 106 MHC-matched minor antigen-
mismatched TCD 129Sv BM cells. BM-derived 129Sv T cells and supplied B6 T cells were distinguished by CD45.2 and CD45.1 expression 
respectively. Rejection was de ned as a sustained peripheral blood CD45.2+CD3+ T-cell number below 50 cells/μL. BM-derived CD45.2+CD3+ T 
cells numbers at day 42 are shown for all individual recipients of no T cells (n = 5), 104 T cells (n = 5), 105 T cells (n = 11) and 106 T cells (n = 5).
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Figure 2. IL-7 mediated peripheral T-cell expansion.
C57BL/6-RAG-1-/- supplied with escalating numbers of congenic B6 CD45.1+ T cells received either 3 Gy irradiation followed by a TCD minor 
antigen-mismatched BMT or 6 Gy irradiation followed by a fully MHC-mismatched BMT. PBS or IL-7 were administered subcutaneously (1 µg 
daily) from day 1 to day 42. Peripheral expansion of B6 T cells was studied by single-platform  ow cytometry of peripheral blood samples taken 
at weekly intervals. Mean absolute numbers (± SEM) of CD45.1+CD3+ T-cells/μL blood are shown for (A) PBS (, n = 14) and IL-7 (, n = 
16) treated recipients of 105 B6 T cells and a minor antigen-mismatched BM graft (129Sv) and (B) PBS (, n = 8) and IL-7 (, n = 9) treated 
recipients of 103 B6 T cells and a MHC-mismatched BMT (Balb/c). *P < 0.05. **P < 0.01.
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IL-7 enhances BM- and congenic T-cell-derived Treg recovery following MHC-matched minor antigen-
mismatched BMT
IL-7 administration following minor antigen-mismatched allo-SCT resulted in fewer rejections 
despite peripheral expansion of mature congenic T cells. As Treg are known to be important 
mediators of postgrafting immunosuppression, we evaluated the e ect of IL-7 treatment 
on endogenous Treg recovery by  ow cytometric analysis of cell surface co-expression of 
CD4 and CD25. Absolute numbers of BM- and congenic T-cell-derived CD4+CD25high T cells 
were determined in peripheral blood samples taken at weekly intervals after BMT. As shown 
in Figure 3, mice treated with IL-7 showed an increased recovery of both BM-derived CD4+
and CD4+CD25high T cells compared to PBS-treated mice. The frequency of CD4+CD25high Treg 
within the CD45.2+CD4+ T-cell pool was similar in IL-7-treated and PBS-treated mice. Next 
we studied the e ect of IL-7 administration on the CD4+CD25high Treg present in the supple-
mented congenic CD45.1 T-cell pool. IL-7 treatment not only resulted in increased numbers 
of CD45.1+CD4+ T cells, but also in a moderate increase in numbers of CD45.1+CD4+CD25high
Treg (Figure 3). Then we analyzed the suppressive ability of CD4+CD25high T cells from IL-7-
treated mice. Sorted CD4+CD25high T cells, selected from spleens of IL-7-treated mice 35 days 
following transplantation, inhibited the anti-CD3-induced proliferation of CD4+CD25- T cells 
in vitro, demonstrating their regulatory capacity (Figure 4).
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Figure 3. IL-7 enhances BM- and congenic T-cell derived CD4+ and CD4+CD25high T-cell recovery.
3 Gy irradiated C57BL/6-RAG-1-/- supplied with 105 congenic B6 CD45.1+ T cells received 12.5 x 106 TCD 129Sv BM cells. PBS or IL-7 were 
administered subcutaneously (1 μg daily) from day 1 until day 49. Peripheral blood CD4+ and CD4+CD25high T-cell recovery were studied by single-
platform  ow cytometry. Mean absolute numbers (± SEM) of BM-derived CD4+ and CD4+CD25high T cells/μL blood and congenic T-cell derived 
CD4+ and CD4+CD25high T cells/μL blood in PBS-treated mice (, n = 6) and IL-7-treated mice (, n = 6) are shown. *P < 0.05. **P < 0.01
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IL-7 enhances Foxp3 expression in peripheral blood cells of Rag-1-/- mice following MHC-matched minor 
antigen-mismatched BMT
Since Foxp3 is a more selective marker for murine Treg, Foxp3 expression was determined by 
real-time quantitative RT-PCR of Foxp3 mRNA expression in peripheral blood at day 21 and 
day 49 following BMT. At day 21, the expression of Foxp3 mRNA in the IL-7-treated mice was 
higher than in PBS-treated mice. PBS-treated recipients showed a mean expression of 165 x 
10-4 (range: 42-313) relative transcripts as compared to a mean expression of 436 x 10-4 (range: 
146-947) relative transcripts in IL-7-treated mice (P = 0.04; Figure 5). At day 49, IL-7-treated 
mice showed a strong increase in expression of Foxp3 mRNA compared to the expression at 
day 21, whereas Foxp3 mRNA expression in PBS-treated mice was only moderately enhanced. 
In PBS-treated mice a mean expression of 267 x 10-4 (range: 17-994) relative transcripts was 
detected compared to a mean expression of 1150 x 10-4 (range: 167-2320) relative transcripts 
in IL-7-treated mice (P = 0.02; Figure 5). Moreover, Foxp3 mRNA expression levels inversely 
correlated with rejections irrespective of IL-7 treatment. Mice that did not reject their bone 
marrow graft had a higher mean expression of Foxp3 mRNA as compared to mice that re-
jected their graft. In the no-rejection group mice had a mean Foxp3 expression of 1316 x 
10-4 (range: 994-2320) relative transcripts whereas mice that rejected their graft had a mean 
Foxp3 expression of 129 x 10-4 (range: 17-193) relative transcripts (P = 0.006; Figure 5). As our 
data indicate that CD4+Foxp3+ Treg respond to IL-7, we analyzed CD127 (IL-7Rα) expression 
on CD3+CD4+Foxp3+ Treg of normal B6 mice by four-color  ow cytometry. CD3+CD4+Foxp3+
Treg indeed express CD127 albeit at a lower level of expression than CD3+CD4+Foxp3- T cells 
which is in line with recently published observations by Liu et al showing a lower CD127 
expression on murine CD4+Foxp3+ T cells in comparison to Foxp3- T cells.26 Results are shown 
in Figure 6.
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Figure 4. CD4+CD25high Treg from IL-7-treated mice have suppressive ability in vitro.
Sorted CD4+CD25– T cells from C57BL/6 mice (5 x 104) stimulated with anti-CD3 mAb (0.5 µg/mL) and RAG-1-/- spleen cells (2 x 105) as antigen 
presenting cells (APC) were cultured in the presence or absence of sorted CD4+CD25high Treg from IL-7-treated mice (5 x 104). T-cell proliferation 
was measured by 3H-TdR incorporation as shown by mean counts per minute (cpm ± SD) of quadruplicate samples.
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IL-7 treatment does not alter the Th1/Th2 balance in RAG-1-/- recipients of MHC-matched minor antigen-
mismatched BMT
As type-2 T-helper cells (Th2) and type-2 cytotoxic T cells (Tc2) play an important role in 
the prevention of GVH- and HVG reactions,27 the observed protective e ect of IL-7 on HVG 
reactivity following MHC-matched minor-antigen mismatched BMT might well be a direct 
e ect on T-cell phenotype and cytokine pro le thereby altering the Th1/Th2 balance. There-
fore, we evaluated the e ect of IL-7 on the frequency of IFN-γ producing Th1 cells and IL-4 
producing Th2 cells. RAG-1-/- recipients of MHC-matched minor-antigen mismatched BMT 
were sacri ced at day 35 posttransplant and spleens were harvested. Cells were stimulated 
with PMA and ionomycin to increase cytokine production as no cytokine signals could be 
detected without stimulation. The percentage of splenic IFN-γ producing T cells within the 
CD45.1+CD4+ T-cell compartment was approximately 60-70% both in PBS- and IL-7-treated 
mice. Moreover percentages were similar in mice that did and did not reject the bone marrow 
graft. Results are shown in Figure 7. As numbers of IL-4 producing CD45.1+CD4+ T cells were 
always below 5% in both groups of mice irrespective of rejection (data not shown), the Th1/
Th2 balance was una ected by IL-7 treatment.
Discussion
IL-7 has been studied for its possible immunorestorative capacities following SCT and has 
been shown to enhance posttransplant immune recovery predominantly by peripheral T-cell 
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Figure 5. IL-7 enhances Foxp3 expression in peripheral blood cells.
3 Gy irradiated C57BL/6-RAG-1-/- supplied with 105 congenic B6 CD45.1+ T cells received 12.5 x 106 TCD 129Sv BM cells. PBS or IL-7 were 
administered subcutaneously (1 μg daily) from day 1 until day 49. Foxp3 mRNA and RI mRNA were determined by real-time quantitative RT-PCR 
of peripheral blood samples taken at day 21 and day 49 after BMT. Relative Foxp3 expression is shown for PBS () and IL-7 () treated mice at 
day 21, PBS () and IL-7 () treated mice at day 49 and mice with () and without () graft rejection irrespective of cytokine treatment (n 
= 5-6 mice per group).
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expansion.13-22 A major concern of posttransplant administration of IL-7 may be its possible 
aggravating e ect on GVH and HVG reactivity by enhancement of the allo-antigen-reactive 
T-cell population. Reports concerning the e ect of IL-7 on GVH reactions have yielded con-
 icting results and at present it is unknown whether IL-7 may a ect HVG alloreactivity.15,23,24
Therefore, we applied IL-7 in an experimental SCT model using RAG-1-/- mice supplied with B6 
CD45.1 congenic T cells to study the e ect of IL-7 administration on HVG reactivity following 
SCT across major and minor histocompatibility barriers. We show that posttransplant admin-
istration of IL-7 results in a reduced incidence of allograft rejection in recipients of minor 
antigen-mismatched bone marrow.
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Figure 6. CD4+Foxp3+ regulatory T cells express CD127.
Peripheral blood cells from normal B6 mice were stained with CD3, CD4, Foxp3 and IgG2a or CD127 mAbs and analyzed by four-color  ow 
cytometry. Cells were gated on CD3+CD4+ lymphocytes and analyzed for CD127 and Foxp3 expression. Dotplots of isotype- and CD127- stained 
CD3+CD4+ T cells as representative examples of 7 individual mice are shown.
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Figure 7. IL-7 treatment does not alter the Th1/Th2 balance in RAG-1-/- recipients of MHC-matched minor antigen-mismatched BMT.
3 Gy irradiated C57BL/6-RAG-1-/- supplied with 105 congenic B6 CD45.1+ T cells received 12.5 x 106 TCD 129Sv BM cells. Flow cytometric analysis 
of splenic IFN-γ producing congenic T-cell-derived CD45.1+CD4+ T cells was performed at day 35 posttransplant both in PBS () and IL-7 () 
treated recipient mice either with or without graft rejection. The percentage of CD45.1+CD4+IFN- γ+ T cells in PBS- and IL-7-treated mice without 
stimulation and after stimulation with PMA and ionomycin is shown.
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Several possible explanations for the observed protective e ect were considered. As 
postgrafting immunosuppression is important for prevention of graft rejection7,8 and 
CD4+CD25+Foxp3+ Treg are important mediators of postgrafting immunosuppression,28 we 
 rst hypothesized that IL-7 might reduce allograft rejection by increasing the number of 
Treg after BMT. In our longitudinal analysis of T-cell recovery in recipients of MHC-matched 
minor antigen-mismatched bone marrow cells, we indeed found an enhanced recovery of 
CD4+CD25+ T cells and increased levels of Foxp3 mRNA in IL-7-treated mice as compared to 
PBS-treated control mice. Moreover, signi cantly higher levels of Foxp3 mRNA were mea-
sured in all mice that did not reject the marrow graft as compared to mice that did reject 
the graft. Early after transplantation, all Treg are derived from the supplied CD45.1 congenic 
mature T cells. From day 21 onwards, Treg originating from the bone marrow appear and 
gradually become the major population of peripheral blood Treg. Both populations of Treg 
are increased by IL-7 treatment and may have contributed to the observed reduction in HVG 
reactivity. Our  ndings compare well to several other reports showing that adoptive transfer 
of Treg may prevent bone marrow graft rejection.10,12,29 Rejection of MHC-matched minor 
antigen-mismatched bone marrow is a protracted process that may be modulated both early 
and later after transplantation. Early after BMT, adoptively transferred CD62Lhi Treg suppress 
bone marrow rejection by suppression of the priming of alloreactive T cells in secondary 
lymphoid organs.10 At later stages, e ector/memory like CD62E/P+CCR5+ Treg may migrate 
into peripheral sites to suppress the expansion, cytokine secretion and/or cytolytic function 
of alloreactive e ector T cells.30-32
An alternative explanation for the observed protective e ect of IL-7 could have been a 
direct immunosuppressive e ect of IL-7 on T cells by a ecting the Th1/Th2 balance. In our 
model of MHC-matched minor-antigen mismatched BMT the Th1/Th2 balance was una ected 
by IL-7 administration. Our observations are in line with reports by Alpdogan et al showing 
that IFN-γ and IL-4 production are not signi cantly di erent between IL-7- and PBS-treated 
transplant recipient mice.15,20
In contrast to minor antigen-mismatched bone marrow graft rejection, the incidence of 
fully MHC-mismatched graft rejection was not a ected by IL-7. As the frequency of allo-MHC 
reactive T lymphocytes is much higher in comparison to the frequency of minor antigen 
reactive T lymphocytes, rejection following fully MHC-mismatched BMT may be more dif-
 cult to suppress by Treg. Moreover, natural killer (NK) cells, next to T lymphocytes, might 
have contributed to MHC-mismatched graft rejection. NK cells have proven to be a barrier 
to engraftment of fully MHC-mismatched bone marrow and although Treg are capable of 
inhibiting NK-cell function in vitro, the inhibitory e ect might be overcome in conditions 
resulting in signi cant cytokine production as acute infection or allo-SCT.33,34
IL-7 and its role in alloreactivity have been subject of study in several reports which, so far, 
all concerned GVH reactivity. Sinha and co-workers applied IL-7 in a MHC-mismatched parent 
→ F1 model and showed signi cantly increased GVH reactivity in IL-7-treated recipients of 
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escalating ‘subthreshold’ numbers of T cells.23 In contrast, Alpdogan and co-workers showed 
signi cantly reduced GVH reactivity following MHC-mismatched BMT (parent → F1) and 
no di erence in GVH reactivity between PBS- and IL-7-treated recipients of minor antigen-
mismatched BMT.15 Di erences in dose of IL-7 used and duration of therapy might have 
contributed to the observed di erences between the two studies. Recently, Gendelman et al 
reported a higher incidence of GVH reactivity in IL-7-treated recipients of MHC-mismatched 
bone marrow, which, however, was restricted to unirradiated mice. In irradiated transplant 
recipients GVH reactivity was not aggravated by IL-7 treatment.24 Collectively, these studies 
do suggest that IL-7 might signi cantly worsen GVH reactivity. In contrast, in this  rst study 
concerning the e ect of IL-7 on HVG reactivity, alloreactivity was de nitely not increased by 
IL-7. More importantly, we even observed diminished HVG reactivity following minor antigen-
mismatched BMT, which was associated with enhanced recovery of Treg. So apart from its 
immunorestorative capacities, IL-7 might also be of use for the induction of transplantation 
tolerance especially in the setting of T-cell-depleted allogeneic stem cell grafts.
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Opportunistic infections following allogeneic stem cell transplantation
Incidence of opportunistic infections following allogeneic stem cell transplantation
Opportunistic infections are considered a frequent and serious complication of allo-SCT. 
Postengraftment infections in particular cause substantial transplant-related morbidity 
and mortality and the occurrence of postengraftment infections has been described as the 
dominant independent factor associated with increased non-relapse mortality.1 In Chapter 2, 
we describe the incidence of postengraftment day 30 to day 365 infections following HLA-
identical sibling partially TCD-BMT in comparison to PBPCT. Approximately 70% of patients 
experienced at least one severe (CTC grade 3-4) postengraftment infection without signi cant 
di erences between BM and PBPC recipients (Figure 1). Overall infection-related mortality 
was no less than 20% again without signi cant di erences between BMT and PBPCT. How do 
these data compare to other and earlier reports of postengraftment infection rates?
In the late seventies, Atkinson et al were  rst in studying the incidence of late postengraft-
ment infections in recipients of HLA-matched sibling transplants. In a study period of 6 to 
20 months posttransplant, Atkinson et al reported cumulative incidences of 66% and 86% 
with an infection-related mortality rate of 9%.2,3 The introduction of PBPC as alternative stem 
cell source promised well for the future of opportunistic infections as one hypothesized that 
the faster immune recovery associated with unmanipulated and partially TCD sibling PBPCT 
would lead to lower postengraftment infection rates. With respect to partially TCD-PBPCT, 
the results were disappointing as shown in our retrospective analysis described in Chapter 2 
and shown in Figure 1. A previous randomized prospective analysis by Storek et al including 
recipients of unmanipulated sibling BM and PBPC did show a signi cantly lower day 30 to day 
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Figure 1. Kaplan-Meier curve of time to a  rst severe CTC grade 3-4 infection by stem cell source.
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365 infection rate following PBPCT. Overall infection-related mortality was still 10% within 
the study period, however with a signi cantly lower incidence of infection-related deaths 
following PBPCT.4
Apart from sibling BM and PBPC grafts, stem cells from unrelated donors are being used 
more and more frequently for allo-SCT. Ochs et al retrospectively studied the incidence of 
late infections occurring between day 50 and 2 years posttransplant in recipients of unma-
nipulated related and unrelated BMT. Overall 74% of the 249 evaluable patients experienced 
at least one late posttransplant infection including 68% of related donor transplant recipients 
(6/6 and 5/6 HLA matched) as compared to 85% of unrelated donor transplant recipients (P 
= 0.009) with  fteen percent of all infectious episodes resulting in death of the patient.1 A 
recent study of severe posttransplant infections by Parody et al comparing unrelated BMT, 
PBPCT and umbilical cord blood transplantation (UCBT) still showed cumulative incidences 
at three year follow-up of 69%, 67% and 85% respectively.5
In conclusion, overall postengraftment infection-related morbidity and mortality is high 
and according to the aforementioned studies largely unchanged in over twenty- ve years of 
transplantation medicine although transplantation of PBPC may be associated with a reduc-
tion in postengraftment infection rates. Use of non-myeloablative conditioning regimens 
may even further reduce infectious morbidity, which, however, has only been shown for the 
early and intermediate posttransplant period whereas late day 91-365 infection rates are 
signi cantly higher as compared to conventional myeloablative PBPCT.6 Therefore accurate 
prevention and treatment of late postengraftment infections still seems vital as is the de ni-
tion of its potential risk factors.
Risk factors of opportunistic infections following stem cell transplantation
The risk of developing a posttransplant opportunistic infection may be determined by several 
important pretransplant- as well as posttransplant factors. Quantitative depletion of mature T 
cells from the stem cell graft may be an important pretransplant risk factor of posttransplant 
opportunistic infections as recovery of immune functions may be delayed. T-cell depletion 
has proven to be an e ective means of reducing both incidence and severity of acute and 
chronic GVHD.7,8 However, adverse e ects have been associated with T-cell depletion like loss 
of graft-versus-leukemia activity and higher incidence of graft failure. Partial T-cell deple-
tion was developed leaving a low residual number of T cells in the graft to counterbalance 
these e ects.9 Our evaluation of postengraftment infections as described in Chapter 2 was 
performed in recipients of such partially TCD stem cell grafts. T-cell depletion was performed 
either by E-rosetting or CD34+ selection leaving 1-2 x 105 T cells/kg in the graft. Infection 
rates and infection-related mortality in recipients of HLA-identical sibling partially TCD 
grafts were signi cantly higher as compared to reported numbers in recipients of similar 
but unmanipulated grafts4 suggesting that partial T-cell depletion may indeed be a risk fac-
tor of posttransplant opportunistic infections. However, two earlier comparative studies of 
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unmanipulated and CD34+ cell-selected transplantation, although with limited numbers of 
patients, suggested otherwise as no di erences with respect to infectious morbidity and mor-
tality could be detected.10,11 So partial T-cell depletion in itself does not necessarily have to be 
associated with an increased risk of posttransplant opportunistic infections. Infection control 
with such low numbers of administered T cells in the graft, however, may be disturbed in the 
presence of additional risk factors including older age, use of unrelated or haploidentical 
donors, and GVHD. Adult recipients of SCT have a signi cantly higher probability of develop-
ing a life-threatening infection as compared to pediatric patients both following related as 
unrelated SCT.1,12,13 With respect to donor source, Ochs et al reported a 2.73-fold signi cantly 
increased risk of opportunistic infections in recipients of unrelated unmanipulated SCT 
and comparable results were obtained by Small et al in recipients of unrelated partially 
TCD grafts.1,13 Additionally, haploidentical SCT may be associated with an infection-related 
mortality as high as 40%.14 Apart from age and donor source, GVHD is considered a major 
posttransplant risk factor as both GVHD per se and the immunosuppressive drugs used for its 
prophylaxis and treatment are associated with impaired immune recovery and concomitant 
infectious morbidity. Even in our analysis of postengraftment infections (Chapter 2), GVHD 
turned out to be a very important contributing risk factor as GVHD was involved in no less 
than 60% of infection-related deaths. At one year posttransplant, 23% of BM recipients and 
36% of PBPC recipients had experienced chronic extensive GVHD, indicating that a procedure 
of partial T-cell depletion leaving 1-2 x 105 T cells/kg in the graft did not su  ciently prevent 
GVHD especially in case of PBPCT, which, together with already little T-cell immunity, resulted 
in high infection-related morbidity and mortality. Therefore, a more stringent depletion of 
T cells might be preferred in patients at high risk of GVHD whereas patients at lower risk 
of GVHD might bene t from the conventional approach based on unmanipulated SCT and 
posttransplant immunosuppression.
Immune recovery and postengraftment infections
Age, graft manipulation, alternative donor source, and/or GVHD; all these factors are re-
sponsible for impaired posttransplant immune reconstitution putting patients at increased 
risk of postengraftment opportunistic infections. As the human immune system is very 
extensive and multiple defects of immunity have been described, it is of particular interest 
which speci c defect may account for the increased susceptibility of allo-SCT recipients for 
postengraftment infections.
Several studies have shown an association between low B-cell immunity and late post-
transplant infections. Storek et al analyzed mononuclear cell subset counts in 108 alloge-
neic marrow recipients and showed a signi cant association between low B-cell numbers 
at day 80 and late day 100-365 infections.15 Earlier reports had already shown a correlation 
between serum IgG levels and late infections. Sheridan et al found a signi cant correlation 
between the incidence of late (> 6 months) pneumococcal infections and serum IgG2 and 
94 Chapter 6
IgG4 levels at the time of infection and comparable results were obtained by Riches et al 
reporting a 3.5-fold increased incidence of late infections in patients with low serum IgG2 
and IgG4 levels.16,17 Correlation between T-cell immunity and postengraftment infections was 
shown predominantly in reports concerning CMV reactivation and disease. CMV has been 
frequently documented as causative infectious agent accounting for nearly half of all de nite 
postengraftment viral infections (Chapter 2). CD8+ CMV-speci c CTL are primarily responsible 
for elimination of active CMV infection and in absence of adequate CD8+ cytotoxic activity in 
vitro, patients are at increased risk of developing severe CMV disease.18-20 Furthermore, lack of 
HLA-speci c CD8+ CMV-speci c CTL as quanti ed by using so-called tetramers, is associated 
with persistent CMV antigenemia and CMV disease.21 Help of CD4+ T cells has proven to be 
indispensable for adequate CMV speci c CTL responses and failure of an adequate CD4+ Th 
response is highly associated with non-detectable CD8+ CTL responses. Analysis of late (> day 
+100) CMV infection and disease in 146 allogeneic marrow recipients showed a signi cant 
correlation between CD4+ T cell counts below 50 cells/mm3 and the probability of late CMV 
disease.22 Previous reports concerning limited numbers of allogeneic marrow transplant 
recipients had already identi ed a low CD4+ T-cell count as independent and signi cant risk 
factor for overall infectious morbidity. 13,23 Even the probability of late invasive aspergillosis, 
which may account for half of all fatal postengraftment pneumonias (Chapter 2), seems as-
sociated with CD4+ lymphopenia.24 So, CD4+ Th cells have a central role in postengraftment 
T-cell immunity. Given the interaction of CD4+ Th cells and B cells,25 it is likely that CD4+ Th 
cells are also important to restore postengraftment B-cell immunity. An IgG2/IgG4 de ciency 
as described earlier, for example, might have resulted from insu  cient T-cell help for produc-
tion of immunoglobulins.
Mere quanti cation of posttransplant lymphocyte numbers may be insu  cient for predic-
tion of postengraftment infectious morbidity and mortality. As shown in Chapter 2, rates of 
severe and life-threatening infections were comparable between BM and PBPC recipients 
despite faster quantitative CD4+ and CD8+ T-cell recovery following PBPCT. T-cell functioning, 
however, might well have been impaired due to chronic GVHD and its immunosuppressive 
treatment, which was observed signi cantly more frequently following PBPCT. If quantitative 
assays like  ow cytometry and tetramer staining would be combined with functional assays 
including intracellular cytokine staining, a more accurate analysis of postengraftment T-cell 
immunity towards various pathogens could be accomplished.
Thymus
Thymic function and immune reconstitution
Delayed reconstitution of CD4+ T cells following SCT has been shown to be a signi cant risk 
factor for posttransplant infectious morbidity and mortality. How does CD4+ T-cell generation 
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proceeds and how important is the role of the human thymus for reconstitution of CD4+ T 
cells following SCT?
CD4+ T-cell generation is accomplished by two alternative pathways: a thymic-dependent 
maturation of T cells from progenitors through thymopoiesis and a thymic-independent 
peripheral expansion of residual mature T cells either by homeostatic regulation (e.g. IL-7) 
or antigenic stimulation.26 The thymus-dependent pathway is primarily responsible for the 
generation of naive CD4+CD45RA+ T cells with a broadly diverse TCR repertoire.27 Thymic 
generation of naive CD4+ T cells, however, may require months to even years posttransplant 
especially in adult patients due to thymic involution and impairment of thymic function by 
GVHD. In contrast, thymus-independent generation of CD4+ T cells results in early accumu-
lation of large numbers of e ector and memory T cells restoring the peripheral T-cell pool 
within months following transplantation. TCR-repertoire diversity, however, remains limited 
even in recipients of unmanipulated stem cell grafts containing a higher T-cell inoculum.28,29
In view of the limited TCR diversity and lack of new naive CD4+ T cells able to respond to 
neo-antigens, thymic generation of naive CD4+ T cells even following unmanipulated SCT is 
considered to be necessary for a durable and complete reconstitution of immunity. Impair-
ment of HY-disparate skin graft rejection in thymectomized transplanted female hosts is 
one example of limited TCR diversity and relative inability to respond to neo-antigens in the 
absence of thymopoiesis.30 Additionally, thymic function as measured by  ow cytometry (RA 
phenotype), restoration of TCR diversity and levels of TRECs is correlated with the patient’s 
capacity to respond to vaccinations and posttransplant infectious morbidity and mortality.31
Monitoring of thymic function
Thymus-dependent T-cell lymphopoiesis is important for long-term immune competence 
following SCT. Thymic output may be estimated by using several di erent tools including 
measurement of thymic volume by chest computer tomography or magnetic resonance and 
quanti cation of phenotypically naive T cells by  ow cytometry. Thymic tissue volume, how-
ever, may not correlate with thymic output and  ow cytometry will not distinguish between 
recently emigrated naive T cells and long-lived naive T cells in the periphery. TRECs produced 
during TCRD deletion by δRec to ψJα rearrangement have been proposed as adequate and 
direct markers of thymic output. TRECs are stable, not duplicated during mitosis and conse-
quently diluted with each cellular division.32
Chapter 3 describes the development of a speci c and sensitive RQ-PCR for quanti cation 
of δRec- ψJα TRECs in mice. As in humans, mice use the δRec and ψJα gene segments to 
delete the TCRD locus.33 However, we measured an approximately twofold lower TREC level 
as compared to frequencies detected in human lymphocytes. In humans, approximately 70% 
of TCRD gene deletion rearrangements are mediated via the classical δRec and ψJα gene 
segments. Przybylski et al have identi ed an additional human cluster of seven δRec TCRD-
deleting elements (δRec2.1-2.7), which are used at a 100-fold lower frequency as compared 
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to the classical δRec rearrangements.34 In mice, three δRec TCRD-deleting elements (δRec1-3) 
have been identi ed with only δRec1 being used in our assay. It seems that the murine δRec1 
gene segment is used in a lower frequency than the classical human δRec element explaining 
the di erence in observed TREC levels. A di erential usage of the three murine δRec deleting 
elements might also be the explanation for the observed di erences in TREC levels between 
di erent mouse strains as described in Chapter 3. Concerning strain di erences, the observed 
polymorphism in the δRec-ψJα TREC sequence was striking and should be taken into account 
with TREC analysis in murine studies.
Apart from possible polymorphisms, which other more important factors need to be 
considered when interpreting TREC data in human and animal studies? First and most im-
portantly, cell division may in uence TREC levels in peripheral blood lymphocytes. Peripheral 
immune activation may result in expansion of the naive T-cell pool without loss of its naive 
phenotype but with subsequent TREC dilution.35 In Chapter 3, we describe an age-related 
decline in peripheral blood T-cell TREC content, which might be related to an age-related de-
cline in thymic output. However, continuous low levels of immune activation during life with 
short episodes of increased immune activation during infections might result in naive T-cell 
expansion and TREC dilution without apparent changes in thymic output of naive T cells.35
Second, little is still known of possible intracellular degradation of TRECs. So far, it seems 
that the half-life of TRECs in primates is rather substantial.36 In humans, TRECs were detected 
in peripheral blood CD4+ and CD8+ T lymphocytes 3-39 years following thymectomy and 
in thymectomized rhesus monkeys TRECs were still detectable one year postthymectomy. 
In chickens, however, the approximate half-life of TRECs is only two weeks. In Chapter 3, 
evaluation of TREC levels in thymectomized mice showed that TRECs were still detectable in 
peripheral blood seven months postthymectomy.
In conclusion, measurement of TRECs is another way of estimating thymic output of RTEs. 
However, earlier problems arising with cellular phenotyping still remain, as RTEs and long-
lived peripheral naive T cells are still indistinguishable by TREC quanti cation. Additionally, 
peripheral T-cell division rate, cellular death and possible intracellular degradation should be 
taken into account when interpreting TREC data. Collectively, these considerations indicate 
that more reliable and de nitive quantitative measures of posttransplant thymic output need 
to be developed in the future. One might think of additional cell surface markers able to phe-
notypically distinguish between RTEs and non-RTE naive T cells. In chickens, the thymocyte-
speci c antigen ChT1 has been identi ed as a reliable marker of RTEs.37 In humans, McFarland 
et al identi ed CD103 as cell surface marker of a distinct population of naive CD8+ RTEs.38
In anticipation of more accurate quantitative measures, immunophenotypic monitoring of 
naive T-cell recovery following allo-SCT may be preferred with additional TREC analysis if 
necessary. Functional immunity including T-cell reactivity and antibody production may be 
of interest only after T- and B-cell numbers have recovered. Monitoring of antigen-speci c 
immune reconstitution, quantitative as well as qualitative, might be very interesting as has 
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been shown for CMV and EBV. However, as multiple di erent pathogens may be involved 
following allo-SCT (Chapter 2), routine monitoring seems infeasible.
Interleukin-7
Interleukin-7 and posttransplant thymic function
Improvement of thymic function following allo-SCT has become subject of interest as the 
thymus has proven to be essential for naive CD4+ T-cell recovery, which is necessary for a 
complete and durable immune reconstitution. Are we able to improve posttransplant thymic 
function and which tools are available?
Posttransplant thymic function may be improved by protecting the nursing stromal cell 
compartment, which may be accomplished by administration of KGF or GH or by directly 
stimulating thymopoiesis.39 Several di erent candidate cytokines have been proposed as 
capable of improving posttransplant T-cell recovery by stimulating thymopoiesis including 
Flt3-Ligand, SCF and IL-7. The focus of this thesis has mainly been improvement of thy-
mopoiesis following SCT by IL-7. In Chapter 4, we describe an experimental congenic BMT 
model using T-cell-de cient RAG-1-/- mice. In this particular model, IL-7 preferentially a ected 
peripheral expansion of mature T cells either co-infused with the graft or recently emigrated 
from the thymus, whilst thymopoiesis itself appeared virtually una ected. Reports concern-
ing the possible thymus-restoring capacities of IL-7 have shown contradictory results. Bolotin 
et al reported application of IL-7 in a syngeneic myeloablative BMT model and showed 
increased thymic cellularity in IL-7-treated normal C57BL/6 mice.40 Alpdogan et al applied 
IL-7 in an allogeneic murine transplantation model and showed increased thymopoiesis in 
both young and middle-aged IL-7-treated recipient mice.41 Mackall et al were the  rst to 
study peripheral expansion in addition to thymic generation of T cells.42 Peripheral antigen 
driven expansion was signi cantly increased in IL-7-treated mice. Additionally, upregulation 
of thymic-dependent progeny was observed, which may be interpreted as a direct e ect on 
thymopoiesis. However, in view of Chapter 4, that observation might well have been a re ec-
tion of peripheral expansion of RTEs. Moreover, results obtained in aged mice of 18-24 months 
were striking, as IL-7 did not a ect thymopoiesis at all.42 Collectively, these observations sug-
gest that a de cient thymopoiesis as observed in aged mice with involuted thymuses and in 
RAG-1-/- mice cannot be fully restored by exogenous IL-7 administration. Further preclinical 
studies in non-human primates by Storek et al showed increased CD4+ T-cell recovery in IL-7-
treated primates again due to stimulation of peripheral expansion instead of de novo genera-
tion of T cells.43 In summary, IL-7 may be a promising immunorestorative agent in patients 
experiencing extreme lymphopenia, although a true increase in thymopoiesis seems to play 
a minor role especially in case of impaired thymic function. Therefore, further research con-
cerning improvement of posttransplant thymic function seems to be necessary. One might 
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think of other immunorestorative agents like Flt3-Ligand and SCF, thymic stroma protecting 
cytokines like KGF or a combination of the two. Complete replacement of the adult involuted 
thymus with a ´neo-thymus´, however, will be the ultimate goal of future research. Already 
in the nineteen-seventies, successful fetal thymic transplantation in patients with complete 
diGeorge syndrome was described.44 With the scarcity and concomitant ethical drawbacks of 
using fetal tissues, reports emerged using cultured postnatal thymic tissue for transplantation 
in complete diGeorge syndrome, which showed successful reconstitution of the peripheral 
T-cell compartment.45,46 As cell-based therapies are now being developed with the use of 
stem cells originating from embryonic, fetal or adult tissues as inexhaustible source of any 
adult tissue, interest in formation of a complete and functional thymic microenvironment 
from thymic epithelial stem/progenitor cells is growing. Boyd and co-workers already identi-
 ed a progenitor population of thymic epithelial cells in mice able to reconstitute the thymic 
epithelial microenvironment and support normal T-cell development using the cell surface 
expression of MTS24.47 Recent studies in mice have shown that a so-called bi-potent progeni-
tor cell exists in the embryonic epithelial compartment able to give rise to both cortical and 
medullary epithelial cells with evidence that a similar progenitor cell may be present in the 
postnatal thymus.48-50 Isolation of that rare bi-potent progenitor cell may be the basis of cell-
based therapies for thymic disorders including age-related thymic involution and congenital 
defects in thymus development.
IL-7 and alloreactivity
IL-7 has been shown to enhance posttransplant immune recovery predominantly by a ect-
ing peripheral homeostatic expansion of T cells either co-infused with the graft or recently 
emigrated from the thymus. One major concern of posttransplant administration of IL-7 is its 
possible aggravating e ect on alloreactivity as it might enhance the response of mature T cells 
to alloantigens. IL-7 and its role in alloreactivity has been subject of study in several earlier 
reports, however, all concerned graft-versus-host reactivity thus far. In Chapter 5, we applied 
IL-7 in a MHC-matched minor antigen-mismatched murine transplantation model to study 
the e ect of IL-7 administration on host-versus-graft reactivity and subsequent rejection and 
show that posttransplant IL-7 treatment may protect against minor antigen-mismatched graft 
rejection. Alpdogan et al already suggested that IL-7 might have an anti-GVHD e ect as IL-7 
was found to consistently ameliorate GVHD following MHC-mismatched BMT.41 In contrast, 
IL-7 has also been shown to aggravate GVHD by lowering the ´threshold´ T-cell dose required 
for induction of clinical and lethal GVHD following MHC-mismatched BMT although by using 
a signi cantly higher dose of IL-7 during a longer posttransplant period of time.51
What mechanism might be responsible for the observed protective e ect of IL-7 both 
on host-versus-graft and graft-versus-host reactivity? Alpdogan et al suggested an IL-7-
dependent shift towards a Th2 cytokine pro le as IL-7 administration resulted in fewer TNF-α 
expressing allogeneic T cells. However, no signi cant di erences between IL-7 and placebo 
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treated mice were found in the intracytoplasmic expression of other type 1 and 2 related 
cytokines including IFN-γ, IL-2, IL-4 and IL-10 nor in cytolytic T-cell activity.41 Our observations 
are in line with Alpdogan et al. As shown in Chapter 5, T-cell phenotype and Th1/Th2 balance 
as expressed by the IL-4/IFN-γ ratio remained unaltered and una ected by IL-7 administra-
tion. We suggest that IL-7 protects against MHC-matched minor antigen-mismatched BMT 
via peripheral expansion of CD4+CD25highFoxp3+ Treg. Treg play an important role in the 
regulation and suppression of host-versus-graft reactivity. Pretransplant depletion of recipi-
ent CD25+ T cells has been shown to reduce levels of donor engraftment and the adoptive 
transfer of large numbers of CD4+CD25+ Treg at the time of allo-SCT may prevent bone marrow 
graft rejection.52-54 As shown in Chapter 5, IL-7 treatment of MHC-matched minor antigen-
mismatched marrow recipients resulted in enhanced recovery of CD4+CD25highFoxp3+ Treg. 
That observation might be explained by a direct e ect of IL-7 through its receptor, which 
was expressed on CD4+Foxp3+ Treg although at lower levels as compared to their CD4+Foxp3-
counterparts (Chapter 5). Recent reports in humans, however, have suggested a downregula-
tion of IL-7Rα expression on CD4+CD25highFoxp3+ Treg.55 Furthermore, IL-7Rα (CD127) has been 
proposed as biomarker for human Treg as CD127 expression inversely correlates with Foxp3 
expression and concomitant suppressor function.56,57 Alternatively, IL-7 may indirectly a ect 
recovery of Treg through another growth factor. As key regulator of CD4+CD25highFoxp3+ Treg, 
IL-2 has been shown to increase the frequency of peripheral blood CD4+CD25high Treg as well 
as Foxp3 expression.58 In vitro studies have shown induction of CD25 (IL-2Rα) expression on 
CD4+ T cells following IL-7 treatment.59,60 IL-7 may have facilitated endogenous IL-2 activity by 
upregulation of IL-2Rα expression on CD4+ T cells, thereby indirectly a ecting the recovery of 
CD4+CD25highFoxp3+ Treg in our murine alloreactivity model.
IL-7 and hematopoietic stem cell transplantation: future perspectives
A ecting T-cell lymphopoiesis, peripheral T-cell homeostasis, and transplantation tolerance: 
the many faces of IL-7. Is it time to change from bench to bedside?
Clinical development of IL-7 is currently underway and so far one clinical report has 
emerged which describes administration of four di erent doses of rhIL-7 to twelve patients 
with metastatic cancer.55 IL-7 administration was well tolerated and resulted in a rapid and 
signi cant increase in peripheral blood CD4+ and CD8+ T lymphocytes. Considering its biologi-
cal properties and preclinical data, IL-7 could potentially serve as lymphoid growth factor to 
correct T-cell lymphopenia following hematopoietic SCT. Allogeneic transplant recipients in 
particular might bene t from IL-7 treatment as these patients experience a prolonged period 
of immunode ciency due to impaired recovery of thymic dependent naive T cells, which is 
indispensable for a durable and complete immune reconstitution both following TCD- and 
unmanipulated allo-SCT. Posttransplant thymic dysfunction is a consequence of multiple 
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factors including age, direct e ects of chemoradiotherapy and GVHD and may be associated 
with loss of IL-7 producing thymic epithelial cells (TECs) and subsequent IL-7 de ciency. IL-7-
treated aged mice show signi cant increases in thymic weight and numbers of intrathymic 
TN thymocytes and thymic levels of IL-7 mRNA are signi cantly decreased in irradiated versus 
normal mice.61-63 In contrast, treatment of very aged mice with IL-7 does not lead to increases 
in thymic output and analysis of IL-7 mRNA expression in adult human thymi does not show 
an age-associated decline.64,65 Moreover, IL-7 has been shown to enhance thymopoiesis in 
several experimental transplantation models, although only in young, and to a lesser extent in 
middle-aged otherwise healthy wild-type mice, whereas in aged and RAG-1-/- mice increases 
in thymic-dependent progeny have not been observed.40-42 Therefore it appears unlikely that 
an isolated IL-7 de ciency is the sole cause of thymic dysfunction associated with allo-SCT. 
Apart from intrathymic IL-7 production, normal thymic T-cell development depends on 
signals provided by a functionally competent 3-dimensional meshwork of primarily cortical 
and medullary TECs. Thymic aging is featured by development of an abnormal architecture 
with loss of corticomedullary distinction and the appearance of areas devoid of epithelial 
cells.66 Additionally, GVHD as major allo-SCT related complication is associated with loss of 
thymic architecture and subsequent aberrant T-cell development. In a radiation-independent 
haplo-identical murine transplantation model, it was shown that acute GVHD and to a 
lesser extent chronic GVHD caused severe morphologic alterations in the thymic stromal 
microenvironment.67 Recent in vitro and in vivo data indicate that IFN-γ mediated signalling 
is causally linked to thymic epithelial injury.68 Although exogenous IL-7 may substitute for 
a possible intrathymic IL-7 de ciency due to impaired TEC function, strategies directed at 
protection of TECs from transplant-related injuries seem necessary to improve thymic de-
pendent T-cell reconstitution following allo-SCT. Promising results have been obtained with 
KGF, a mesenchymally derived member of the  broblast growth factor family important for 
maintenance of TECs. In a non-conditioned haplo-identical murine transplantation model, 
KGF preserved normal thymic development despite the systemic presence of acute GVHD 
and a recent report by Min and colleagues showed improved thymopoiesis by KGF in two 
experimental murine models of aging.67,69 Although a true increase in thymopoiesis will likely 
play a minor role in the clinical e ect of IL-7 treatment, it still may provide important bene ts 
for patients with profound T-cell lymphopenia through its e ect on homeostatic peripheral 
T-cell expansion and postthymic homeostatic cycling of RTEs.70 IL-7 might even have a role 
in posttransplant induction of tolerance through its positive e ects on Treg that play a 
major role in the regulation and suppression of alloreactivity. Such a role might especially 
be envisaged in alternative donor transplantation associated with higher incidences of graft 
failure, such as UCBT, which is associated with the infusion of low numbers of hematopoietic 
progenitor cells, especially in adult recipients. Such tolerizing e ects, however, need to be 
explored more in depth  rst and weighed against possible negative e ects with respect to 
anti-tumor activity, which may be suppressed in the presence of Treg.71 Further research in 
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preclinical murine and non-human primate models seems essential. Currently, promising ex-
periments are performed in non-human primates combining KGF as cytoprotective agent for 
TEC and IL-7 as key regulator of peripheral T-cell homeostasis. In anticipation of more decisive 
and unambiguous results, application of IL-7 should be limited to TCD-allo-SCT especially as 
possible aggravating e ects on GVHD should still be kept in mind.51
102 Chapter 6
References
 1. Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A, Miller W, Weisdorf D. Late infections 
after allogeneic bone marrow transplantation: comparison of incidence in related and unrelated 
donor transplant recipients. Blood 1995;86:3979-3986.
 2. Atkinson K, Storb R, Prentic RL, Weiden PL, Witherspoon RP, Sullivan K, Noel D, Thomas ED. Analy-
sis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979;53:
720-731.
 3. Atkinson K, Farewell V, Storb R, Tsoi MS, Sullivan KM, Witherspoon RP, Fefer A, Clift R, Goodell B, 
Thomas ED. Analysis of late infections after human bone marrow transplantation: role of geno-
typic non-identity between marrow donor and recipient and of non-speci c suppressor cells in 
patients with chronic graft-versus-host disease. Blood 1982;60:714-720.
 4. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, Witherspoon RP, Bensinger 
W, Flowers ME, Martin P, Storb R, Appelbaum FR, Boeckh M. Immune reconstitution after allo-
geneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:
3380-3389.
 5. Parody R, Martino R, Rovira M, Vazquez L, Vázquez MJ, de la Cámara R, Blazquez C, Fernández-
Avilés F, Carreras E, Salavert M, Jarque I, Martín C, Martínez F, López J, Torres A, Sierra J, Sanz 
GF; Infectious/Non-infectious Complications Subcommitte of the Grupo Español de Trasplante 
Hematopoyético (GETH). Severe infections after unrelated donor allogeneic hematopoietic stem 
cell transplantation in adults: comparison of cord blood transplantation with peripheral blood 
and bone marrow transplantation. Biol Blood Marrow Transplant 2006;12:734-748.
 6. Maris M, Boeckh M, Storer B, Dawson M, White K, Keng M, Sandmaier B, Maloney D, Storb R, 
Storek J. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative 
conditioning. Exp Hem 2003;31:941-952.
 7. Kernan NA. T-cell depletion for the prevention of graft-vs.-host disease. In: Thomas DE, Blume KG 
and Forman SJ, editors. Malden Hematopoietic Cell Transplantation (2nd ed.). Blackwell Science 
1999:186–196.
 8. Cornelissen JJ, Löwenberg B. Developments in T-cell depletion of allogeneic stem cell grafts. Curr 
Opin Hematol 2000;7:348-352.
 9. Verdonck LF, Dekker AW, de Gast GC, van Kempen ML, Lokhorst HM, Nieuwenhuis HK. Allogeneic 
bone marrow transplantation with a  xed low number of T cells in the marrow graft. Blood 1994;
83:3090-3096.
 10. Martínez C, Urbano-Ispizua A, Rozman C, Martín P, Rovira M, Sierra J, Montfort N, Carreras E, 
Montserrat E. Immune reconstitution following allogeneic peripheral blood progenitor cell 
transplantation: Comparison of recipients of positive CD34+ selected grafts with recipients of 
unmanipulated grafts. Exp Hematol 1999;27:561-568.
 11. Behringer D, Bertz H, Schmoor C, Berger C, Dwenger A, Finke J. Quantitative lymphocyte subset 
reconstitution after allogeneic hematopoietic transplantation from matched related donors with 
CD34+ selected PBPC grafts, unselected PBPC grafts or BM grafts. Bone Marrow Transplant 1999;
24:295-302.
 12. Small TN, Avigan D, Dupont B, Smith K, Black P, Heller G, Polyak T, O´Reilly RJ. Immune reconstitu-
tion following T-cell depleted bone marrow transplantation: e ect of age and post-transplant 
graft rejection prophylaxis. Biol Blood Marrow Transplant 1997;3:65-75.
 13. Small TN, Papadopoulos EB, Boulad F, Black P, Castro-Malaspina H, Childs BH, Collins N, Gillio 
A, George D, Jakubowski A, Heller G, Fazzari M, Kernan N, MacKinnon S, Szabolcs P, Young JW, 
O´Reilly RJ. Comparison of immune reconstitution after unrelated and related T-cell depleted 
bone marrow transplantation: e ect of patient age and donor leukocyte infusions. Blood 1999;
93:467-480.
 14. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei 
C, Latini P, Reisner Y, Martelli MF. Treatment of high-risk acute leukemia with T-cell-depleted stem 
cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:
1186-1193.
General discussion 103
 15. Storek J, Espino G, Dawson MA, Storer B, Flowers ME, Maloney DG. Low B-cell and monocyte 
counts on day 80 are associated with high infection rates between days 100 and 365 after al-
logeneic marrow transplantation. Blood 2000;96:3290-3293.
 16. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass de ciency and 
pneumococcal infection after allogeneic BMT. Blood 1990;75:1583-1586.
 17. Riches PG, Walker SA, Rogers TR, Hobbs JR. Relative de ciency of serum IgA, IgG2 and IgG4 during 
reconstitution following BMT: relationship to infection. Bone Marrow Transplant 1986;1(suppl 
1):53.
 18. Quinnan GV Jr, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos GW, Saral R, 
Burns WH. Cytotoxic T cells in cytomegalovirus infection: recovery from cytomegalovirus infec-
tion in bone marrow transplant recipients. N Engl J Med 1982;307:7-13.
 19. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomega-
lovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation 
with cytomegalovirus infection and disease. Blood 1991;78:1373-1380.
 20. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomega-
lovirus (CMV)-speci c T-cell responses after allogeneic bone marrow transplant: correlation with 
CMV disease and e ect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
 21. Gratama JW, van Esser JW, Lamers CH, Tournay C, Löwenberg B, Bolhuis RL, Cornelissen JJ. 
Tetramer-based quanti cation of cytomegalovirus (CMV)-speci c CD8+ T lymphocytes in T-cell 
depleted stem cell grafts and after transplantation may identify patients at risk for progressive 
CMV infection. Blood 2001;98:1358-1364.
 22. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers 
ME, Cunningham T, Corey L. Late cytomegalovirus disease and mortality in recipients of alloge-
neic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 
2003;101:407-414.
 23. Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R. Infectious morbidity in long-term survi-
vors of allogeneic marrow transplantation is associated with low CD4 T cell counts. Am J Hematol 
1997;54:131-138.
 24. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell 
transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-4366.
 25. Smith KM, Pottage L, Thomas ER, Leishman AJ, Doig TN, Xu D, Liew FY, Garside P. Th1 and Th2 
CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner 
in vivo. J Immunol 2000;165:3136-3144.
 26. Hakim FT, Gress RE. Reconstitution of the lymphocyte compartment after lymphocyte depletion: 
a key issue in clinical immunology. Eur J Immunol 2005;35:3099-3102.
 27. Spits H. Development of alphabeta T cells in the human thymus. Nat Rev Immunol 2002;2:760-
772.
 28. Dumont-Girard F, Roux E, van Lier RA, Hale G, Helg C, Chapuis B, Starobinski M, Roosnek E. 
Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the 
repertoire by thymic emigrants. Blood 1998;92:4464-4471.
 29. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, 
Shad AT, Steinberg SM, Wexler LH, Gress RE. Age, thymopoiesis, and CD4+ T-lymphocyte regen-
eration after intensive chemotherapy. N Engl J Med 1995;332:143-149.
 30. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE. Thymic-independent T cell regen-
eration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is 
limited in diversity and prone to skewing. J Immunol 1996;156:4609-4616.
 31. Roux E, Dumont-Girard F, Starobinski M, Siegrist CA, Helg C, Chapuis B, Roosnek E. Recovery of im-
mune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. 
Blood 2000;96:2299-2303.
 32. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, Polis MA, Haase AT, Feinberg 
MB, Sullivan JL, Jamieson BD, Zack JA, Picker LJ, Koup RA. Changes in thymic function with age 
and during the treatment of HIV infection. Nature 1998;396:690-695.
 33. Hockett RD Jr, Nuñez G, Korsmeyer SJ. Evolutionary comparison of murine and human delta T-cell 
receptor deleting elements. New Biol 1989;1:266-274.
104 Chapter 6
 34. Przybylski GK, Wanzeck J, Verschuren MC, van Dongen JJ, Serke S, Schmidt CA. Identi cation of a 
new cluster of T-cell receptor delta recombining elements. Immunology 2003;108:16-23.
 35. Hazenberg MD, Otto SA, Cohen Stuart JW, Verschuren MC, Borle s JC, Boucher CA, Coutinho RA, 
Lange JM, Rinke de Wit TF, Tsegaye A, van Dongen JJ, Hamann D, de Boer RJ, Miedema F. Increased 
cell division but not thymic dysfunction rapidly a ects the T-cell receptor excision circle content 
of the naive T cell population in HIV-1 infection. Nat Med 2000;6:1036-1042.
 36. Hazenberg MD, Verschuren MC, Hamann D, Miedema F, van Dongen JJ. T cell receptor excision 
circles (TRECs) as markers for recent thymic emigrants. Basic aspects, technical approach, and 
guidelines for interpretation. J Mol Med 2001;79:631-640.
 37. Kong F, Chen CH, Cooper MD. Thymic function can be accurately monitored by the level of recent 
T cell emigrants in the circulation. Immunity 1998;8:97-104.
 38. McFarland RD, Douek CD, Koup RA, Picker LJ. Identi cation of a human recent thymic emigrant 
phenotype. Proc Natl Acad Sci USA 2000;97:4215-4220.
 39. Wils EJ, Cornelissen JJ. Thymopoiesis following allogeneic stem cell transplantation: new pos-
sibilities for improvement. Blood Rev 2005;19:89-98.
 40. Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after 
bone marrow transplant by in vivo interleukin-7. Blood 1996;88:1887-1894.
 41. Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA Rich BE, van 
den Brink MR. Administration of interleukin-7 after allogeneic bone marrow transplantation 
improves immune reconstitution without aggravating graft-versus-host disease. Blood 2001;98:
2256-2265.
 42. Mackall CL, Fry TJ, Bare C, Morgan P, Galbraith A, Gress RE. IL-7 increases both thymic-dependent 
and thymic-independent T-cell regeneration after bone marrow transplantation. Blood 2001;97:
1491-1497.
 43. Storek J, Gillespy T 3rd, Lu H, Joseph A, Dawson MA, Gough M, Morris J, Hackman RC, Hom PA, 
Sale GE, Andrews RG, Maloney DG, Kiem HP. Interleukin-7 improves CD4 T-cell reconstitution after 
autologous CD34 cell transplantation in monkeys. Blood 2003;101:4209-4218.
 44. August CS, Berkel AI, Levey RH, Rosen FS, Kay HE. Establishment of immunological competence in 
a child with congenital thymic aplasia by a graft of fetal thymus. Lancet 1970;1:1080-1083.
 45. Markert ML, Boeck A, Hale LP, Kloster AL, McLaughlin TM, Batchvarova MN, Douek DC, Koup RA, 
Kostyu DD, Ward FE, Rice HE, Maha ey SM, Schi  SE, Buckley RH, Haynes BF. Transplantation of 
thymus tissue in complete diGeorge syndrome. N Engl J Med 1999;341:1180-1189.
 46. Martkert ML, Devlin BH, Alexie  MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He 
M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge 
anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. 
Blood 2007;109:4539-4547.
 47. Gill J, Malin M, Holländer GA, Boyd R. Generation of a complete thymic microenvironment by 
MTS24(+) thymic epithelial cells. Nat Immunol 2002;3:635-642.
 48. Gordon J, Wilson VA, Blair NF, Sheridan J, Farley A, Wilson L, Manley NR, Blackburn CC. Functional 
evidence for a single endodermal origin for the thymic epithelium. Nat Immunol 2004;5:546-
553.
 49. Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. Clonal analysis reveals a common progenitor 
for thymic cortical and medullary epithelium. Nature 2006;441:988-991.
 50. Bleul CC, Corbeaux T, Reuter A, Fisch P, Mönting JS, Boehm T. Formation of a functional thymus 
initiated by a postnatal epithelial progenitor cell. Nature 2006;441:992-996.
 51. Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL. Interleukin 7 worsens graft-versus-host disease. 
Blood 2002;100:2642-2649.
 52. Taylor PA, Panoskaltsis-Mortari A, Swedin JM, Lucas PJ, Gress RE, Levine BL, June CH, Serody JS, 
Blazar BR. Lselectinhi but not Lselectinlo CD4+CD25+ regulatory T cells are potent inhibitors of 
GVHD and BM graft rejection. Blood 2004;104:3804-3812.
 53. Johnson BD, Konkol MC, Truitt RL. CD25+ Immunoregulatory T-cells of donor origin suppress al-
loreactivity after BMT. Biol Blood Marrow Transplant 2002;8:525-535.
 54. Jo re O, Gorsse N, Romagnoli P, Hudrisier D, van Meerwijk JP. Induction of antigen-speci c toler-
ance to bone marrow allografts with CD4+CD25+ T lymphocytes. Blood 2004;103:4216-4221.
General discussion 105
 55. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Mor-
ton KE, Mavroukakis SA, Morre M, Bu et R, Mackall CL, Gress RE. IL-7 administration to humans 
leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J 
Immunother 2006;29:313-319.
 56. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas 
de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely 
correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203:
1701-1711.
 57. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, 
Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 
receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:
1693-700.
 58. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, 
Soi er RJ, Frank DA, Ritz J. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T 
cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. 
Blood 2006;108:1571-1579.
 59. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. Regulation of human T cell proliferation by 
IL-7. J Immunol 1990;144:938-941.
 60. Managlia EZ, Landay A, Al-Harthi L. Interleukin-7 signalling is su  cient to phenotypically and 
functionally prime human CD4+ naïve T cells. Immunology 2005;114:322-335.
 61. Aspinall R, Andrew D. Thymic atrophy in the mouse is a soluble problem of the thymic environ-
ment. Vaccine 2000;18:1629-1637.
 62. Andrew D, Aspinall R. IL-7 and not stem cell factor reverses both the increase in apoptosis and the 
decline in thymopoiesis seen in aged mice. J Immunol 2001;166:1524-1530.
 63. Chung B, Barbara-Burnham L, Barsky L, Weinberg K. Radiosensitivity of thymic interleukin-7 
production and thymopoiesis after bone marrow transplantation. Blood 2001;98:1601-1606.
 64. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002;99:3892-3904.
 65. Sempowski GD, Hale LP, Sundy JS, Massey JM, Koup RA, Douek DC, Patel DD, Haynes BF. Leukemia 
inhibitory factor, oncostatin M, IL-6, and stem cell factor mRNA expression in human thymus 
increases with age and is associated with thymic atrophy. J Immunol 2000;164:2180-2187.
 66. Takeoka Y, Chen SY, Yago H, Boyd R, Suehiro S, Shultz LD, Ansari AA, Gershwin ME. The murine 
thymic microenvironment: changes with age. Int Arch Allergy Immunol 1996;111:5-12.
 67. Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL, Weinberg KI, Krenger W, Holländer GA. 
Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment dur-
ing experimental graft-versus-host disease. Blood 2002;100:682-691.
 68. Hauri-Hohl MM, Keller MP, Gill J, Hafen K, Pachlatko E, Boulay T, Peter A, Holländer GA, Krenger W. 
Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone 
marrow transplantation. Blood 2007;109:4080-4088.
 69. Min D, Panoskaltsis-Mortari A, Kuro-O M, Holländer GA, Blazar BR, Weinberg KI. Sustained thy-
mopoiesis and improvement in functional immunity induced by exogenous KGF administration 
in murine models of aging. Blood 2007;109:2529-2537.
 70. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J 
Immunol 2005;174:6571-6576.
 71. Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, 
Klebano  CA, Overwijk WW, Rosenberg SA, Restifo NP. CD8+ T cell immunity against a tumor/self-
antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory 
cells. J Immunol 2005;174:2591–2601.

Chapter 7
Summary/Samenvatting

Summary 109
Summary
Allogeneic stem cell transplantation (allo-SCT) has been established as important treatment 
modality for patients with hematological malignancies, aplastic anemia, and inborn errors of 
hematopoietic progenitor cells. Nevertheless, major lethal and non-lethal complications still 
prohibit a full implementation of allo-SCT. Opportunistic infections are considered a frequent 
and serious complication of allo-SCT due to impaired immune reconstitution following allo-
SCT. Delayed recovery of thymus-dependent naive CD4+ T cells, in particular, is associated 
with signi cant susceptibility to opportunistic infections and subsequent transplant-related 
morbidity and mortality.
Improvement of thymopoiesis following allo-SCT has become subject of interest. Inter-
leukin-7 (IL-7) has been identi ed as key regulator of T-cell lymphopoiesis and peripheral 
homeostatic T-cell expansion. Preclinical evaluation of posttransplant administration of IL-7 
has shown e ects both on thymic T-cell development and peripheral T-cell expansion. 
Considerable controversy exists with respect to IL-7 and its e ect on alloreactivity. The 
work as described in this thesis aims to further clarify the immunorestorative capacities of 
posttransplant IL-7 administration and its role in alloreactivity using experimental murine 
transplantation models.
Chapter 1 represents an introduction to allo-SCT with emphasis on posttransplant im-
mune reconstitution and IL-7.
Chapter 2 describes a retrospective study of postengraftment day 30 to day 365 opportu-
nistic infections in a population of allogeneic HLA-identical T-cell-depleted (TCD) transplant 
recipients. Postengraftment opportunistic infections, in particular, may cause substantial 
transplant-related morbidity and mortality. Incidence, cause and outcome of postengraft-
ment infections were compared between 47 recipients of bone marrow (BM) vs. 40 recipients 
of peripheral blood progenitor cells (PBPC). PBPC grafts contained signi cantly more CD34+
cells and transplantation of PBPC was associated with signi cantly faster neutrophil and 
lymphocyte recovery as compared to BM. PBPC recipients experienced signi cantly more 
chronic graft-versus-host disease (GVHD). At one year following transplantation, 65% of BM 
recipients had experienced at least one severe (CTC grade 3-4) postengraftment infection 
compared to 68% of PBPC recipients. Viruses were the most important infectious agents both 
in BM and PBPC recipients followed by bacteria and fungi. Treatment-related mortality at one 
year following transplantation was 30% versus 34% in recipients of BM and PBPC respectively 
without signi cant di erences in infection-related mortality. It was concluded that the higher 
incidence of chronic GVHD as observed in PBPC recipients may have blunted the favorable 
e ect of faster hematopoietic recovery by putting patients at increased risk of opportunistic 
infections.
Chapter 3 describes the development and validation of a real-time quantitative poly-
merase chain reaction for detection of signal joint T-cell receptor rearrangement excision 
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circles (sjTRECs) in lymphoid organs and peripheral blood leukocytes of mice. As in humans, 
quanti cation of sjTRECs in mice may allow for a more accurate assessment of thymic output 
in murine stem cell transplantation models. The assay was shown to be sensitive with a 
detection limit of approximately 1 sjTREC in 100 ng DNA corresponding to 15 000 nucleated 
cells. Speci city was demonstrated by absence of sjTRECs in RAG-1-/- mice. B6 mice showed 
an unexpected polymorphism in the sjTREC sequence necessitating design of an additional 
primer/probe combination with comparable e  ciency. SjTREC levels declined in aging and 
thymectomized mice. Over a lifespan of 2.5 years, a tenfold drop in sjTREC frequency was ob-
served in B6 mice. Moreover, signi cant mouse strain-dependent di erences were observed. 
It was concluded, that quanti cation of sjTRECs may allow for accurate assessment of thymic 
output in age- and strain-matched mice, which may be of use in experimental transplanta-
tion models studying thymic output and T-cell recovery following SCT.
In Chapter 4, quanti cation of sjTRECs supplementary to adequate  ow cytometric analy-
sis of various T-cell subsets were used to study the e ect of exogenous IL-7 on posttransplant 
lymphocyte recovery using T-cell-de cient RAG-1-/- mice as recipients of congenic TCD- or 
T-cell-replete BM grafts. As both thymic T-cell development and peripheral T-cell expansion 
may be a ected by exogenous IL-7, we asked the question whether IL-7 would preferably 
promote thymopoiesis or rather expand recent thymic emigrants (RTEs) or mature peripheral 
T cells following SCT in the setting of compromised thymopoiesis. Unirradiated B6-RAG-1-/-
mice received a TCD congenic B6-Ly5.1 BM graft supplemented with B6-Ly5.2 mature splenic 
T cells. BM-derived and supplemented T cells were distinguished by CD45.1 and CD45.2 
expression respectively. Posttransplant IL-7 administration resulted in an early and sustained 
increase of CD45.2+CD3+ T cells as compared to PBS treatment whereas the recovery of BM-
derived CD45.1+CD3+ T cells remained una ected even after increasing the dose of IL-7. In 
contrast, IL-7 administration signi cantly enhanced BM-derived T-cell recovery following 
TCD-BMT. SjTREC levels in thymus, spleen en peripheral blood leukocytes suggested expan-
sion of BM-derived T cells after export from the thymus whereas thympoiesis seemed only 
moderately a ected. It was concluded, that peripheral expansion of either RTEs or mature T 
cells may be a preferential mechanism by which IL-7 enhances T-cell recovery following SCT.
Chapter 5 addresses the major concern of posttransplant IL-7 administration, which is its 
possible aggravating e ect on alloreactivity by enhancement of the alloantigen-reactive 
T-cell population. Reports concerning the e ect of IL-7 on graft-versus-host reactions have 
yielded con icting results and it is unknown whether IL-7 may a ect host-versus-graft 
(HVG) alloreactivity. Therefore, we applied IL-7 in an experimental stem cell transplantation 
model using RAG-1-/- mice supplied with B6 CD45.1 congenic T cells to study the e ect of IL-7 
administration on HVG reactivity following SCT across major and minor histocompatibility 
barriers. Rejection was de ned as a sustained peripheral blood CD45.2+CD3+ T-cell number 
below 50 cells/μL, which was monitored by  ow cytometry at weekly intervals. Rejection 
of minor antigen-mismatched bone marrow was signi cantly reduced in IL-7-treated re-
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cipients as compared to PBS-treated control mice. The incidence of graft rejection following 
fully MHC-mismatched bone marrow transplantation was not reduced nor enhanced by IL-7 
administration. In search of possible explanations for the observed protective e ect of IL-7 
on host-versus-graft reactivity following minor antigen-mismatched bone marrow transplan-
tation (BMT), we hypothesized that IL-7 might reduce allograft rejection by increasing the 
number of regulatory T cells (Treg) after BMT. As shown earlier, Treg play an important role 
in the regulation and suppression of host-versus-graft reactivity. IL-7 administration indeed 
resulted in enhanced recovery of peripheral blood CD4+CD25high regulatory T cells (Treg), 
including BM-derived Treg and Treg derived from the supplemented congenic T-cell pool. 
Enhanced recovery of Treg was accompanied by a signi cant increase in peripheral blood 
Foxp3 mRNA expression. T-cell phenotype and Th1/Th2 balance as expressed by the IL-4/
IFN-γ ratio remained unaltered and una ected by IL-7 administration, which argued against 
a direct immunosuppressive e ect of IL-7 on T cells. These results indicate that IL-7 mediated 
protection against minor antigen-mismatched allograft rejection may be due to suppressive 
e ects of Treg following their increased recovery induced by IL-7.
Chapter 6 as  nal chapter represents a general discussion in which the observed im-
munorestorative and tolerogenic e ects of IL-7 will be discussed in more depth and within 
the perspective of current and future developments in immune reconstitution following 
hematopoietic stem cell transplantation.
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Samenvatting
Allogene stamceltransplantatie (allo-SCT) heeft een belangrijke plaats in de behandeling van 
patiënten met kwaadaardige ziekten van bloed en beenmerg. Allo-SCT kan echter gepaard 
gaan met ernstige complicaties, hetgeen een bredere toepassing nog steeds in de weg staat. 
Infecties worden beschouwd als een belangrijke, ernstige complicatie van allo-SCT. De inci-
dentie van infecties na transplantatie is hoog en een gevolg van het trage herstel van het af-
weersysteem na transplantatie. Met name het zeer trage herstel van naïeve, nieuwgevormde 
T-cellen is signi cant geassocieerd met het optreden van infecties na transplantatie. Derhalve 
staat verbetering van het T-cel herstel na allo-SCT uitdrukkelijk in de belangstelling.
Interleukine-7 (IL-7) is een boodschapper eiwit van het afweersysteem (cytokine) dat een 
centrale rol speelt tijdens de vorming van T-cellen in de thymus (T-lymfopoiese) en bij de 
expansie van T-cellen in het bloed. Preklinisch onderzoek toonde reeds aan, dat het toedie-
nen van IL-7 na transplantatie een positief e ect kan hebben op T-lymfopoiese enerzijds en 
expansie van perifeer bloed T-cellen anderzijds. Eerder onderzoek naar de e ecten van IL-7 
op directe en omgekeerde afstoting na transplantatie leverde nog geen eenduidig antwoord 
op. Het experimentele onderzoek, dat in dit proefschrift beschreven wordt, is gericht op het 
verkrijgen van een beter inzicht in de e ecten van IL-7 op herstel van het afweersysteem en 
met name het T-cel herstel, als ook op een beter inzicht in het e ect van IL-7 op afstoting na 
transplantatie.
Hoofdstuk 1 is een algemene introductie, waarin herstel van het afweersysteem (immuun-
reconstitutie) na transplantatie en IL-7 in het bijzonder worden toegelicht.
Hoofdstuk 2 beschrijft de resultaten van een retrospectief onderzoek naar opportunisti-
sche infecties welke tussen dag 30 en dag 365 na allo-SCT zijn opgetreden. Met name deze 
zogenaamde ´postengraftment´ infecties zijn geassocieerd met aanzienlijke complicaties 
en ook sterfte na transplantatie. De incidentie, oorzaak en gevolgen van ´postengraftment´ 
infecties werden bestudeerd in 47 ontvangers van weefsel-identiek beenmerg en vergeleken 
met 40 ontvangers van weefsel-identieke stamcellen, die uit het perifere bloed werden 
verkregen. Alle transplantaten in deze studie werden bewerkt, waarbij het grootste gedeelte 
van de aanwezige T-cellen werd verwijderd teneinde omgekeerde afstoting (graft-versus-
host ziekte) te voorkomen. De transplantaten, die uit het perifere bloed werden verkregen, 
bleken signi cant meer CD34+ voorlopercellen te bevatten, hetgeen geassocieerd bleek met 
een signi cant sneller herstel van de bloedaanmaak na transplantatie, waaronder neutro ele 
granulocyten, T-cellen en bloedplaatjes. Ontvangers van perifeer bloed stamcellen kregen 
signi cant vaker graft-versus-host ziekte. Eén jaar na transplantatie had 65% van de been-
merg ontvangers tenminste één ernstige infectie doorgemaakt vergeleken met 68% van de 
ontvangers van per eer bloed stamcellen. Virussen bleken vaak als verwekker van infecties 
in beide groepen patiënten voor te komen, bacteriën en schimmels daarentegen iets min-
der vaak. Eén jaar na transplantatie bedroeg de transplantatie gerelateerde sterfte 30% in 
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ontvangers van beenmerg versus 34% in ontvangers van perifeer bloed stamcellen, zonder 
signi cante verschillen in sterfte ten gevolge van infecties. Geconcludeerd kon worden, dat 
ontvangers van perifeer bloed stamcellen welliswaar een sneller T-cel herstel laten zien, maar 
niet minder infecties doormaken, mogelijk als gevolg van meer graft-versus-host ziekte in die 
groep van patiënten.
Hoofdstuk 3 beschrijft een techniek om zogenaamde ´signal joint T-cell receptor rearran-
gement excision circles´ (sjTRECs) in lymfoïde organen en perifeer bloed van muizen aan te 
tonen. SjTRECs zijn kleine DNA-cirkels, die worden gevormd tijdens het herschikkingsproces 
van de T-cel receptor gensegmenten. Dit herschikkingsproces is een belangrijke stap in de 
ontwikkeling van de T-cel in de thymus. SjTRECs worden niet gekopieerd bij de celdeling en 
derhalve uitverdund. Het kwanti ceren van dergelijke sjTRECs kan derhalve als maat gebruikt 
worden voor de activiteit van de thymus. De techniek, om sjTRECs aan te tonen, betreft een 
polymerase kettingreactie waarmee kwantitatief de aanwezigheid van dergelijke DNA-cirkels 
kan worden gemeten. De techniek bleek zeer gevoelig met een detectiegrens van 1 sjTREC 
in 100 ng DNA overeenkomend met 15.000 kernhoudende cellen. De speci citeit van de 
techniek werd aangetoond in RAG-1-de ciënte (-/-) muizen, die door afwezigheid van het 
´recombination-activation gene´ hun T-cel receptor gensegmenten niet kunnen herschikken 
en derhalve ook geen sjTRECs produceren. Dergelijke muizen hebben dan ook geen rijpe 
T-cellen in het bloed. In gezonde muizen namen sjTREC aantallen in perifeer bloed af met de 
leeftijd en na thymectomie. In 2.5 jaar tijd werd een tienvoudige afname in sjTREC aantallen 
aangetoond in B6 muizen. Bovendien werden opvallende verschillen in sjTREC aantallen 
tussen verschillende muizenstammen aangetoond. B6 muizen bleken een onverwacht 
polymor sme in de sjTREC DNA volgorde te hebben, waarvoor een nieuwe primer/probe 
combinatie met vergelijkbare PCR e  ciëntie ontwikkeld werd. Geconcludeerd kon worden, 
dat in muizen van gelijke leeftijd en achtergrond, sjTRECs als maat voor de activiteit van de 
thymus gebruikt kunnen worden. Het kwanti ceren van sjTRECs zou derhalve een toepas-
sing kunnen hebben in experimenteel transplantatie onderzoek, waarin de activiteit van de 
thymus en T-cel herstel na transplantatie worden bestudeerd.
In Hoofdstuk 4 wordt het e ect van IL-7 op het T-cel herstel na beenmergtransplantatie 
(BMT) in muizen bestudeerd. De hoeveelheid sjTRECs in combinatie met  owcytometrische 
analyse van T-cellen werden gebruikt om het e ect van IL-7 op T-cel herstel na transplanta-
tie te bestuderen in RAG-1-/- muizen. Daar IL-7 zowel de T-lymfopoiese als de expansie van 
perifeer bloed T-cellen kan beïnvloeden, hebben wij gekeken of IL-7 bij voorkeur e ect zou 
hebben op T-lymfopoiese danwel op expansie van perifeer bloed T-cellen. Onbestraalde 
RAG-1-/- muizen werden getransplanteerd met T-cel-gedepleteerd congeen Ly5.1 beenmerg 
aangevuld met Ly5.2 geselecteerde rijpe T-cellen afkomstig uit de milt. T-cellen afkomstig uit 
het beenmerg en T-cellen afkomstig uit de toegevoegde miltcellen konden onderscheiden 
worden door middel van  owcytometrie. Behandeling met IL-7 na transplantatie resulteerde 
in een vroege en voortdurende toename van T-cellen, die afkomstig waren uit de milt en 
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aan het transplantaat waren toegevoegd. IL-7 had daarentegen geen e ect op de uit het 
beenmerg afkomstige T-cellen. IL-7 had wel een signi cant e ect op herstel van deze uit 
het beenmerg afkomstige T-cellen in RAG-1-/- ontvangers van T-cel-gedepleteerd beenmerg. 
SjTREC aantallen in de thymus, milt en perifeer bloed suggereerden dat dit e ect vooral 
perifere expansie betrof van uit het beenmerg afkomstige T-cellen, zodra deze aan het bloed 
worden afgegeven door de thymus. Geconcludeerd kon worden dat IL-7 herstel van de afweer 
na BMT vooral kan versnellen door een sterk e ect op expansie van T-cellen in het bloed.
Hoofdstuk 5 betreft de belangrijke vraag of behandeling met IL-7 na BMT afstotingsreac-
ties kan verergeren. Vooralsnog lieten studies naar het e ect van IL-7 op graft-versus-host 
ziekte (omgekeerde afstoting) tegenstrijdige resultaten zien. Bovendien werd het e ect van 
IL-7 op directe afstoting (rejectie; host-versus-graft reactiviteit) nog niet eerder bestudeerd. 
Derhalve werd een experimenteel transplantatiemodel opgezet om het e ect van IL-7 op 
rejectie na BMT te bestuderen. RAG-1-/- muizen werden allereerst voorzien van congene 
antigeen-reactieve T-cellen en vervolgens getransplanteerd met minor antigeen-mismatched 
of major antigeen-mismatched beenmerg. Rejectie werd gede nieerd als een perifeer bloed 
T-cel aantal, dat voortdurend lager was dan 50 cellen/μL. Na transplantatie werd het aantal 
T-cellen in het perifere bloed wekelijks door middel van  owcytometrie geëvalueerd. De 
incidentie van rejectie na minor antigeen-mismatched BMT bleek signi cant lager in IL-7 
behandelde muizen dan in placebo behandelde muizen. De incidentie van rejectie na major 
antigeen-mismatched BMT daarentegen was niet lager maar ook niet hoger na behandeling 
met IL-7. Vervolgens werd de vraag opgeworpen hoe het geobserveerde, beschermende 
e ect van IL-7 verklaard kon worden. Een mogelijke verklaring betreft een beter herstel van 
zogenaamde regulatoire T-cellen (Treg) na transplantatie. Eerdere studies hadden reeds 
aangetoond dat dergelijke Treg een belangrijke rol spelen in de regulatie en suppressie van 
host-vs-graft reactiviteit. Flowcytometrische analyse toonde inderdaad aan dat behandeling 
met IL-7 resulteerde in een versneld herstel van Treg afkomstig uit het beenmerg en ook van 
Treg afkomstig uit het perifere bloed. Deze resultaten laten zien, dat IL-7 kan beschermen te-
gen rejectie van een minor antigeen-mismatched beenmergtransplantaat, hetgeen mogelijk 
verklaard kan worden door een gelijktijdig beter herstel van regulatoire T-cellen.
Hoofdstuk 6 bevat tenslotte een algemene discussie, waarin de beschreven e ecten van 
IL-7 op het herstel van T-cellen na transplantatie als ook het e ect op afstotingsreacties in het 
bredere perspectief van huidige en toekomstige ontwikkelingen op transplantatiegebied 
worden geplaatst.
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Abbreviations
Allo-SCT allogeneic stem cell transplantation
APC allophycocyanin
BM(T) bone marrow (transplantation)
Cα constant gene segment of T-cell receptor alpha gene
CD cluster designated
cDNA complementary DNA
CFU-GM granulocyte-macrophage colony forming units
CMV cytomegalovirus
Ct threshold cycle
CTC common toxicity criteria
CTL cytotoxic T lymphocyte
DNA deoxyribonucleic acid
dNTP deoxyribonucleotide triphosphate
DP double positive
E e  ciency
EBV Epstein-Barr virus
FACS  uorescence activated cell sorter
FCS fetal calf serum
FITC  uorescein isothiocyanate
Flt3 fms like tyrosine kinase 3
γc gamma chain
G-CSF granulocyte colony stimulating factor
GH growth hormone
GVH(D) graft-versus-host (disease)
HIV human immunode ciency virus
HLA human leukocyte antigen
3H-TdR tritium thymidine
HVG host-versus-graft
IEA immediate early antigen
IFN interferon
Ig immunoglobulin
IL interleukin
IL-7Rα interleukin-7 receptor alpha
KGF keratinocyte growth factor
LP-1 lymphopoietin-1
LPD lymphoproliferative disease
mAb monoclonal antibody
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(m)Ag (minor) antigen 
MHC major histocompatibility complex
mRNA messenger ribonucleic acid
NK cell natural killer cell
OS overall survival
PBPC(T) peripheral blood progenitor cell (transplantation)
PBS phosphate-bu ered saline
PCR polymerase chain reaction
PE phycoerythrin
PerCP peridinyl cholorophyllin
PMA phorbol-12-myristate 13-acetate
PMN cell polymorphonuclear cell
RAG recombination activation gene
rh recombinant human
RI ribonuclease inhibitor
RNA ribonucleic acid
RTE recent thymic emigrant
RT-PCR reverse transcriptase polymerase chain reaction
RQ-PCR real-time quantitative polymerase chain reaction
SCF stem cell factor
SCID severe combined immunode ciency
SCT stem cell transplantation
SEM standard error of the mean
(sj)TREC (signal joint) T-cell receptor rearrangement excision circle
SP single positive
Tc cytotoxic T cell
TCD T-cell depleted
TCR T-cell receptor
TCRA T-cell receptor alpha
TCRD T-cell receptor delta
TEC thymic epithelial cell
Th helper T cell
TN triple negative
Treg regulatory T cell
TRM transplant/treatment-related mortality
TSLP thymic stromal-derived lymphopoietin
UCBT umbilical cord blood transplantation
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Dankwoord
In dit laatste en tevens meest gelezen deel van een proefschrift wil ik een ieder die aan de 
totstandkoming van dit boekje heeft bijgedragen heel hartelijk bedanken.
Prof.dr. J.J. Cornelissen, beste Jan! Dit proefschrift is toch wel dé manier om ons tweede lustrum 
te vieren. In 10(!) jaar tijd van medisch student tot doctor en dat alles onder jouw inspirerende 
leiding. Veel dank voor je vertrouwen ondanks die momenten waarop ik je geduld op de proef 
heb gesteld. Ik heb het zeer gewaardeerd dat je tot het laatste moment bereid bent geweest 
mijn teksten al dan niet met anglicismen van meer of minder rood te voorzien, al ging dit soms 
gepaard met pittige discussies. Hopelijk kunnen we onze samenwerking in de toekomst voort-
zetten en wil je mij de  jne kneepjes van het stamceltransplantatievak bijbrengen. 
Prof.dr. B. Löwenberg, beste Bob, hartelijk dank dat je mij de gelegenheid hebt geboden 
om onderzoek te doen op de afdeling hematologie en voor het kritisch lezen van de manus-
cripten en dit proefschrift. Ik hoop nog veel van je te mogen leren. 
Prof.dr. J.J.M. van Dongen, Prof.dr. G. Wagemaker en Prof.dr. H. Spits wil ik bedanken voor het 
plaats nemen in de kleine commissie en de snelle en kritische beoordeling van het proefschrift. 
Dr. E. Braakman, beste Eric, veel dank voor je oneindige geduld en betrokkenheid. Ik heb 
je behulpzaamheid en kritische noot bij het bedenken en uitvoeren van de experimenten en 
het schrijven van manuscripten altijd zeer gewaardeerd. 
Dr. B. van der Holt, beste Ronnie, inmiddels ben je gepromoveerd van doctorandus naar 
doctor. Dank dat ik weer gebruik heb mogen maken van je statistisch toetsvermogen. 
Dr. J.W. Gratama, beste Jan-Willem, en overige medewerkers van de afdeling Klinische- en 
Tumor immunologie aan de overkant van de Maas, dank voor jullie bijdrage en positieve 
samenwerking. 
Dr. J.P.P. Meijerink, beste Jules, dank voor je expertise op het gebied van ‘real-time’ PCR. Je 
was altijd bereid te helpen en kritisch mee te denken.
Alle collega’s van de 13e wil ik bedanken voor de goede samenwerking. Nuray, Paula en Susan, 
ik vond het erg gezellig met jullie een kamer te delen en ik ben blij dat we nog regelmatig con-
tact hebben. Ons vertrek uit het AIO-hok heeft geresulteerd in een signi cante daling van de 
kamertemperatuur en het aantal niet-wetenschappelijke discussies. Susan, succes met de laatste 
loodjes. Elwin, mijn redder in de nood: de  guren zijn prachtig geworden. Evert-Jan, gedeelde 
smart is halve smart. Succes met het afronden van je proefschrift. Marieke, dank dat ik jou ‘potje’ 
Treg heb mogen ‘lenen’ voor hoofdstuk 5. Jij ook veel succes met het afronden van je proefschrift. 
Peter, je kennis van ruim 30 jaar proefdierkunde is zeer waardevol geweest. Sebastiaan en Vincent, 
als medisch studenten hebben ook jullie je bijdrage aan het IL-7 project geleverd. 
Medewerkers van het dierexperimenteel centrum, dank voor jullie enthousiasme en inzet. 
Annemarie wil ik in het bijzonder bedanken voor de verzorging van de proefdieren alle dagen 
van de week en in het weekend. 
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Prof.dr. M.A.D.H. Schalekamp, Prof.dr. H.A.P. Pols en dr. J.C.L.M. van Saase, dank voor de 
geboden kans om wetenschap met een internistenopleiding te combineren. Drs H.L. Tjiong, 
lieve Lies, dank dat ik op de valreep van je pensioen nog zoveel van je mag leren. 
De collega’s van de afdeling interne geneeskunde van het Erasmus MC wil ik bedanken 
voor de goede samenwerking, de borrels op vrijdag, en de altijd weer zeer geslaagde ski- en 
zeilweekenden. Annemiek, ik kijk uit naar onze volgende autorit. Hannelore, samen dienst 
doen is veel leuker. Adrienne, van co-assistent tot ganggenoot. Ward, het volgende feest 
is voor jou. Robin-’copy-paste’-Robin. Mattijs, 4-midden ‘forever’. Ook alle collega’s van de 
interne geneeskunde van het Sint Franciscus Gasthuis wil ik bedanken voor de zeer gezellige 
samenwerking. Ik denk nog regelmatig met veel plezier terug aan de maanden die ik heb 
mogen doorbrengen op de IC afdeling en de privécursus ‘luisteren’ op de afdeling cardiolo-
gie. Drs. A.P. Rietveld, beste Arie, dank dat je bereid was deze ‘jonge moeder’ voor een jaar 
onder je hoede te nemen. 
Clementien en Wieke, studievriendinnen voor het leven! Jullie weten als geen ander hoe het 
voelt om voor een promotiecommissie te staan (of zitten). Marieke, Rotterdam-Nijmegen is 
maar 120 kilometer. ‘Down under’ Cas en Fré, ik heb de Sint vast een brief geschreven. Jan, Els, 
Erik en Francijn, dank jullie wel. Ik kijk uit naar het nieuwe familielid!
Lieve Nanna, ik ben heel blij dat jij in 1995 besloot om lid te worden van het ‘Rotterdamsch 
Studenten Gezelschap’. Een biertje drinken in Midgard of dansen in Thor liggen inmiddels al 
weer even achter ons, maar vriendinnen zijn we gelukkig gebleven. Als a-creatief wezen dat 
ik ben, is het fantastisch om je als kunstenaar en ‘dutch doll’ aan het werk te zien. Van ‘Heel 
Kapot’ tot ‘About’, van haring tot rookworst, van cellen tot bellen, van dj tot paranimf en een 
vleugje Vera de muis. Voor jou en je ‘verkering’ Casper alle liefde en geluk en weet dat Berlijn 
net als Boston praktisch naast de deur ligt.
Lieve Sandra, ‘mijn’ analist en paranimf van het eerste uur. Je hebt je altijd voor de volle 
100% ingezet voor het IL-7 project. Vele uren hebben we samen doorgebracht achter FACS 
en MACS veelal met heel veel plezier maar soms ook met grote frustratie met name als 
MACS weer eens kuren had. Ondanks dat we niet meer dagelijks samenwerken, gaan we nog 
regelmatig onder het genot van een hapje en een drankje oude ‘muizen’ uit de sloot halen. 
Stompie is voor altijd in mijn hart.
Terug naar de basis: lieve papa en mama, ik kan jullie niet missen. Papa, ik ben heel blij dat 
het spreekwoordelijke ‘oog van de naald’ echt bestaat en dat je weer van het leven mag en 
kunt genieten. Mama, ik vind je een fantastische vrouw. Je bent mijn beste vriendin. Lieve 
Jeroen, de strafpleiter van de familie. Je bent mijn ‘grote’ broer en daar ben ik trots op. Wan-
neer mag ik weer mee naar het kasteel? SP-AR-TA!
Mijn allerliefste Jorick, dank voor je geweldige steun, enorm relativerend vermogen en on-
voorwaardelijke liefde. Lieve Bram, ‘mama is klaar met leren’.
121Addendum
Curriculum Vitae
Annoek Broers werd geboren op 20 september 1975 te Schiedam. In 1993 behaalde zij haar 
VWO diploma aan de Christelijke Scholengemeenschap ´ Blaise Pascal´ te Spijkenisse. Aanslui-
tend ging zij geneeskunde studeren aan de Erasmus Universiteit te Rotterdam. Gedurende 
haar studie geneeskunde behaalde zij haar propedeuse psychologie aan de Universiteit van 
Leiden. In 2000 behaalde zij haar artsexamen met lof en begon aansluitend als AGIKO met het 
in dit proefschrift beschreven onderzoek op de afdeling hematologie (Prof.dr. J.J. Cornelissen 
en Prof.dr. B. Löwenberg) en haar opleiding tot internist in het Erasmus Medisch Centrum 
en Sint Franciscus Gasthuis te Rotterdam (Prof.dr. H.A.P. Pols, Dr. J.C.L.M. van Saase en Drs. 
A.P. Rietveld). Vanaf 1 januari 2008 zal zij zich gaan specialiseren in het aandachtsgebied 
hematologie (Prof.dr. B. Löwenberg).
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